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Abstract 
 
Gastrointestinal peptides like insulin and glucagon-like peptide are not only essential 
metabolic hormones but can also modulate important brain function, unrelated to feeding 
behaviour and glucose homeostasis. Different evidence suggests that these peptides, as well 
as synthetic insulin secretagogue such as, tolbutamide, can affect cognition, motivation, 
addiction as well as neuronal survival.  
In this thesis, we have investigated in rats whether insulin, or the insulin-releasing 
agent tolbutamide, and the stable glucagon-like-peptide-1 (GLP-1) receptor agonist exendin-4 
as well as putative GLP-1 congener geniposide, can affect the electrical activity of dopamine 
neurons in the ventral tegmental area (VTA) and of pyramidal neurons in the prefrontal 
cortex (PFC), using single-unit activity recording techniques. We have also investigated, 
whether these peptides can alter some dopamine-dependent behaviours such as, D-
Amphetamine (a dopamine-releasing agent) -induced motor activity, quinpirole (a dopamine 
D2/D3 receptor agonist) and pramipexole (a dopamine D3 preferred receptor agonist) -induced 
yawning, pica eating and pelvic grooming activities, as well as phencyclidine ( an N-Methyl-
D-aspartate receptor antagonist)-induced cognitive deficit. We also examined the 
pharmacological mechanism of these drugs on radiometric in vitro [DA] release and uptake 
assays and investigated whether GLP-1 can modulate the effect of diet modification in form 
of chronic sucrose intake on behavioural and electrophysiological parameters. 
Interestingly, in uptake assay, exendin-4 and insulin weakened dopamine D2/D3 
agonist (pramipexole and quinpirole)-induced [DA] uptake which suggests a potential 
interaction with D2/D3 receptor signalling. In addition, insulin and tolbutamide similarly 
reduced basal [DA] in striatal synaptosomes. 
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Our electrophysiological data shows that GLP-1 receptor activation can change the 
excitability of prefrontal cortex neurons, an effect that can be associated to the putative pro-
cognitive action of some GLP-1 analogues. Interestingly, on VTA dopamine neurons, GLP-1 
receptor activation potentiated a moderate inhibitory action of insulin on firing activity. 
However, a slight progressive decrease in the firing activity of ventral tegmental area 
dopamine neurons was observed, when insulin was administered through an electrode to 
allow for local diffusion into the brain region. The insulin secretagogue agent tolbutamide 
exerts biphasic or excitatory effects on VTA dopamine and PFC neurons, probably via K+ATP  
channels  blockage through sulphonylurea receptors activation, indicating that most 
dopamine neurons and PFC neurons can be metabolic-sensitive. On sucrose treated rats, we 
noticed that sucrose treatment induced a partial but significant decrease in the sensitivity of 
dopamine autoreceptors which was surprisingly exacerbated by exendin-4 co-administration, 
indicating that exendin-4 may interact negatively with both pre- and post-synaptic dopamine 
receptors. 
Our behavioural data shows that exendin-4 and insulin alter dopamine-dependent 
behaviour with a remarkable inhibitory effect on D-amphetamine-induced motor activity and 
pramipexole and quinpirole-induced yawning, pica eating, and pelvic grooming activities. As 
this behaviour is mainly mediated by dopamine D3 receptors our data suggest the existence of 
an interaction between GLP-1 and dopamine D3 receptors. This may implicate GLP-1 
mediated neuronal processes as a particularly interesting therapeutic target for disorders 
involving dopamine D2/D3 receptors and dopamine transporter malfunction. GLP-1 also 
exhibited a pro-cognitive effect on PCP-induced cognitive impairment, through the enhanced 
glutamatergic transmission. Finally, data on sucrose revealed that prolonged ad libitum 
access to sucrose by adolescent rats may alter brain circuits related to dopamine 
neurotransmission. It increases the behavioural responses of dopamine agonists, and is 
possibly associated with hypersensitivity of some postsynaptic dopamine receptors. These 
effects were partially prevented by exendin-4, which may elicit some protective effects on 
dopamine receptor function. In succinct, gut peptides impact on neurotransmission as well as 
behavioural activities and potentially modulate psychostimulant effects. 
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Introduction  
 
The concept of the gut-brain axis   
The concept of the gut-brain axis (GBA) has typically been studied in connection with 
intestinal motility, secretion, and vascularity (Track, 1983). The earlier researchers have 
viewed this paradigm in the circumstance of behavioural eating and appetite alteration 
(Leclercq et al., 2014). However, brain imaging and electrophysiology techniques have 
further provided deeper insight into this phenomenal association between the central nervous 
system (CNS) and gastrointestinal tract (Ringel, 2002). A shred of more compelling evidence 
that underscores the role of GBA in brain function is its involvement in neuromodulation and 
neurotransmission processes as well as homeostasis balancing (Cryan, 2016). The term as 
coined, GBA exists due to biochemical signaling phenomenon between the gut and the 
central nervous system (Wang and Kasper, 2014). GBA involves a bidirectional 
communication between the CNS and gastrointestinal tract (GIT) impacting on cognitive and 
reward centers of the brain, with influence on enteric nervous system functions (Mayer et al., 
2014). However, it was originally thought to be limited to physiologic maintenance of GIT 
homeostasis but, recent advances in research has shown the involvement of this phenomenon 
in more complex brain communications involving motivation and reward (Strandwitz, 2018). 
In a more holistic approach, the GBA encompasses the CNS, neuroendocrine and 
neuroimmune systems, extending to the hypothalamic–pituitary–adrenal axis (HPA axis) and 
the gut microbiota (Dinan and Cryan, 2015). 
The morphological basis of the gut-brain axis  
The GBA includes a connection of autonomic neurons that link the central nervous system 
CNS specifically, the caudal brainstem and spinal cord—to the esophagus, gastrointestinal 
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tract, liver, and pancreas (Furness, 2006; Jänig, 1996). The axonal extensions connect via the 
vagus, splanchnic, mesenteric and pelvic spinal nerves to innervate the abdominal viscera 
(Figure 1). 
 
 
Figure (Fig.) 1: Anatomic formation of the gut-brain axis. 
The principal anatomical and functional sub-classifications of a mammalian GBA are 
denoted with neurons associated with the enteric and extrinsic autonomic systems in 
contrasting colours. The enteric nervous system is entirely accommodated within the 
gastrointestinal wall.  Abbreviations: NTS, nucleus tractus solitaris; AP, area postrema; 
DMV, dorsal motor nucleus; DRG, dorsal root ganglion; IML, intermediolateral nucleus; 
VSG, vertical sleeve gastrectomy(Gautron, 2013). 
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It is worth noting that the morphological examination of the gut-brain axis has a phenomenal 
long history. Claudius Galenus (Galen), circa A.D. 130–200 discovered the vagus nerve, as 
reported by Ackerknecht, (1974). However, the full anatomy of the GBA remained not 
available to scientists for certain period due to indistinction within the nerve cells as they 
move into the peripheral organs. Hence, it was not until the late 19th century that 
postganglionic neurons located in the gastrointestinal wall (also known as enteric neurons) 
were discovered by Auerbach and  Meissner (Furness, 2008). Enteric neurons, together with 
postganglionic neurons in the gallbladder and pancreas, are the portion of the gut-brain axis, 
as they allow direct input from, and send information to, the rest of the autonomic nervous 
system (ANS). Nevertheless, enteric neurons are also able of operating autonomously of the 
gut-brain axis (Morris et al., 1985; Powley, 2000). Functionally, GIT receives a two-way 
external innervation from ANS. This includes parasympathetic (cholinergic); vagal and 
pelvic nerves and sympathetic (noradrenergic): splanchnic nerves. The GIT accepts both 
excitatory and inhibitory innervations, the first is provided mainly by the parasympathetic 
nerves and last, by the sympathetic nerves (Dockray, 2009). The ENS has about 100 million 
neurons working as local sensory neurons, interneurons, and effector motor neurons. ENS is 
thought to be a part of CNS that has been replaced during development from the brain to the 
gut but preserving with brain two-way communication pathways (parasympathetic and 
sympathetic), each together with efferent and afferent nerves. The efferent extrinsic 
parasympathetic nerves are pre-ganglionic fibers terminating on cholinergic ENS neurons 
either of the myenteric plexus to control motor activity of the gut or in the submucous plexus 
to regulate the secretory activity of glandular cells or visceral circulation (Konturek et al., 
2004). The efferent extrinsic sympathetic (mainly noradrenergic) nerves are postganglionic 
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and some of them terminate on postganglionic cholinergic neurons of ENS to inhibit 
acetylcholine release via activation of their alpha-presynaptic receptors or directly on 
intestinal smooth muscle cells to affect motility of the gut or of vasoactivity of visceral 
vessels to influence the visceral circulation (Langley, 1994). 
Features of the enteric nervous system (ENS) 
The special feature of ENS from extrinsic autonomic nerves is its network of diverse neurons 
and potential to detect and relay sensory information; it can also function autonomously 
alongside with CNS. However, GIT may function without extrinsic innervation such as 
pyloric dilatation. The independent activity of ENS is known as  “gut-brain” that is exhibited 
over GIT homologous with that of CNS exercising control over the somatic part of the body 
(Langley, 1994). Subsequently, ANS which comprises of sympathetic (regulates 
cardiovascular, reflex and stress activities) and parasympathetic nervous system (controls 
visceral and skeletal activities), including ENS originates from the neural crest from which 
the cells migrate to the gut during development. The moving cells occupy the gut wall to 
form its intrinsic innervation (Baynashet al., 1994; Trupp et al., 1996). 
Microbiota-gut-brain axis 
The microbiome colonizing the gut includes all microbes together with their genomic 
material residing the intestinal tract. This is the hallmark of two-way GBA that 
metamorphoses through initial habitation in which the brain and gut are linked together in an 
organism's health (Sarkar et al., 2016). The central research that formed the basis of this 
paradigm was established when mice groomed in sterile conditions devoid of residence 
bacteria (bacteria-free mice) exhibited an escalated physiological reaction to stress as 
compared to control mice. These abnormal reactions were reversed when probiotic was 
ingested leading to bacterial recolonization of the gut system (Sudo et al., 2004). The 
5 
 
outcomes of this study established the microbiome's as functional biomarkers in the 
development of the hypothalamic–pituitary–adrenal (HPA) axis. In view of this background, 
gut bacteria have since been found to have overwhelming influence in controlling various and 
vital physiological activities, including immunomodulation, neuromodulation, homeostasis, 
drugs, and nutrients metabolizing, synthesis of vitamins and bioactive molecules and  
electrophysiological activity of the ENS (Kau et al., 2011; Hooper et al., 2012; Le Chatelier 
et al., 2013). A recent advance in this area of research has in no doubt considered the 
presence of gut bacteria as the major factor in GBA. This reservoir has been the abode to over 
billion numbers of microbes heterogeneously inhabiting the gut, out-numbering the number 
of human cells and influencing almost all aspects of human biology (Cryan, 2016). In the 
light of this background, two important food agents that that are  related to microbiota and 
provide vital physiologic effects in the gut have been identified namely; probiotic and 
prebiotic.  
Probiotics are  useful microbes that when administered possess favourable effect in 
the prevention and management of definite pathologic conditions leading to a positive health 
outcome (Chow, 2002; Lin et al., 2018; Sanders, 2015). These bacteria produce therapeutic 
effects through manipulation and colonization of resident gut bacteria, maintenance of human 
homeostasis  leading to a therapeutic condition whereby the indigenous anaerobic flora limits 
the population of potentially pathogenic (mostly aerobic) flora in the digestive tract (Chow, 
2002; Mogilnicka and Ufnal, 2018). The bacteria of popular concern are the Gram-positive 
Bifidobacterium and Lactobacillus families (Burnet and Cowen, 2013; Mayer et al., 2014). 
The ingestion of these microorganisms is followed by the immunological response in which 
pro and anti-inflammatory cells are differentiated, the antigenic cells being the pro-
inflammatory (Sansonetti and Medzhitov, 2009). 
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Prebiotics, on the other hand, are non-digestible food materials that advantageously 
affect host well-being by particularly enhancing the growth and/or activity of 1 or a finite 
number of bacteria in the colon (Chow, 2002). They achieve this activity by eliciting 
compositional changes on intrinsic commensal bacteria when fermented in the gut (Gibson et 
al., 2010). Fructooligosaccharide (FOS), is a prebiotic found naturally in wheat, onions, 
bananas, honey, garlic, or leeks. It has been found in chicory root and can be produced in the 
laboratory with sucrose as the substrate (Linardi et al., 2001). Important prebiotic of vital 
relevance in the pharmaceutical formulation used as a daily supplement is Galacto-
oligosaccharides (B-GOS). Gronier et al., (2018), demonstrated the effect of B-GOS on an in 
vivo iontophoresis electrophysiology on the rat frontal cortex and effect on the performance 
of the attentional set-shifting task. The study revealed increased neuronal responses to N-
Methyl-D-aspartic acid (NMDA) in the rat frontal cortex and greater cognitive flexibility in 
the animals administered with B-GOS, an effect reported to be associated with an increased 
NMDA receptor function in the cortical brain region. A more recent finding has adopted new 
term called psychobiotics for  prebiotics and probiotics, due to well-established evidence of 
impact on neurotransmission, reward, social behaviour, motivation, cognitive ability, 
systemic and central processes in animals and humans (Sarkar et al., 2018). 
Gut-brain axis signalling 
Specific physiologic activities such as digestion, circulation, endogenous, and exogenous 
secretion and peristaltic movement are controlled by the preganglionic vagal and pelvic 
nerves hence, these processes are mediated by the ENS via CNS (Fox et al., 1983). The 
overall signalling pathway is aided by the efferent fibers in this line. However, the 
postganglionic efferent neurons control the sympathetic outflow from the CNS via the gut 
which is active during trauma, stress or external stimulation (Jänig and Morrison, 1986). On 
the other hand, afferent vagal and sympathetic (spinal) nerves are connected to the afferent 
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fibers of the gut-brain mediating the signalling pathway that is transmitted to the CNS (Jänig 
and Green, 2014). This responds to specific physiologic processes such as muscular 
contraction and dilatation, secretion of various chemical substances like acids and nutrients in 
the gut, neuro-endocrine agents such as gut hormones, gut peptides, neurotransmitters, 
neuromodulators, cytokines and other agent of inflammation (Langley, 1994; Sharkey and 
Savidge, 2014; Holzer and Farzi, 2014).  
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Figure. 2:  Schematic illustration of bidirectional signaling of GBA 
The nervous system can regulate many functions of the gut and alters the recognition of gut 
impulse through a set of similar outflows circuit called eMs, which consists of the 
parasympathetic and sympathetic divisions of the ANS, the HPA. The stimulation of eMs 
takes place through interoceptive and exteroceptive stressors. The enteric microbiotas are 
likely to interact with gut-based effector systems and with visceral afferent pathways, which 
establish a bidirectional brain –gut-enteric microbiota axis. Abbreviations: ANS, authonomic 
nervous system; CNS, central nervous system; eMs, emotional motor system; Gi, 
gastrointestinal; HPA, hypothalamus-pituitary-adrenal (Rhee et al., 2009).  
In general, vagal nerves stimulation exerts anti-inflammatory effect (Thán et al., 
2000),  improves depression (Jarczok et al., 2018), alters feeding behavior (Pelot and Grill, 
2018), ameliorates pain (Chakravarthy et al., 2015; Usichenko et al., 2017; Zhu and 
Marmura, 2016), calms anxiety (Fanselow, 2013; Genheimer et al., 2017), and 
therapeutically used in seizure management (Chen et al., 2012a; Connor et al., 2012; 
Lisowska and Daly, 2012).  It is noteworthy, to emphasize the importance of gut bacteria, as 
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they have a pronounced effect on the electrophysiological balance connected with ENS 
neurons (McVey Neufeld et al., 2013). A classic example is myenteric neurons, which when 
incubated with Bifidobacterium longum NCC3001-fermented substances exhibited a decrease 
in action potentials after electrical stimulation (Bercik et al., 2011). Kunze et al.,(2009), 
reported increased excitability when colonic AH-neurons (the chief sensory neurons in the 
colon) were treated with Lactobacillus rhamnosus, a response as a result of the closing of 
calcium-controlled potassium gates. A study by Collins et al.,(2014) established  an intestinal 
neural abnormality in the jejunum and ileum of germ-free mice in comparison to controls. 
However, in signaling related to neurotransmission through gut bacteria activity, dopamine 
and noradrenaline are produced by members of the Bacillus family, gamma-aminobutyric 
acid(GABA) by the Bifidobacteria family, serotonin by the Enterococcus and Streptococcus 
families, noradrenaline and serotonin by the Escherichia family, and GABA and 
acetylcholine by the Lactobacilli family (Lyte, 2011; Barrett et al., 2012; Dinan et al., 2015). 
Though there is a paucity of data to adduce these claims, these neurotransmitters modulate 
synaptic activity in the proximal neurons of the ENS, an important area future research 
opportunity. 
Gut peptides 
Gut peptides refer to a group of molecules with vital physiological activities, in the 
endocrine, nervous, digestive, circulatory and other systems (Abdulla et al., 2014). They were 
first discovered as hormone over a century ago, being a factor originating from the duodenum 
that could stimulate pancreatic fluid production (Kreymann et al., 1987). Secretin, the peptide 
hormone was eventually discovered to be responsible for this activity (Bayliss and Starling, 
1902). After these discoveries, more than 50 regulatory peptides have been established and  
the majority of which are present in both endocrine and paracrine cells and/or the intrinsic 
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nerves of the gastrointestinal tract (Harmar, 2004). The physiological functions mediated in 
the gut by these peptides include the control of motility (Avau et al., 2013), influence  
secretion of fluid (Jin et al., 1994; Johard et al., 2003), regulate metabolic and enzymatic 
activities (Seufert, 2017; Wang et al., 2017), modulate cell proliferation and survival 
(Parthsarathy and Hölscher, 2013; Khan et al., 2016), maintain vascular and immune 
functions (Guéniche et al., 2006; Bellin et al., 2017) and perform inflammation role 
(Dandonaet al., 2018). In general, gut peptides elicit their effects through G protein-coupled 
receptors, a family of numerous membrane proteins, 87 of which are presently known to have 
peptide ligands (Williams and Schonbrunn, 1994; Al-Sabah et al., 2014). The GPCRs has 
three division with a distinct molecular structure consisting of seven transmembrane domains, 
three extracellular loops, three intracellular loops, an amino-terminal extracellular domain 
and an intracellular carboxyl terminus (Wu et al., 2017). 
Appetite and satiety signalling  
Gut peptides hormones are linked to many food-related gastric and intestinal signaling 
pathways(Read et al., 1994). In recent times, researches have tried to establish the 
relationship between gastric signaling and release of gut peptides as it affects appetite, 
particularly hunger with satiety (Maljaarset al., 2007; Gribble, 2012; Stengel and Taché, 
2012; Sirohi et al., 2017). In (Fig. 3), Orexigenic (appetite stimulant) property expressed by 
gut peptides hormone is predominantly due to ghrelin and is produced solely in the stomach, 
belonging to ligand  growth hormone secretagogue receptor (Kojima et al., 2011; Nakazato et 
al., 2001). There is a surge in  plasma ghrelin peaks before a regular meal, then reduces later 
to increase to another peak just before the next meal, suggesting that ghrelin may be a meal 
inducer (Lutter et al., 2008). It is also suggested to play a role in long-term regulation of 
energy balance as continuous ingestion of ghrelin in rodents results in hyperphagia   and 
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weight gain without  growth hormone (Karra et al., 2013; Uchida et al., 2013). The effects of 
ghrelin on eating behavior are mediated via the infundibular nucleus and the solitary tract 
nucleus of the hypothalamus, connected with vagal afferent loops thereby, opposing  the 
actions of leptin through disinhibition of second-line neuropeptides such as neuropeptide Y 
(NPY) and agouti gene-related peptide (Abbott et al., 2005). 
 
 
Figure 3: Appetite signaling from gut peptides and enteric nerves to Brain  
Afferent gastrointestinal signals controlling food intake. CCK, cholecystokinin; NPY, neuropeptide; 
AgRP, Agouti gene-related peptide; α-MSH, α-melanocyte stimuli; ARC, arcuate nucleus; NTS, 
nucleus tractus solitarius; GLP-1, glucagon-like peptide-1; PYY, peptide tyrosine tyrosine (Näslund 
and Hellström, 2007). 
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In starvation, there is ghrelin increase which boosts appetite and reduced  levels of 
ghrelin in obesity may be a secondary response to over-eating (Scott et al., 2012). The overall 
finding with ghrelin  is a negative correlation  with percentage body fat, fasting insulin, and 
fasting leptin, all of which are elevated in obesity (Nowroozi-Asl et al., 2016; Kyrgios et al., 
2013; Amini et al., 2012; Cakiroglu et al., 2013). In converse, many among the gut peptides 
are anorexigenic (appetite suppressant) namely; cholecystokinin (CCK), glucagon-like 
peptide-1 (GLP-1) and peptide YY(3-36) (PYY(3-36)), which all are recognized as 
physiologic regulators of food intake (Muurahainen et al., 1988; Flint et al., 1998; Beglinger 
and Degen, 2006). The most studied of all gut peptides is CCK,  regulating control of food 
intake and this has gathered extensive review of researches over the years(Yu and Smagghe, 
2014; Kaloudi et al., 2015; Boyce et al., 2016). PYY, PYY(3-36), NPY and NPY(3-36) are  
released after a meal from the GI tract and induce satiety effect mediated through different Y 
receptors (Moriya et al., 2009, 2010). Specifically, the antisecretory mucosal mechanisms by 
which these peptides exert their effects are the same in human and mouse colon, with Y1 
receptor-mediated responses being solely epithelial, while Y2-mediated effects are neuronal 
in origin (Hyland et al., 2003; Cox, 2007). 
The traditional role of Glucagon-like peptide-1 (GLP-1) 
Glucagon-like peptide(GLP-1) and glucagon-like peptide-2 (GLP-2) are produced and 
secreted from endocrine L-cells in the mucosa of the ileum and colon (Gil-Lozano et al., 
2014). After food ingestion, GLP-1 and GLP-2 are released in equal concentration into the 
systemic circulation (Elliott et al., 1993). GLP-1 is a major contributor to the ileal brake 
mechanism of the upper GI tract, thereby modulating gastric emptying and acid secretion 
(Giralt and Vergara, 1999). Two vital physiologic effects of GLP-1 is its insulinotropic and 
glucagonostatic actions (Holst, 2007). It stimulates not only insulin gene transcription but 
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also all steps of insulin biosynthesis (Nathan et al., 1992). GLP-1 is capable of inducing new 
β cells in subjects with an insufficient number of these cells (Buteau et al., 1999). Drucker, 
(2003) and Farilla et al., (2003) reported the actions of GLP-1as a stimulant of  β cell 
differentiation and proliferation and inhibit apoptosis in β cells, the processes that lead to an 
eventual increase in the β cell mass and function over a long-term period. In addition to its 
effect on the β cells, GLP-1 reduces glucagon secretion, all the overall effects qualify it as a 
suitable therapeutic agent for type 2 diabetes (Avgerinos et al., 2018; Patel et al., 2018c). For 
this thesis, we have concentrated on describing physiological and therapeutic effects of 
exendin-4 (Ex-4) a GLP-1 agonist and geniposide (GPO) an iridoid glycoside compounds 
with a putative GLP-1effect.  Also, tolbutamide a sulphonylurea with Kir6.2/Katp channels 
blocking activity use in treating type 2 diabetes mellitus as well as insulin, an hormonal 
peptides were the focus of our study. 
The central functions of Glucagon-like peptide-1  
GLP-1 modulates hippocampal neuronal activity  
Looking beyond energy homeostasis, GLP-1 has assumed new roles in food and drug 
reward (Dickson et al., 2012a). It has been reported that hippocampal GLP-1R activation 
signals food reward behavior (Hsu et al., 2015a). The receptor activation consequently 
triggers neuronal spontaneous firing of the CA1 region of the hippocampal cell. This effect 
can be inhibited by 6-cyano-7-nitroquinoxaline-2-3-dione (CNQX), a glutamate antagonist 
and demonstrated that GLP-1R signaling facilitates excitatory synaptic transmission in the 
hippocampus (Oka et al., 1999). This study further reported a biphasic response to GLP-1 
agonist starting with increased and followed by reduced single-unit activity in the CA1 region 
of the hippocampus (Oka et al., 1999). Similarly, GLP-1 prevents Aβ1-40-induced 
attenuation in the occurrence of excitatory post synaptic currents in the hippocampal neurons 
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(Wang et al., 2013). There is an abundance of GLP-1R in the caudal area of CA1 and CA3 
which may suggest the involvement of GLP-1 in volume transmission (Cork et al., 2015; 
Hamilton and Hölscher, 2009; Hsu et al., 2015b). The CA3 pyramidal neurons are also 
controlled by GLP-1R signalling and activation by Ex-4 an analogue of GLP-1, enhances 
both the frequency and amplitude of spontaneous inhibitory postsynaptic currents (IPSCs); 
nonetheless, these actions are inhibited by tetrodotoxin (TTX), which is indicating that action 
potentials are necessary (Korol et al., 2015). Another credible report is that GLP-1Ractivation 
facilitates depolarization of presynaptic inhibitory neurons which eventually enhance the 
inhibitory tone on the postsynaptic CA3 neurons of the hippocampus. GLP-1R activation has 
also been reported to stimulate GABAA receptors through endogenous synaptic GABA even 
when neurotoxin, tetrodotoxin was injected (Korol et al., 2015). Consequently, GLP-1 
amplifies GABAA signalling in the CA3 region of hippocampus via both pre- and 
postsynaptic channels. It was reported however, that in the dentate gyrus (DG) region of the 
hippocampus GLP-1R blocker (Ex-9) facilitates the input-output relation and lowers the 
paired-pulse ratio (PPR) of excitatory postsynaptic potentials (EPSPs), indicating that 
endogenous GLP-1R inhibition enhances excitatory synaptic transmission in animal 
model(Kobayashi et al., 2013). The effects of GLP-1R activation or blockage in the 
hippocampus can be summed up to depend on the neuronal subtypes that are engaged, which 
can either be Gs or Gi/o of the G protein signaling cascades to produce its effect (Montrose-
Rafizadeh et al., 1999; Hällbrink et al., 2001). A recent study of GLP-1 relating to CNS 
disorders reported that, the drug improves repeated restraint stress-induced depression-like 
behaviour in mice by a reduction in neuronal apoptosis through GLP-1R/AKT signaling 
pathway (Zhao et al., 2018). 
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GLP-1 influences the hypothalamic function  
Beyond the homeostatic function of the hypothalamic nuclei, dysfunction in this centre may 
lead to alteration in feeding behaviour (Hetherington and Ranson, 1942). The expression of 
GLP-1Rs are ubiquitously present in the paraventricular nucleus (PVN), arcuate nucleus 
(ARC), dorsal medium hypothalamus (DMH) and lateral hypothalamic area (LHA) (Cork et 
al., 2015). It is of interest to know that, NTS GLP-1 neurons present on the NTS are only 
connected to the PVN and DMH in hypothalamus, but not in the ARC (Gu et al., 2013), 
indicating that the PVN and DMH receives an indirect synaptic control by GLP-1 produced 
from the NTS, while ARC neurons are modulated by volume GLP-1 input, either from NTS 
or from circulating GLP-1. It was also reported by (Acuna-Goycolea and van den Pol, 
2004a), that activation of  GLP-1R in the orexin LHA neurons causes an enhanced firing 
frequency of neuronal activity, but does not effect on  melanocortin- concentrating hormone 
(MCH)-expressing neurons. The increase in firing frequency of action potential  in orexin 
neurons may be  dependent on both the facilitation of excitatory synaptic transmission and 
direct postsynaptic depolarization of the cell membrane (Acuna-Goycolea and van den Pol, 
2004a). The study further reported that promotion of excitatory synaptic transmission by 
GLP-1 may also be mediated by the afferent nerve terminal, as only the frequency but not the 
amplitude of mEPSCs in the presence of TTX is increased. Hence, blockages of synaptic 
inputs to LHA orexin neurons are also positively controlled by GLP-1R activation via 
presynaptic regulation. These inputs to LHA, which can be regulated by GLP-1, may come 
from PVN or ARC, as both nuclei have abundant GLP-1 receptor expression (Acuna-
Goycolea and van den Pol, 2004a). More study by Calvo et al., (1995), showed  an increase 
in endogenous glutamine (a precursor for GABA) concentration after treatment with GLP-1. 
Astrocytes, notwithstanding are responsible for the production of this amino acid. Therefore, 
GLP-1 may regulate astrocyte functions through a glutamine-dependent pathway in the 
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VMH. A more recent study suggested that GLP-1R activation in the astrocytes may also be 
responsible for its anorexic property of (Reiner et al., 2016). In summary, GLP-1 controls 
hypothalamic neuronal activity via presynaptic regulation and a recent study has suggested 
the involvement of synaptotagmin-7 (Syt7) in phosphorylation by GLP-1 (Wu et al., 2015) 
and Syt7 is abundantly expressed in the CNS including hypothalamus (Sugita et al., 2001).  
 
GLP-1 regulates reward through the mesolimbic system 
The mesolimbic dopamine (DA) pathway is an important system  that is responsible for  food 
and drug reward signalling (Kenny, 2011a; Volkow et al., 2011a). GLP-1 receptors are 
abundantly expressed in reward neural centres, which is made up of nucleus accumbens 
(NAc) and the ventral tegmental area (VTA) (Merchenthaler et al., 1999a), and the activation 
of GLP- 1R in both regions results in decreased  food intake (Mietlicki-Baase et al., 2013a, 
2014a). Both the NAc and VTA receive projections from NTS GLP-1 neurons although this 
does not take place in the hippocampus (Gu et al., 2013a). Inhibition of GLP-1R increases 
highly palatable high-fat food consumption, which shows that these relationship are 
biochemically relevant for the control of feeding behaviour  (Alhadeff et al., 2012a) GLP-1R 
activation enhances excitatory synaptic inputs to medium spiny neurons (MSNs) in the NAc 
core of rats (Mietlicki-Baase et al., 2014a) likely via increase of presynaptic release 
probability (increased mEPSC frequency, no change in mEPSC amplitudes, and a reduction 
in PPR (Mietlicki-Baase et al., 2014a). However, administering GLP-1 to the NAc core has 
no effects on DA release, indicating no presynaptic regulation on DAergic nerve terminals. It 
is worthy of note that, GLP-1 seems to cause hyperpolarization in MSN cells and suppresses 
the input–output necessary for the generation of action potentials when injecting currents 
(Mietlicki-Baase et al., 2014a). The overall results from these data indicate that within the 
NAc, the functions of GLP-1 in regulating MSN functions are of many features. The effect of 
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GLP-1 in the VTA has been studied. GLP-1 analogue applied to the VTA of a rat was 
reported to enhance excitatory synaptic VTA DA neurons through the presynaptic pathway, 
an effect likely to reduce the PPR and enhance the frequency of sFPCs (Mietlicki-Baase et 
al., 2013a). However, a more recent study has revealed that the effect of GLP-1 on DA and 
non DA neurons in the VTA is cell-type dependent. While GLP-1R activation enhances 
excitatory synaptic VTA DA neurons, such activation causes depression of synaptic impulse 
of non-DA neurons that are projected to the NAc (Wang et al., 2015a). The two reports 
indicate the paradoxical effect of GLP-1 activity on VTA, which is dependent on  cell type 
and further suggest that VTA DA neurons  extended to both NAc and prefrontal cortex,  
response differently to drug and food rewards (Lammel et al., 2011, 2012). 
 
The roles of GLP-1 in caudal hindbrain neurons  
Preproglucagon (PPG)  neurons  producing GLP-1 are widely present in the NTS  part of the 
brain region (Gu et al., 2013b). Direct vagus inputs are received by the NTS and have been 
found to play a key function in food intake reward. GLP-1R activation in the NTS reduces  
intake of palatable high-fat food, operant responding for sucrose under a progressive ratio 
schedule of reinforcement, and the conditional place preference for a palatable food 
(Alhadeff and Grill, 2014). However,  using a transgenic mouse model, it has been shown 
that GLP-1-producing PPG neurons are not affected  by GLP-1 itself but generates fast 
electrical impulse by leptin (Hisadome et al., 2010). More studies found out that GLP-1Rs are 
not present in the  preproglucagon neurons in the nucleus of the solitary tract (NTS-PPG 
neurons), PPG-GFP but a reduction in leptin receptors on GLP-1 producing neurons causes 
hyperphagia (Hayes et al., 2010, 2011; Scott et al., 2011). Base on this premise, GLP-1 
signaling in the NTS is likely controlled by non- PPG neurons located in the NTS. Part of the 
brain stem that provides the preganglionic motor fibres is dorsal motor nucleus of the vagus 
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(DMV) which is connected  to the visceral organs (Travagli et al., 2006), innervates the 
intrapancreatic ganglia, and controls pancreatic secretory functions, including insulin 
secretion and glucose homeostasis (Sakaguchi et al., 1994; Trapp et al., 1994a). About fifty-
percent of the pancreas-projecting neurons in the DMV respond specifically to GLP-1 (Wan 
et al., 2007), showing that regulation of this system is mediated through some specific 
population of neurons in the DMV. Activation of  GLP-1R in DMV  depolarizes a 
subpopulation of neurons through inhibiting K+currents, which is not affected by TTX, 
suggesting a postsynaptic inhibition of K+-conductance, similar as reported previously 
(Acuna-Goycolea and van den Pol, 2004b). Taken together, GLP-1 treatment activates DMV 
preautonomic neurons, which project to the pancreas and results in insulin exocytosis and/or 
inhibition of glucagon release.  
Functions of GLP-1 in behavioural paradigm 
Recent studies have reported the role of GLP-1 agonist in drug-mediated behavioural 
activities with an animal model. These studies report that, treatment with Ex-4 attenuates the 
rewarding properties of amphetamine as well as cocaine-induced locomotor stimulation 
(Egecioglu et al., 2013a; Graham et al., 2013), impaired alcohol-induced behaviours in 
rodents  (Egecioglu et al., 2013b) and attenuates nicotine-induced locomotor stimulation as 
well as accumbal dopamine release (Egecioglu et al., 2013c), all suggesting that GLP-1R 
signaling is largely implicated in behavioural and neurochemical processes. Further research 
has demonstrated that,  intestinal L cells express VGLUT2 and secrete glutamate along with 
GLP-1 (Zheng et al., 2015a). Because of this, GLP-1-positive neurons within the caudal 
(visceral) nucleus of the solitary tract (cNST) also are glutamatergic and may enhance 
glutamate release when stimulated (Zheng et al., 2015b). All these suggest a role of GLP-1R 
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agonist in neurotransmission and potentially play a novel function in motivation, cognition 
and reward behaviours. 
 
Geniposide, a putative GLP-1R agonist action on the CNS 
Geniposide is a water-soluble iridoid glycoside, a major constituent in the fruits of Gardenia 
jasminoides (Gardenia fruits), which is a popular Chinese herb widely used in the traditional 
management of liver disorders, inflammatory disorders, contusions and brain disorders (Chen 
et al., 2010; Wang et al., 2012). More researches have recently developed attention on 
neuroprotective (Lv et al., 2014a), antitumor (Hsu et al., 1997), modulation of DNA 
expression (Gálvez et al., 2005), analgesic (Gong et al., 2014a),  anti-inflammatory, coloretic 
and hepatoprotective effects (Chou et al., 2003; Liu et al., 2010; Ma et al., 2011) of 
geniposide. The drug confers protection on memory impairment and maintenance of 
cognitive responses, exhibited in animal behavioral studies (Gao et al., 2014; Lv et al., 
2014b). Molecular screening via a high throughput for GLP-1 receptor agonists shows that 
geniposide is an agonist for the GLP-1 receptor with Kdof ~6.1"μM (Liu et al., 2006). The 
GLP-1 receptor belongs to the class B family of G protein-coupled receptors (GPCRs GLP-1 
just like insulin and IGF-1 activates second messenger signaling pathways that are commonly 
linked to growth factor signaling (Hölscher, 2014a). Liu et al., (2012) also demonstrated that 
stimulation of GLP-1 receptor by geniposide promotes neurotrophic and neuroprotective 
effect in cells. 
Insulin action in the brain 
Insulin, on the other hand, is an important hormone for controlling peripheral glucose 
homeostasis. The brain is now regarded as insulin-sensitive organ due to abundance presence 
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of both insulin receptors (IRs) and insulin, alongside with series of a cascade of signaling 
processes that are associated with many brain regions (Havrankova et al., 1978). The group 
also described the relative abundance of brain’s insulin, that it is independent of peripheral 
insulin, because plasma insulin levels did not affect the brain’s insulin concentration at any 
time (Havrankova et al., 1979). Also, escalated insulin levels had been reported both in the 
human brain and in many rodents models (Dorn et al., 1983). Meanwhile, the availability of 
huge concentrations of insulin in the brain has become a debatable concept, raising the 
question about its source. Interestingly, the presence of insulin in the cerebrospinal fluid 
(CSF) could not be solely ascribed to its ability to cross the blood-brain barrier (BBB), but 
thought to be partly due to receptor-mediated transport  system for circulating peptides 
(Banks et al., 1997a; Pardridge, 1999). The IRs identified has been linked with important 
physiological activities on the CNS such as, neuronal cell differentiation, glucose 
homeostasis, feeding trends, additive behaviour and body mass control, as well as cognitive 
processes which include memory and learning (Derakhshan and Toth, 2013). However, in 
addition to these metabolic roles of the brain insulin receptor, a recent study further 
demonstrated that insulin resistance in brain induces dopaminergic dysfunction leading to 
anxiety and behavioural disorders (Kleinridders et al., 2015a) this shows a new function for 
insulin signaling in neuronal control. Further study with rodents without brain insulin 
receptor substrate 2 (IRS2), suggests a potential role of IRS2 in the modulation of 
hippocampal synaptic function and plasticity in mice, which could be mediated via the N-
methyl-D-aspartate (NMDA) receptor and the phosphoinositide 3-kinase (PI3K) signalling 
pathway (Costello et al., 2012). This implies that, dysfunctional insulin signalling in the brain 
is one of the major indicators in neurodegenerative and cognitive disorders. Apart from 
regulating neural circuits and involved in maintaining energy homeostasis, insulin also affects 
cognitive functions through its actions on synaptic plasticity and long-term potentiation in the 
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hippocampus and other brain regions responsible for  learning and memory (Stranahan et al., 
2008). More studies also have shown a strong correlation between Alzheimer's disease and 
CNS insulin resistance (Zhao et al., 2008). Alzheimer's disease is a neurodegenerative disease 
leading to progressive decline of memory and cognitive function and is the commonest form 
of dementia, accounting for more than 50% of cases (Querfurth and LaFerla, 2010). Though 
aging is the most leading risk factor, now there is ample evidence that people with glucose 
intolerance, insulin resistance and metabolic syndrome are at higher risk for cognitive 
impairment and dementia compared to age- and gender-realated controls (Arvanitakis et al., 
2004; Whitmer et al., 2008). A meta-analysis and a large-scaled pooled analysis demonstrate 
that diabetes is associated with an approximately 60–70% increased risk of all types of 
dementia (Chatterjee et al., 2016). Therefore, Alzheimer's disease is sometimes referred as 
type 3 diabetes, a brain specific impairment of insulin signaling (de la Monte and Wands, 
2008). Multifactorial pathogeneses that can be linked to brain insulin signaling defects, such 
as oxidative stress due to hyperglycemic toxicity, chronic inflammatory processes, 
mitochondrial dysfunction, abnormal cholesterol metabolism, adverse vascular changes and 
severe hypoglycemia are thought to trigger the development of dementia in people with 
metabolic disturbances (Blázquez et al., 2014).  
` Diet alteration may also play an important part in the development of insulin 
resistance in the brain. Indeed, diet-induced changes such as, high liquid sugar and high fat 
diet in the peripheral insulin sensitivity has been shown to contribute to alterations in brain 
signalling and cognitive fuctions (Kothari et al., 2017). In hamsters, a diet high in fructose 
induces peripheral as well as neural insulin resistance, as evidenced by decreased insulin-
mediated IR, IRS1, and Akt phosphorylation and elevated protein-tyrosine phosphatase 1B 
(PTP1B) expression in the cerebral cortex and hippocampus (Mielke et al., 2005).  
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This in turns potentially led to cognitive impairment due to insulin resistance. In recent time 
the potential impact of diets rich in free sugar such as sucrose has been found to be associated 
with excess energy intake rather than having a direct detrimental effect on metabolism in 
human (Macdonald, 2016a). Insulin dysfunction such as insulin resistance or low production 
has also been investigated to cause a long-term depression, a functional measure of synaptic 
plasticity, suggesting that brain insulin resistance may contribute to cognitive 
impairment (Mielke et al., 2005). High fat feeding of rats also impaired neuronal insulin 
signaling and long-term depression in the CA1 region of the hippocampus (Pratchayasakul et 
al., 2011). Furthermore, insulin treatment rescued impaired hippocampal neuron proliferation 
in mice with experimental diabetes Taken together, insulin's action in the CNS is crucial in 
maintaining cognitive function in animals (Ho et al., 2012). 
Metabolic drug effect on the CNS 
In addition to gut peptides, this Ph.D. research also investigates metabolic agents such 
as sulphonylureas, a prototype of which is tolbutamide. These are molecules primarily 
responsible for controlling blood sugar levels. Tolbutamide is a first generation sulfonylurea, 
an oral-hypoglycemic agent used in the management of type-2 diabetes (Rennie and 
Anderson, 1963). It stimulates insulin secretion by binding to a high-affinity subunit (SUR1) 
of the beta-cell potassium-sensitive ATP channel (K channel). Binding results in blocking of 
K+ efflux through the Kir6.2 channel, depolarization of the beta cell, the opening of voltage-
sensitive Ca++ channels, an influx of Ca++, and insulin secretion (Bryan and Aguilar-Bryan, 
1999). However, recent evidence has demonstrated a possible CNS and neuronal effect of 
this agent, which may influence cognition and neurotransmission, through K+ sensitive ATP 
modulation, particularly on K6.2 channel. It is widely accepted that an opening of KATP 
channels causes hyperpolarization of the cell membrane by increasing the K+-conductance 
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and the K+-efflux (Roeper et al., 1990). On the other hand, blockade of these channels 
decreases K+-conductance and K+-efflux causing depolarization of the cell with a consecutive 
increase of cytosolic Ca2+and secretion of hormones or transmitter substances (Schmid-
Antomarchi et al., 1990). Furthermore, a previous investigation shows that KATP channel 
blockade with the sulfonylurea derivative glibenclamide provided robust protection to 
dopamine neurons undergoing spontaneous and selective degeneration in midbrain cultures 
(Toulorge et al., 2010).  Thus, in the presence of diazoxide, a KATP channels opener, the 
signalling process is reversed as the propagation of action potential initiation is shut down 
resulting in inhibition of insulin secretion. Also, some studies have shown the important 
modulatory effect of the channels on the excitability of substantia nigra neurons (Peltier and 
Vecchio, 1961; Röper and Ashcroft, 1995; Schiemann et al., 2012a) and dopaminergic 
midbrain neurons (Liss et al., 1999). Interestingly, Liss et al., (1999) further revealed that 
dopaminergic substantia nigra (SN) neurons express K-ATP  channels subtypes with different 
sulphonylurea-sensitive receptors. These channels are configured in pore-forming subunits 
namely, Kir6.1 and Kir6.2 as well as a sizeable supplementary subunit, the sulfonylurea 
receptor (SUR1, SUR2A, and SUR2B) (Tinker et al., 2018). Thus, the Kir6.0 series is part of 
the inwardly rectifying member of potassium channels (KATP) while; the SUR is part of the 
adenosine triphosphate (ATP)-binding class of proteins. 
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      Objectives 
Gut peptides are primarily considered an important hormone for glucose and lipid 
homeostasis. However, recent studies over the years have shown that insulin and newer 
insulin-releasing antidiabetic agents such as glucagon-like peptide (GLP-1), as well as 
synthetic insulin secretagogue like tolbutamide, may be involved in regulation of dopamine 
transmission, influence addictive behaviour, and also affect cognition, motivation, and  
neuronal survival (Calsolaro and Edison, 2015a; Mansur et al., 2018a). However, most of the 
mechanisms underlying the central effect of these peptides are yet to be completely 
understood. Thus, interaction with dopamine transporters (DAT) (Egecioglu et al., 2013b, 
2013a; Jones et al., 2017), dopamine signalling processes (García-Tornadú et al., 2010; 
Anderberg et al., 2014; Stouffer et al., 2015), glutamatergic AMPA/kainite signaling (Gheni 
et al., 2014; Mietlicki-Baase et al., 2014a; Nampoothiri et al., 2014) as well as mesolimbic 
reward system (Davis et al., 2010; Dickson et al., 2012b; Tiedemann et al., 2017; 
Wakabayashi et al., 2018) have been hypothesized to be associated with the central activity of 
these peptides.  
 Here, using radiometric [DA] release and uptake assays, we will test the in vitro 
activities of insulin, exendin-4, geniposide and tolbutamide on the striatal slices of rats. We 
will also confirm the outcomes of these peptides in the regulation of the in vivo electrical 
activities of ventral tegmental area dopamine neurons and prefrontal cortex pyramidal 
neurons, using single cell extracellular electrophysiology technique. We will also examine 
whether these peptides can alter some dopamine-dependent behaviours such as, D-
Amphetamine-induced motor activity, quinpirole (a dopamine D2/D3 receptor agonist) and 
pramipexole (a dopamine D3 preferred receptor agonist) -induced yawning, pica eating and 
pelvic grooming activities, as well as phencyclidine (an N-Methyl-D-aspartate receptor 
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antagonist)-induced cognitive deficit and motor activation. In another series of behavioural 
experiment, we will test whether GLP-1 can modulate the effect of diet modification in form 
of chronic sucrose intake on body weight, feeding pattern, and depressive phenotype, as well 
as assess the behavioural and electrophysiological impacts of continuous sucrose 
consumption. 
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Chapter I- Behavioural, neurochemical and 
electrophysiological responses following acute 
and repeated administration of dopaminergic 
agonists 
 
I-1- Introduction 
 Psychostimulants acting as indirect non-selective agonists, used in the management of 
ADHD, like d-amphetamine (D-AMP), methamphetamine and methylphenidate, cause, when 
acutely administered, a wide range of behavioural changes (Archer et al., 1988; Leng et al., 
2004). These involve a robust increase in horizontal motor activity accompanied by an 
increase in rearing trait (Russell et al., 1987), the latter reflecting a specific activation of 
dopaminergic neurotransmission (Kozler et al., 2017). On the other hand selective or 
preferential dopamine D2/D3 receptor agonists (like quinpirole (QNP), a dopamine D2 
selective and pramipexole (PPX), a D3 preferred agonist) unveil some specific behaviours 
such as yawning, penile erection (pelvic grooming), hypothermia and pica eating, which are 
either D2 or D3 receptors mediated (Zharkovsky et al., 1993; Ohmura et al., 2011). D-AMP 
and related psychostimulants, exert their action by blocking DA reuptake to enhance DA 
release via competitive interaction with DAT. As a result of stimulating effect on DA 
autoreceptors and negative feedback mechanisms from DA-triggered regions, the increased 
DA release causes an inhibition of midbrain DA neurons’ firing (Bunney et al., 1973; 
Einhorn et al., 1988), through the  of activation of dopamine autoreceptors found on the cell 
bodies of the dopamine neurons (Ford, 2014). Previous studies have provided evidence that 
this DA-mediated response could be altered, after chronic administration with 
psychostimulants and have been implicated to play a principal role in behaviours associated 
with abuse of psychostimulants (Kamata and Rebec, 1983; White and Wang, 1984). Further 
works have shown that firing and burst activity of DA neurons in DA-rich brain region such 
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as the VTA has a direct correlate with behavioural modification during a reward-associated 
experience in humans and animal subjects (Hollerman and Schultz, 1998; Paladini and 
Roeper, 2014). A recent study from our laboratory has also demonstrated that chronic 
methylphenidate treatment during early but not during late adolescence enhanced D-
amphetamine-induced rearing activity, as well as midbrain dopamine cell excitability (firing, 
burst, and population activity). Furthermore, this effect was associated with partial 
desensitization of dopamine D2 auto-receptors (Di Miceli et al., 2019a). On the other hand, 
pramipexole (PPX), a D3 preferring dopamine receptor agonist primarily used in the 
management of Parkinson’s disorder and restless legs syndrome, has been reported to inhibit  
DA neuronal firing in the VTA (Guttman and Jaskolka, 2001; Reichmann et al., 2006; 
Chernoloz et al., 2009a). This drug is clinically used as monotherapy for Parkinson disease 
and has demonstrated antidepressant and antimanic clinical effects (Salawu, 2012). 
Interestingly, the long-term administration of PPX has been reported to desensitize dopamine 
cell bodies D2/D3 autoreceptors, thereby preventing inhibition of the basal firing activity of 
DA neurons in the VTA during its chronic administration (Chernoloz et al., 2009a). On the 
other hand, the effects of an administration (chronic or sub-chronic) of D-AMP on D2 /D3 
autoreceptors have not been clearly characterized. 
The present chapter addresses some vital issues related to the effects of D-
amphetamine on dopamine neurotransmission using different paradigms (neurochemistry, 
electrophysiology, behaviour). It is crucial to this thesis, as it provides the basis as well as the 
template for our other studies on GLP-1 and insulin on brain functions particularly on 
dopamine neurotransmission. We have attempted to identify for the first time, possible 
electrophysiological effects of PPX on dopamine neurons in naïve rats and rats previously 
exposed twice to D-AMP on a week interval. This is to generate new data on DA D2/D3 
sensitivity subsequent to two doses of D-AMP administration. Also, we have studied 
28 
 
behavioural, as well as neurochemical activities of PPX and QNP.  In particular, we have 
assessed radiometric release and uptake processes of dopamine in striatal brain slices and 
synaptosomes respectively.  
I-2-Materials and Methods 
 I-2-A-Subjects 
  Adult male Sprague-Dawley rats were purchased from Charles River, UK. 
Animals were then housed in groups of 4 animals per cage, maintained at 20-22oC with 
humidity rates above 40% under a 12:12 L/D cycle with lights on at 07h00 AM (Ante 
Meridiem). Animals were kept in polypropylene cages measuring 56x38x17 cm. Food and 
water were provided ad libitum. Rats were allowed a 3-day acclimatization period after 
taking the delivery into the animal house. All experiments were performed during the light 
phase and with permission from the UK Home Office and De Montfort University Ethics 
Committee under the Project License 10B9FE34 and with the Personal License 
128F91DAAQ. 
 
I-2-B- Drugs  
  All drugs were purchased from Sigma (Sigma-Aldrich, UK), except for PPX 
in dose of 0.1 mg/kg given intraperitonially (i.p.) (Hellobio, UK), apomorphine hydrochloride 
(i.p.) (Tocris, UK) as well as NGB 2904 and QNP in dose of 0.05 mg/kg (i.p.) (Tocris, UK). 
The drugs were dissolved into Krebs (release assays) and HEPES (uptake assays) buffers, as 
appropriate. The drugs were dissolved in distilled water or saline for studies involving 
behavioural and electrophysiological profiling. 
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I-2-C- In vitro3H-dopamine release assay 
  Male Sprague-Dawley rats were sacrificed by cervical dislocation and the 
brains were then quickly removed and placed on an ice-cold platform for further dissection. 
Tissue from the striatum (Fig. 4) was rapidly dissected out and placed in ice-cold oxygenated 
Krebs buffer(NaCl 125 mM, MgSO4 1.2 mM, KCl 2.5 mM, CaCl2 2.5 mM, KH2PO4 1.2 
mM, NaHCO3 25 mM, glucose 10 mM, pargyline 10 μM -in order to reduce dopamine 
metabolism-, pH 7.4). Slices were then cut into 350×350 μm prisms using a McIlwain tissue 
chopper, washed three times in fresh, oxygenated Krebs buffer and allowed to recover for 30 
min at room temperature. After this stage, all experiments were made under constant 
oxygenation and at 37 °C. Tissue prisms were loaded with 3H-dopamine (1.0 μCi/mL, 
specific activity 30-40 Ci/mmol) for 40 mins, then washed three times with fresh Krebs 
buffer to allow a washout period. Tissue prisms were then separated into 6 even portions, 
each one being loaded into one perfusion chamber. An equilibrating period of 40 mins started 
with superfusions (0.6 ml/min) of either normal (125 mM) or low Na+ (25 mM by 
substitution of equimolar NaCl with Choline Chloride) Krebs buffers passing through all 
perfusion chambers. Four samples (2.4 ml/sample) were collected at 4-min intervals to 
determine basal 3H-dopamine outflow for each. At the end of the experiment, tissue prisms 
were collected and dissolved in 1 ml of tissue solubilizer. All samples were analyzed by 
liquid scintillation spectrometry. Drugs were diluted in the appropriate modified or 
unmodified Krebs medium. In this chapter, brain slices were prepared from the striatal region 
of the brain throughout the study. However, in this chapter, a dopamine agonist, QNP 10µM 
and a powerful dopamine-releasing drug, D-AMP 10µM were investigated to determine their 
capacity to induce tritiated dopamine release on striatal brain slices. 
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Figure 4: Region of interest for in vitro neurotransmitter efflux experiments. 
Striatum location is represented by shaded area which corresponds to regions of interest for in 
vitro neurotransmitter release. Scales represent distances (in mm) from the midline and the 
surface of the brain. Coronal slices adapted from Paxinos and Watson (1997). 
 
 
I-2-D-In vitro3H-dopamine uptake assay 
  A range of male Sprague-Dawley rats weighing 200-350g was used. Animals 
were sacrificed by cervical dislocation and the brains were then quickly removed and placed 
on an ice-cold platform for further dissection. Tissue from the striatum was quickly removed 
and placed in ice cold sucrose homogenization buffer (320 mM sucrose, 5 mM HEPES, pH 
7.4). The tissue is then homogenized (5 strokes) on ice in 5 mls of fresh oxygenated sucrose 
buffer using a Potter-Elvehjem tissue homogenizer. The homogenate was centrifuged at 
1000g for 10 min at 4°C to remove nuclear debris. The supernatant was then centrifuged 
again at 16,000g for 20 min at 4°C. The supernatant was discarded and the pellet was washed 
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twice, by resuspending the pellet in 15 ml ice cold synaptosome uptake buffer (HBSS: 0.137 
M NaCl, 5.4 mMKCl, 0.25 mM Na2HPO4, 10 mM D-glucose, 4.2 mM NaHCO3, 0.44 mM 
KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4 supplemented with 10 μM pargyline (a 
monoamine oxidase B (MAO-B) inhibitor) and 100 mM ascorbic acid, PH 7.4) and 
recentrifuging at 14,000g, 4°C for 20 min. The final pellet is resuspended in 8ml of HBSS. 
This is referred to as synaptosome, subsequently 250µl of synaptosome preparation was 
incubated with either 50µl of HBSS buffer or 50µl of methylphenidate 10µM (dopamine 
uptake inhibitor) or the tested drugs (for 4 minutes in a 370C water bath or at 40C. The uptake 
is initiated by adding 50µl of 3H-Dopamine) in 10 seconds intervals and the specific 
dopamine uptake at different second’s intervals. The incubation is left for 5 minutes and is 
terminated by the addition of 5mls of ice cold HBSS buffer also in 10 seconds intervals 
between each tube. The samples are then immediately filtrated through GF/B Whatman filters 
on a vacuum filtration manifold. The filters were washed twice with HBSS buffer and were 
transferred to scintillation vials. 1ml of filter count was added to each vial and was left 
overnight to dissolve, scintillation liquid is then added and the radioactive counting is 
recorded. The total uptake is measured from the samples containing buffer, whereas the 
unspecific uptake is measured from the samples with methylphenidate. The specific 
dopamine uptake at different concentrations is calculated by subtracting nonspecific binding 
counts from the total count concentrations is calculated by subtracting nonspecific binding 
counts from the total count and expressed as a fractional percentage. 
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Figure 5: Radiometric uptake protocol for control (A) and tested samples (B). 
After the brain was isolated, 250µl of synaptosomes preparation was incubated with either 
50µl of HBSS buffer or 50µl of methylphenidate 10µM (dopamine uptake inhibitor for 
determining nonspecific uptake), and the tested drugs or buffer (50µl) for 4 minutes in a 370C 
water bath or at 40C. The uptake is initiated by adding 50µl of 3H-Dopamine. The total 
reaction mix was 400 µl in each test tube. 
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I-2-E-Behavioural assessments  
  Psychostimulants such as D-AMP are known to alter locomotion (Amini et al., 
2004; Paulus and Geyer, 1991;Fang and Tan, 1998), grooming (Taylor et al., 2010; Wooters 
and Bardo, 2009), scratching (Antoniou et al., 1998; Malin and Goyarzu, 2009), stereotypes 
and rearing activities (Bonasera et al., 2008; Rebec et al., 1997). The consequences of D-
AMP on such behaviours were assessed. Male Sprague-Dawley naïve rats weighing 300 
grams were housed individually at the beginning of the behavioural experiments and allowed 
to acclimatize with the environment for 30 days. All drugs were dissolved into saline. 
Animals received a single intraperitoneal injection of either: 0.8 ml/kg of saline (NaCl 147 
mM) or 1.0 mg/kg D-amphetamine. Animals were then scored for behavioural parameters 
during a 15mins-time period and up to a total of 60 minutes. Counting of well-defined 
behavioural traits such as rearing, scratching, grooming, jumping, running, climbing, 
catalepsy and stereotypical movements were done manually through physical scoring. In 
another series of experiments, we assessed the behavioural parameters induced by dopamine 
agonists such as QNP and PPX. In these experiments, animals received a single 
intraperitoneal injection of either 0.2ml/kg of saline (NaCl 147 mM), 0.1 mg/kg QNP or 0.05 
mg/kg PPX. Animals were then scored for behavioural manifestations during a 15mins period 
and up to a total of 60 minutes. Counting of well-defined activities such as yawning, pelvic 
grooming (an index of penile erection) and pica eating were conducted manually. Further 
experiments on the effect of D2 and D3 receptor antagonists were studied on D-AMP induced 
locomotor activity. While additional groups of animals were exposed to a single 
intraperitoneal D-AMP 1 mg/kg once weekly for 2 weeks; after behavioural experiments, 
animals were evaluated for electrophysiological profiling. 
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I-2-F- In vivo extracellular single-unit electrophysiology 
  Following behavioural experiments, animals were classified based on the 
degree of locomotor activity exhibited. In this study, we adopted a modified categorization of 
motor activity according to Nakamura et al., (2014) as, low-(10-30 counts/15 min), moderate-
(40-99 counts/15 min) and high-(over 100 counts/15 min) activity phenotypes. Two of the 
phenotype group (moderate and high) were subjected to electrophysiological recording in the 
ventral tegmental area. Animals were initially deeply anaesthetized with chlorhydrate secured 
to a stereotaxic frame and maintained at 36–37 °C with a heating pad. A catheter was inserted 
into the lateral tail vein to perform systemic drug administration and an incision was made 
across the top of the head and the edges of the skin drawn back to reveal the cranium. 
Bregma was marked and a hole was drilled through the bone at the coordinates of the ventral 
tegmental area according to the atlas of Paxinos and Watson (1997). Electrodes were 
manufactured in house from borosilicate capillaries (1.5 mm, Harvard Apparatus Ltd., UK) 
pulled on PP-830 electrode puller (Narishige, Japan) and filled by hand with an electrolyte 
solution (NaCl 147 mM). The tip of the electrode was broken down under a microscope to an 
external diameter of 1–1.5 μm. Typical resistance was in the range 4–8 MΩ. Single-unit 
recordings with the tested drugs were applied. Outputs from the electrode were sent to a 
Neurolog AC pre-amplifier and amplifier (Digitimer, UK). Signals were filtered and sent to 
an audio amplifier, a Tektronix 2201 digital storage oscilloscope and a 1401 interface 
connected to a computer running Spike 2 (CED, Cambridge, UK) for data capture and 
analysis. Descent of the electrode was carried out using a hydraulic micromanipulator 
(Narishige). Coordinates for the ventral tegmental area were: anteroposterior -4.5 to -5.5 mm, 
lateral 0.3–1.2 mm, dorsoventral 7.5–9 mm below the cortical surface. Drugs were 
administered i.v. via the lateral tail vein after stable recording. In this chapter, the number of 
putative ventral tegmental area dopamine neurons per track was recorded by recording the 
35 
 
total number of active neurons defined as a neuron firing more than 5 spikes per 10s 
encountered during one electrode descent within the region of interest. Midbrain dopamine 
neurons were identified according to electrophysiological criteria summarised by Ungless and 
Grace, (2012): always a low pitch sound, occasionally a notch in the rising phase, usually a 
prominent negative phase and always a long triphasic action potential (>1.5 ms) with a time 
greater than 1 ms from the start of the depolarization to the end of the repolarisation (mostly 
> 1.5 ms). Only presumed dopaminergic neurons were selected in our study (Chenu et al., 
2013; Grace and Bunney, 1984; Ungless et al., 2004; Valenti et al., 2011). A burst activity in 
such neurons is defined as two spikes occurring at an interval of 80 ms or less, followed by a 
silence period of at least 160 ms (Grace and Bunney, 1984; Overton and Clark, 1997; 
Paladini et al., 2003). By adopting this identification criteria, we may exclude a small 
proportion of dopamine neurons, particularly some PFC-projecting and amygdala-projecting 
midbrain dopamine neurons, which may have slightly different electrophysiological 
characteristics, (though it is still disputed) like a shorter action potential (Chieng et al., 2011; 
Ford et al., 2006; Hnasko et al., 2012; Lammel et al., 2008; Margolis et al., 2006, 2008; 
Marinelli and McCutcheon, 2014; Zhang et al., 2010). However, our strict criteria allow for 
the recording of a rather homogenous population of midbrain dopamine neurons. Coordinates 
for the ventral tegmental area were: anteroposterior -4.5 to -5.5 mm to Bregma, lateral 0.3-1.2 
mm, dorsoventral 7.2-9.5 mm below cortical surface. In another series of electrophysiological 
studies, we assessed the impact of intravenously administered PPX on midbrain dopamine 
firing activity both in naïve group as well as D-AMP pre-exposed group.  
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I-2-G- Data analysis 
  All data are expressed as the mean ± standard error of the mean (S.E.M.). 
Statistical analyses were performed using paired or unpaired Student's t-tests or one/two-way 
analysis of variance (ANOVA), followed by appropriate post-hoc Neuman–Keuls (one-way 
ANOVA) or Bonferroni tests (two-way ANOVA). In radiometric release assays, the mixed 
model two-way ANOVA was used when sampling size varied across groups. Probabilities 
smaller than 0.05 were considered to be significant; n values refer to the number of samples 
used. Fractional efflux for each superfusate sample was calculated by dividing the amount of 
tritium in each sample by the total tritium left thereafter. The effect of a tested condition was 
assessed on at least 3 subsequent sample collections and averaged. Normalized efflux values 
are calculated for each chamber as the ratio between the mean tested values (generally from 
at least 3 collections) and average baseline values (usually 3-4 collections). All of the 
experiments presented were repeated on at least 3 animals.  
In radiometric uptake assays, the total uptake is measured from the samples 
containing buffer, whereas the unspecific uptake is measured from the samples with 
methylphenidate. The specific dopamine uptake at different concentration is calculated by 
subtracting nonspecific binding counts from the total count and expressed as a fractional 
percentage. 
For behavioural experiments, the sum of each behavioural trait occurring during 15 
minute interval periods was plotted against the type of drug administered. Results are 
expressed as the mean±standard error of the mean (SEM) of counts for each trait per group. 
Repeated 2-way ANOVA was also conducted when a significance difference was tested. 
For electrophysiology, the mean basal firing activity was evaluated after the neuron 
had attained a stable firing rate, generally after at least 5 min of recording. Pre-drug values of 
firing rate were obtained by averaging the firing rate over at least 4 min immediately before 
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the intravenous administration while post-drug values were obtained by averaging the firing 
over 5 min following drug administration. Individual change in basal firing activity was 
considered significant following drug (or saline) administration when the post-drug value was 
significantly different from the pre-drug value (determined as indicated above, paired 
Student’s t-test analysis). For pre-treated animals, population activity of the neurons were 
expressed as mean±standard errors and compared within the group. When neurons with very 
low spontaneous activity were recorded (baseline activity below 4 spikes per 10 seconds), a 
change of more than 5 spikes per 10 seconds was considered significant, or if the analysis of 
100 spikes before and after drug administration led to significant unpaired Student’s t-test for 
each neuron tested this way. These two methods of analysis did not differ in the results 
obtained. Proportions of a specific type of response in two different groups of animals were 
also compared using Fisher’s exact test (comparing proportions of responses and no 
response/opposite responses in two groups). All burst results are reported as the % of spikes 
in burst. 
 
I-3-Results 
 I-3-A- D-AMP and QNP differentially induce dopamine efflux 
   Fig. 6A shows the time course of dopamine efflux following the application 
of D-AMP in the superfusion medium, confirming that the drug causes a massive dopamine 
release. When applied at the same concentration to the prism chamber, it induced a 
significant increase (t=5.538 df=10) in dopamine efflux (Fig. 6B). As could be expected QNP 
10 μM elicited a significant (t=2.023 df=14) slight reduction in dopamine efflux on the 
striatal slices (50% below baseline, Fig. 6C).  
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Figure 6: Dopaminergic drugs effect on striatal 3H-dopamine release. 
(A): Typical time course profile from an individual experiment showing 3H-dopamine release 
from striatal slices before, during and after exposure to 10 µM D-AMP. Data shows the 
average fractional efflux from 3 perfusion chambers over time. (B): Superfusion of D-AMP 
(10 µM) significantly induced dopamine efflux (C): Effect of quinpirole (QNP, 10 µM), a 
D2/D3 receptor agonist on baseline dopamine efflux, showing a significant reduction from the 
baseline. In this and the following figures, n values indicate the number of tissue samples 
which have been tested (from which an average fractional efflux is calculated from 3-4 
subsequent collections). *P<0.05, ***P<0.0001 vs. baseline, paired Student’s t-test. 
  
 
 
I-3-B- Dopamine agonists PPX and QNP increased DA uptake 
  Uptake process is sensitive to certain conditions such as temperature and time 
of incubation. We tested the impact of pramipexole (PPX, 10µM, and 100µM), a D3 preferred 
dopamine agonist and quinpirole (QNP, 125 nM and 1µM) a D2 preferred dopamine agonist 
on 3H-dopamine uptake a measure of dopamine transporter (DAT) activity. The time of 
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incubation of the reaction mix on the synaptosome was kept constant at 5 mins in all tubes. 
PPX (10µM) did not show any effect on 3H-dopamine uptake (Fig. 7A). However, at a higher 
dose of 100 µM, 3H-dopamine uptake was increased significantly (20% increase over the 
control, Fig. 7B), Student’s t-test **p<0.05 vs control (t=4.367 df=10). When tested at both 
concentrations of 10µM and 100 µM, a dose dependent-significant F (5, 5) =5.180   increase 
in DA uptake was observed. This represents an enhanced activity of DAT in the presence of 
PPX. (***p<0.001, Neuman-Keuls test after ANOVA, Fig. 7C). Conversely, QNP, at lower 
concentration (125 nM) caused a significant increase (t=3.131 df=21) in 3H-dopamine uptake 
(Fig. 8A), while at higher concentration of 1µM; QNP did not show any impact on 3H-
dopamine uptake (Fig. 8B). Both doses were tested under the same condition and the 
difference did not show any dose-response relationship. QNP 125nM in this condition still 
exhibits significant increase (30% increase over control, Fig. 8C). The DAT activity is said to 
be optimum at a dose of 125 nM (***p<0.001, Dunnett Multiple Comparison Test after 
ANOVA). 
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Figure 7: Effect of pramipexole (PPX) on 3H-dopamine uptake activity in synaptosomes 
(A): Incubation of PPX 10 µM shows no effect on the DA uptake activity. (B): PPX at 100 
µM significantly increased DA uptake activity. **P<0.05 vs baseline Student’s test (C): 
Dose- dependent effect of PPX on the striatal synaptosome PPX 100 µM, ***P<0.001 vs 
PPX 10 µM and vs control; Newman-Keuls post hoc tests, after significant one way ANOVA. 
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Figure 8: Effect of quinpirole on 3H-dopamine uptake activity on striatal synaptosomes 
(A): Incubation of QNP 125 nM exhibited a significant increase in DA uptake activity; 
**P<0.005 vs. baseline, Student’s t-test. (B): QNP at 1 µM did not show an effect on DA 
uptake activity. (C): QNP did not show a dose-dependent relationship when both doses were 
tested. ns: not significant, *P<0.05, ***P<0.0001 vs. specific conditions, Newman-Keuls post 
hoc tests, after significant one-way ANOVA. 
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I-3-C- Acute psychostimulant and dopamine agonists’ administration exhibited varied 
behavioural effects 
  I-3-C1- Acute D-AMP administration augments motor activity 
   Behavioural characteristics such as rearing, upright scrambling and 
climbing were assessed in a single-housed cage of dimension 600 cm x453 cm during 60 
minutes after a single D-amphetamine of 1 mg/kg or 3mg. The initial basal activities of the 
rats were assessed by administering distilled water. Then, scoring began after 5 mins of the 
administration of D-AMP. D-AMP-induced hyperactivity in the form of rearing, upright 
scrambling, and climbing activity have been identified as DA-dependent behaviour 
(Avdelidis and Spyraki, 1986). For the purpose of this thesis, we sum up these three traits as a 
single type of motor activity for statistical analysis. We assessed a dose-response relationship 
between the two concentrations, compared with the baseline locomotor activity of the rats. 
We tested 1mg/kg of D-AMP which produced a relatively moderate increase in locomotor 
activity. Then, at a dose of 3 mg/kg, D-AMP strongly increased the frequency of all the 
behavioural traits by 15000% over the baseline and 100% over the initial dose. Both doses 
(D-AMP 1mg/kg or 3 mg/kg) show a significant increase F (6, 35) =0.21 in locomotor 
activity from the baseline.   
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Figure 9: Dose-response relationship of acute D-AMP on motor activity 
In this experiment, the 3 behavioural characteristics (rearing, upright scrambling, and 
climbing) were combined and analysed during the first 60 minutes following intraperitoneal 
drug exposure. Exposure to D-AMP (1 mg/kg), significantly increased the cumulative 
number of behavioural events during the entire observation period, D-AMP 3mg/kg strongly 
increased the number of motor events throughout the recording period. There were significant 
differences at 15 and 60 mins between 1 and 3 mg/ kg D-AMP treated groups.*p<0.05, 
**p<0.001 vs. vehicle,  Bonferroni test after significant repeated measures two-way ANOVA. 
 
   
I-3-C2- Single D-AMP administration at an interval of a week induces 
escalated motor activity and phenotypic behaviours 
   For this thesis, we used D-AMP 1 mg/kg throughout, a dose that is 
sufficient enough to induce motor activity in rats. Motor activity was scored by counting the 
number of rearing and upright scrambling activities according to  (Avdelidis and Spyraki, 
1986). We then study behavioural activity at two different stages within an interval of a 
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week. This is done to evaluate alterations in motor activity and sensitivity, when there is an 
initial exposure to the drug. There was a significant increase F (3, 56) =0.63 in motor activity 
after the 2nd challenge with D-AMP 1 mg/kg (242% above the 1st challenge, Fig. 10A). 
Next, we studied certain phenotypic idiosyncrasies in motor activity. Out of 24 animals tested 
with D-AMP 1 mg/kg acute single dose, 4 showed extremely low motor activity phenotype, 3 
exhibited moderate motor activity phenotype and 4 displayed high motor activity phenotype. 
In fig, 10B, we later studied the electrophysiological responses of these phenotypes, in 
relation to VTA DA neurons firing activity. There were significant F (6, 36) =0.89 changes in 
motor activity within the phenotypic groups. 
 
 
 
Figure 10: D-AMP induces behavioural phenotype and increases motor activity in pre-
treated rats 
(A): Rats acutely pre-exposed to D-AMP (1 mg/kg), significantly increased rearing activity 
during the entire observation period following the 2nd challenge over the 1st challenge, 
**P<0.001 vs. 1st challenge at all time. Bonferroni after significant repeated measures two-
way ANOVA. (B): Rats treated with D-AMP (1 mg/kg) that showed high motor activity 
phenotype exhibited a significant increase in rearing activity particularly during the 15-30 
mins and during the last 15 mins observation periods, compared to low and moderate motor 
activity phenotypes. *P<0.05, vs. low and moderate motor activity groups; ***P<0.0001 vs. 
low and moderate motor activity groups (45-60 mins period) and vs. low motor activity 
throughout the 60 mins duration. Bonferroni after significant repeated measures two-way 
ANOVA.  
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I-3-C3- D-AMP-induced motor activity inhibited by D2 receptor antagonist and 
partially affected by D3 receptor antagonist 
  
  In this experiment, we investigated the role of D2/D3 receptors signalling in D-
AMP induced locomotor activity. Here, we tested the impact of selective D2 receptor 
antagonist eticlopride 50 µg/kg on dopamine-mediated motor activity. Intraperitoneal pre-
treatment with eticlopride 50 µg/kg applied 15mins earlier before D-AMP 1mg/kg (i.p). 
There was complete significant inhibition F (3, 8) =0.35 of locomotor activity accompanied 
by stereotypic manifestation such as frozen behaviour. This indicates that eticlopride can 
modulate the effect D-AMP-induced motor activity (Fig.11A). In converse, we tested 
selective D3 receptor antagonist NGB 2904 1 mg/kg. There was no effect on locomotor 
activity, although the animals became restless and exhibited moderate to high rearing activity 
like for the D-AMP treated control (Fig. 11B). The controls are done at the same time as the 
treated (cage by cage) and also 3 treated rats done at the same time as 3 controls.  
   
 
    
Figure 11: Effect of D2/D3 receptor antagonist on D-AMP induced motor activity 
In (A) following 15mins pre-treatment with 50 µg/kg eticlopride, a D2 selective antagonist, 
there was significant complete inhibition of motor activity during the 60 mins observation. 
***P<0.0001 vs. D-AMP control throughout the 60 mins observation. Bonferroni tests after 
significant repeated measures two-way ANOVA. (B) However, the selective D3 antagonist 
NGB 2904 1 mg/kg, did not have significant effect on D-AMP induced motor activity P>0.05 
vs. DAMP control. 
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I-3-C4- pramipexole and quinpirole differentially induce yawning, pica eating and 
pelvic grooming effects 
  In these experiments, we studied 3 classical behavioural characteristics 
exhibited by PPX and QNP. The well-defined behaviours are yawning, pelvic grooming 
which is an index of penile erection and pica eating. These traits are to some degree 
dependent on selectivity on D2/D3 dopamine receptors (Andersson, 2001; Collins et al., 
2005a). Dose-response relationship of PPX on yawning activity was determined with PPX 
0.05, 0.1 and 0.15 mg/kg (Fig. 12A) following an i.p. administration over 60 mins 
observation. PPX at a dose of 0.05 mg/kg shows the highest yawning activity. This dose 
forms the basis in determining optimum yawning concentration for subsequent studies in the 
thesis. We subsequently accessed the responses to other behavioural traits (pelvic grooming 
and pica eating, Fig. 12B) at 0.05mg/kg. 
 Dose-response relationship with QNP at 0.1 and 0.05 mg/kg on yawning activity was 
determined. The dose at 0.1 mg/kg exhibited a more pronounced yawning effect than 0.05 
mg/kg (Fig. 12C). The two other behavioural characteristics (pelvic grooming and pica 
eating) were also determined at this dose (Fig. 12D) 
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Figure 12: Effect of D2/D3 receptor agonists on yawning, pelvic grooming and pica 
eating behavioural traits 
(A): PPX at a dose of 0.05 mg/kg exhibited a significant increase in yawning activity over 0.1 
mg/kg and more significant yawning activity at 30 mins and 45 mins observation period. 
##P<0.001, *P<0.05 vs. 0.1 mg/kg PPX. Bonferroni tests after significant repeated measures 
two-way ANOVA (B): PPX at an optimum dose (0.05 mg/kg) elicits more significant 
yawning activity than all the 2 behavioural traits; pelvic grooming and pica eating, 
throughout the 60mins observation time.  ###P<0.0001 vs. each trait. Bonferroni tests after 
significant repeated measures two-way ANOVA (C): Conversely, in QNP dose-response 0.1 
mg/kg QNP i.p administration exhibited a significant increase in yawning than 0.05 mg/kg 
for all time ***P<0.0001 vs. 0.1 mg/kg PPX (D): Yawning effect with QNP pooled 
controlled was more significantly pronounced than other behavioural effects, ###P<0.0001 
vs. pelvic grooming and pica eating. Bonferroni tests after significant repeated measures two-
way ANOVA. 
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I-3-D1–Rats exposed to repeated intermittent administration of DAMP induces 
desensitization of midbrain DA neurons to PPX   
 Fig. 13A illustrates the electrophysiological characteristics of a typical VTA DA 
neuron while fig. 13B displays an area of the VTA where our electrodes were placed. In this 
experiment, two groups of animals (n=9) were used. Each group either received 1 mg/kg D-
AMP (ip.) or corresponding vehicle, once a week in a total of 2 weeks. In other words, the 
treated rats received D-AMP challenge twice with one-week interval. We then investigated 
the effect of D-AMP challenge treatment on the ability of the preferential dopamine D3 
receptor agonist PPX (cumulative doses 20-100 µg/kg, iv.) to alter the firing activity of VTA 
dopamine neurons (to test dopamine autoreceptor sensitivity). First, we tested this effect on 
the naïve rats. The naïve rats displayed a complete inhibition/sensitivity to PPX at the 4 th 
dose administered causing a decrease in firing activity followed by decrease in burst activity 
(not shown). The firing rate was reversed by eticlopride 0.2 mg/kg to initial baseline firing 
(Fig. 13C, D). However, few cells (about 22%) displayed moderate desensitization effect to 
PPX in naïve rats. Conversely, in D-AMP challenged rats the mid-brain DA neurons 
exhibited a significant dose-response desensitization of D2 autoreceptor to PPX (Fig.13 C, E). 
There is a statistical significant difference F (3, 28) =9.92 within the group. In the same 
manner, desensitized neurons were reversed by eticlopride 0.2 mg/kg to initial baseline firing 
with decreased firing and burst activities (up to 96% reduction). We also observed that in 
about 60% of the neurons, apomorphine a D1/D2 receptor agonist exhibited desensitization to 
that population of cells and only a population of 20% of the neurons increased the firing rate 
after apomorphine administration.  
49 
 
 
Figure 13:  VTA DA neurons’ responses to pramipexole administration on 
autoreceptors sensitivity 
(A): Electrophysiological criteria of VTA DA neurons, showing burst train and shape of the 
neuron (B): Histological illustration of electrode placement in VTA DA neuron recording 
(C): D-AMP treated rats exhibited significant desensitization of VTA DA autoreceptors to 
PPX when compared to naïve rats. Two-way ANOVA (###P<0.0001). (D): In control naïve 
rats, the VTA DA neurons exhibited a complete inhibition to PPX acute dose. The cell was 
reactivated by eticlopride 0.2mg /kg to its original firing rate. (E): D-AMP treated rats 
showed pronounced desensitization in firing to PPX acute administration. 
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I-3-D2– D-AMP-induced behavioural phenotypic variability correlates with 
electrophysiological studies  
  Data from (Fig. 10B) on behavioural phenotypes induced by D-AMP 1mg/kg 
were subjected to electrophysiological study. Briefly, after 1mg/kg D-AMP administration in 
a single dose/week for 2 weeks, the animals were grouped into major two phenotypes, low 
motor activity and high motor activity. The classification was based on the degree of 
behavioural traits (climbing, rearing, and upright scrambling) exhibited by each group. The 
population activity was then assessed. We observed a slight but significant difference 
between the two phenotypes, the rats that exhibited high motor activity showed VTA neurons 
with increased firing activity, than the rats classified as low motor activity (Fig. 14). 
However, the population size needs to be increased for more reliable statistics. 
 
 
Figure 14: D-AMP-induced behavioural phenotypes correlates electrophysiological 
outcome. 
There exists between the low motor activity and high motor activity rats, a slightly significant 
difference in VTA DA firing activity. *P=0.056, Student’s t-test. 
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I-4-Discussion 
In this study, we have confirmed the capacity of dopamine-releasing drugs to 
differentially modulate dopamine transmission. While D-AMP 10 µM significantly increased 
3[H] dopamine efflux, QNP 10 µM molecularly lowered the release. We also observed 
increases in basal 3[H] uptake induced by QNP and PPX in striatal synaptosome preparations. 
In behavioural experiments, 50µg/kg eticlopride completely blocked D-AMP-induced motor 
activity.  A slight correlation was noticed between DA neurons firing activity in the VTA and 
behavioural phenoytypes of motor activity according to the adopted classification. Though, 
this must be confirmed on a larger population of neurons In parallel to an increased motor 
response to D-AMP following a second challenge with this drug, we observed a notable 
desensitisation of the D2/3 dopamine autoreceptor PPX.  The above findings indicate an 
interesting interaction between the dopamine transporter and D2/D3 receptors at the level of 
the dopamine terminals. 
D-AMP is a powerful dopamine-releasing agent in the striatum when given at the 
lowest concentration of 10 µM (Fig. 6A). This concentration is found to be equivalent to the 
therapeutic dose range (0.5-2 mg/kg) in the clinical management of ADHD (Wallace, 2012). 
D-AMP exhibits its powerful dopamine releasing effect by competitively displacing 
dopamine at the dopamine transporter site, prevents DA uptake and blocks vesicular 
monoamine transporter 2 (VMAT2), that is essential for DA reuptake from the cytosol back 
into the synaptic vesicles (Schwartz et al., 2006; Partilla et al., 2006). The inhibitory action of 
D-AMP on DAT causes a spontaneous dopamine release from the neuron by making the 
transporter to reverse it action for more dopamine output (Brown, 2000; Nickell et al., 2014). 
In addition to homeostatic regulation of vesicular release of dopamine via VMAT 2 
(Mundorf et al., 2000), one crucial regulator of DA signaling is the DA transporter (DAT), 
which swiftly transfers extracellular DA into intracellular content for either vesicular 
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storing or releases of DA through reversal of DAT-mediated transport (Jaber et al., 1997; 
Sitte et al., 1998). More recent preclinical studies have demonstrated that repeated exposure 
to D-AMP for 6 days can induce damage to nerve terminals of DA neurons and alters 
dopaminergic responsiveness (Schrantee et al., 2017), which could be detected by 
pharmacological magnetic resonance imaging (Schrantee et al., 2017). Interestingly, repeated 
D-AMP administration at both toxic dose and lower dose as that used in the management of 
ADHD, potentially cause a long-lasting decrease in striatal dopamine and 
dihydroxyphenylacetic acid (DOPAC); a major metabolite (McCann and Ricaurte, 2004; 
Ricaurte et al., 2005). Apart from DOPAC, two other active metabolites of D-AMP namely, 
4-hydroamphetamine and methyl-p-tyrosine, do accumulate in the brain cells after both acute 
and chronic D-AMP administrations (Cho et al., 1975; Dougan et al., 1986). Besides 
lowering of dopaminergic presynaptic markers, repeated intermittent administration of D-
AMP can cause an escalated DA output (Boileau et al., 2006), which is hypothesized to be 
enhanced by increased DA release and/or reductions in DA reuptake and metabolism (Pierce 
and Kalivas, 1997). Altogether, the disturbances in the brain monoamine homeostasis impel 
hypersensitivity to later drug administration (Smith et al., 2016), which may potentially 
enhance locomotor activity (Antoniou et al., 1998; Kameda et al., 2013) and stereotyped 
behaviour in rats (Feier et al., 2012). We found from this study that D-AMP superfused at a 
concentration of 10 µM on striatal slices significantly increased dopamine release over the 
baseline (Fig. 6B), an investigation consistent with previous studies by Kantor et al., 1999, 
(2002).  
Conversely, quinpirole, a dopamine D2/D3 receptor agonist caused a significant 
decrease in dopamine release compared to the baseline when superfused at a concentration of 
10 µM in striatal brain slices (Fig. 6C). There is substantiated evidence that dopamine D2 
receptor stimulation controls presynaptic dopamine release (Zetterström et al., 1986; Schmitz 
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et al., 2001). These data are consistent with studies that demonstrated that selective D3 
receptor agonist PPX and QNP D2/D3 increase vesicular dopamine uptake (Truong et al., 
2003). Our data is also in line with previous studies that showed that both QNP and PPX 
enhance dopamine uptake and promote eventual redistribution of intracellular dopamine, an 
effect that is reversible and linked with the homeostasis of VMAT2 within the axonal 
terminals (Brown et al., 2001).  
It is also noteworthy, that presynaptic dopamine D2/D3 autoreceptors are involved in 
the regulation of dopamine uptake processes. The dopamine agonists (QNP and PPX), 
according to our data, cause the activation of dopamine D2/D3 mediated uptake and may be 
involved in the homeostasis of membrane DAT into different sub compartmentalized regions 
in the brain. Clinically, this data is of relevance in the pharmacologic management of 
Parkinson disease.  In this condition, dopamine receptor agonists are used to treat symptoms 
emanating from Parkinson disorder. Moreover, the neuroprotective ability is potentially 
possessed by these molecules (Motyl et al., 2018; Tozzi et al., 2018; Wang et al., 2018). PPX, 
for instance, protects the basal ganglia of the brain against loss of nigrostriatal dopamine 
neurons, associated with dopaminergic degeneration in Parkinson disease mouse model (Hall 
et al., 1996; Motyl et al., 2018). We then hypothesize that neuroprotective effect possessed by 
these agents is partially due to dopamine D2/D3 receptor-modulated reorganization of 
vesicles, leading to enhancement in cytoplasmic DA segregation and thereby causing less DA 
to be released for oxidative stress that would have produced lethal neurotoxic radicals; an 
hallmark of Parkinson disease (Fleckenstein and Hanson, 2003; Kita et al., 2003). 
From behavioural point of view, D-AMP at low doses has a calming effect in ADHD 
patients and is a drug of choice that is frequently prescribed in such disorder (Castells et al., 
2018). The increased motor activity exhibited in rodents (Fig. 9A) by this low dose (1-2 
mg/kg) has been attributed to resulting from a behavioural manifestation of enhanced DA 
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activity in the mesolimbic dopamine pathway (Zetterström et al., 1983). However, at high 
dose (Fig. 9A) DAMP (>3 mg/kg) enhanced locomotor activity was observed with additional 
well-defined behavioural manifestations in the form of stereotyped and frozen behaviours. 
There is evidence that hyperactivity caused by D-AMP is fundamentally mediated through 
the reward pathway (ventral tegmental area, nucleus accumbens, and olfactory tubercle), 
while stereotypic manifestations are essentially through the nigrostriatal pathway (Creese and 
Iversen, 1974; Faraone, 2018; Asser and Taba, 2015). D-AMP together with other drugs of 
abuse has both short-term and long-term effects on the brain activity, and sensitization to the 
drug is consequential to dependence in form of behavioural adaptation (Robinson and 
Berridge, 2000). Sensitization to the drug in form of behavioural manifestation can be termed 
as an increase in behavioural reaction triggered by a challenge administration of a drug after 
repeated dosing (Chinen et al., 2006; Robinson and Berridge, 1993; Robinson and Becker, 
1986a). In this study, before the initial single acute treatment of D-AMP 1 mg/kg, we then 
challenged with the same dose after a week. The significant change in locomotor activity 
could be related to neuroadaptation that underlays sensitization to the locomotor-stimulant 
action of D-AMP in rats (Robinson and Berridge, 2001). This further underscores the 
physiological process of drug dependence, drug-seeking and craving manifestation in the 
higher primate. (Solinas et al., 2008). This event has been evinced for most of the molecules 
that elicit abuse tendency particularly, the psychostimulants (Fukushiro and Frussa-Filho, 
2011). The process of D-AMP-induced sensitization in rats has two main stages namely: the 
induction stage and manifestation stage. While the first stage is exhibited subsequent to 
rodents’ responsiveness to initial exposure to the drug, the manifestation stage is 
characterized by unusual escalated responses when the subject is challenged by the drug, 
administered in the same dose (Kalivas and Weber, 1988). Studies have shown that these two 
stages stimulate different brain regions. While the induction stage sensitization is linked with 
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ventral tegmental area stimulation, the manifestation stage is connected to nucleus accumbens 
stimulation (Cador et al., 1995; Perugini and Vezina, 1994; Vezina and Stewart, 1990). In 
another study, Paulson and Robinson, (1991) described that a repeated administration of D-
AMP directly administered into the nucleus accumbens resulted in locomotor agitation in 
rodents that are initially pre-exposed to intravenous administration of D-AMP. Similarly, 
repeated administration of D-AMP directly into the VTA resulted in increased hyper motor 
activity triggered by a challenge intravenous administration of D-AMP in rodents (Kalivas 
and Weber, 1988). In succinct, we can hypothesize that significant increase exhibited by the 
second challenge with D-AMP (Fig. 10A) is associated with activation of the cortico-limbic 
system, with initial propagation from the VTA to nucleus accumbens.  
 In Fig. 10B, we observed three well-defined behavioural phenotypes classified by 
Nakamura et al., (2014) with little modification. These are Low-(10-30 counts/15 min), 
moderate-(40-99 counts/15 min) and high-(over 100 counts/15 min) activity phenotypes 
according to the level of degree of locomotor activity. Adopting the same D-AMP dose of 1 
mg/kg single acute intraperitoneal injection, preliminary data from our laboratory showed 
possible behavioural correlate in response to phenotypes with dopamine electrical activity in 
the mid-brain region. Numerous studies have established dopamine as a principal 
neurotransmitter modulating motivated responses such as reward and motor activity 
(Carlsson, 2001). Thus, DAT plays a fundamental role in dopamine homeostasis 
(Gainetdinov and Caron, 2003). However, we cannot eliminate the role of other transporters 
such as, serotonin transporter (SERT) and norepinephrine transporter (NET) in maintaining 
DA balance; all being a family member of  Na+/Cl−-dependent transporters (Torres and 
Amara, 2007). Gainetdinov and Caron, (2003) also reported that transgenic mice devoid of 
DAT (DAT knockout mice) exhibited an increase in motor activity, due to enormous synaptic 
dopamine level leading to multiple behavioural anomalies associated with cognitive 
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impairment. In addition, blockade of NET may be responsible for DAMP increase activity in 
DAT KO mice. This indicates that other mechanisms may also be involved, such as blockade 
of NET. Since our studies were not carried out on transgenic mice, we can infer from the 
foregoing that even in the wild type rats, the genetic variability of DAT is responsible for 
varied behavioural phenotype responses to D-AMP. 
 Next, we investigated the functional role of dopamine D2 and D3 receptors dynamic in 
D-AMP induced locomotor activity. Dopamine D2 receptors are reported to regulate DA 
transporter (DAT) activity, and mediate some behavioural effects of D-AMP (Sevak et al., 
2007). A study by (Ralph et al., 1999) initially gathered that D2 receptors modulation was 
mainly responsible for D-AMP-induced pre-pulse inhibition, in that, mice devoid of D2 
receptors exhibited less sensitivity to this trait. Further studies to corroborate these findings 
demonstrated that inhibition of D2 receptors by a dopamine antagonist raclopride 
significantly reduced D-AMP triggered hyper locomotor activity (van den Boss et al., 1988). 
In Fig. 8A, B, and C, we have also demonstrated the effect of QNP a D2 receptor agonist on 
the regulation of DAT via increased speed of dopamine uptake in synaptosome. Our finding 
is consistent with Meiergerd et al., (1993)  study on activation of D2 receptors that resulted in 
enhanced DA uptake in vitro and in vivo kinetic evaluations. In Fig. 11A, we have 
demonstrated an effect of eticlopride, a dopamine D2 receptor antagonist on D-AMP-induced 
locomotor activity. There was a complete shutdown of motor activity when compared to D-
AMP treated control. Our study is unequivocally consistent with all the findings enumerated 
earlier. However, more recently, attention is given to the role of dopamine D3 receptors 
subtype in the modulation of D-AMP induced a locomotor response. This was investigated in 
Fig. 11B, by testing with selective dopamine D3 antagonist NGB 2904 and the response 
showed no apparent significant change on the D-AMP treated control. Previous studies have 
shown that dopamine D3 receptors play a vital function in the modulation of animals 
57 
 
locomotor behaviour, as a result, this dopamine subtype has been suggested as a therapeutic 
target for schizophrenia (Richtand et al., 2001), Parkinson disorder (Bézard et al., 2003), 
mania (Ashok et al., 2017) as well as management of addiction (Pritchard et al., 2007). In 
view of this background, more clarity is sought to unravel the behavioural dynamic of 
dopamine D3 receptor activation and inhibition. More proof demonstrates that D3 receptors 
activation plays an antagonistic function in motor response to D-AMP, potentially via 
inhibitory effect to D1 receptor-modulated signal transduction (Xu, 1998; Zhang et al., 2004). 
However, there exists a conflict of findings between in vitro D3 receptor screening and in 
vivo behavioural studies. Early works on  selective D3 antagonists such as, U99194A (14>30-
fold selective D3 vs. D2) (Clifford and Waddington, 1998; Waters et al., 1994), nafadotride 
(9>10-fold selectivity) (Audinot et al., 1998; Sautel et al., 1995) and PD 152255 (45>fold 
selectivity) (Corbin et al., 1998) have generally shown to facilitate increase motor activity in 
rodents. Broadly, these molecules enhance rat’s motor activity at reduced doses and 
antagonize motor activity at much larger strength. Hence, a biphasic action thought to be due 
to antagonism on dopamine D3 receptors subtype with the reduced dose, while activation of 
D2 receptors, at a much larger dose (Levant and Vansell, 1997). Selective D3 blockers have 
also been shown to increase D-AMP-induced motor activity (Waters et al., 1993) and 
behavioural sensitivity to cocaine (Waters et al., 1993) at reduced doses. Further studies have 
been demonstrated on dopamine D3 phenotype receptor variant of mice, in which few (Xu et 
al., 1997), except (Betancur et al., 2001) family demonstrated that  DA D3 mutant rodents are 
extremely active in a new environment. Hence, there are conflicting findings on the 
selectivity properties of the D3 receptor antagonist family. Our aim in this study was to 
compare the behavioural response of selective D3 blocker with D2 receptor antagonist. We 
have observed that while dopamine D2 antagonist eticlopride completely blocked the motor 
response, NGB 2904 a selective DA D3 antagonist, augments the motor activity (Fig. 11B). 
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These findings support previous evidence on the modulatory impacts of dopamine D2/D3 
effect on D-AMP-induced locomotor activity (Lapin and Rogawski, 1995; Calipari et al., 
2014a). 
 Similarly, behavioural evaluation of dopamine D2/D3 receptor agonist was compared 
to selective DA D3 agonist. Classically, apart from motor activity D2/D3 agonists are known to 
influence diversified heterogeneous behavioural responses such as, pelvic grooming (Yamada 
et al., 1986), which is a measure of penile erection  hypothermia (Faunt and Crocker, 1987) 
and pica eating (Takeda et al., 1993a). Here, we determine the dose-response relationship 
between the classes of dopamine agonists being studied. The responses of interest in this 
study are yawning, pelvic grooming and pica eating behavioural traits; all mediated by either 
dopamine D2 or D3 stimulation. PPX at 0.05 mg/kg exhibited more efficacious responses for 
behavioural traits than higher doses (Fig. 12A). Our study is consistent with previous findings 
that reported that D3-preffering agonists stimulate yawning activity at much lower doses 
(Collins et al., 2007). However, at higher dose of PPX, yawning is inhibited. This is 
hypothesized to be due to competing D2 agonist activity as the dose becomes larger (Collins 
et al., 2005b). QNP is a non-selective dopamine D2/D3 receptor agonist that exhibited more 
behavioural traits at a much higher dose of 0.1 mg/kg (Fig.12C). However, even at this dose, 
the AUC of PPX at 0.05 mg/kg was 264 events while QNP 0.1 mg/kg exhibited an AUC of 
168 events. Apparently, more behavioural activities particularly yawning and pelvic 
grooming were more expressed with PPX, a selective D3-preffering agonist at lower doses. 
This is also in line with the study that induction of yawning and pelvic grooming by  DA 
D2/D3 agonist is facilitated by a selective activation of dopamine D3 receptor whereas, the 
inhibition of these two behavioural responses exhibited at high doses is modulated by 
agonistic activation on D2 receptor subtype (Collins et al., 2005b, 2007). 
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 The present electrophysiological investigation has elucidated the acute impact of 
PPX, a clinically used selective dopamine D3 receptor agonist on mid-brain dopamine 
electrical activity. We tested this effect both in naïve and D-AMP intermittently treated rats. 
In the naïve rats, the mean firing activity of DA was significantly reduced with attenuated 
burst activity after the PPX second dose of 0.05 mg/kg (Fig. 13C, D). Physiologically, the 
VTA dopamine autoreceptors modulate spontaneous electrical discharge of dopamine 
neurons (Lacey et al., 1987; Mercuri et al., 1997) via enhancement of inwardly rectifying 
signaling of GIRK activity (Lacey et al., 1987; Kim et al., 1995). Dopamine neurons present 
in the VTA and substantial nigra (SNc) are found to co-express both Kir 3.2 (GIRK2) and Kir 
3.3 (GIRK3) channels (Davila et al., 2003) in a sequence of cascade process, D2 receptors 
essentially couple to GIRK2  channels (Beckstead et al., 2004). Therefore, the activation of 
signaling of GIRK pathway results in release of potassium, which inhibits the action potential 
(hyperpolization) due to increase K+ outflow Presumably, the negative feedback effect of 
dopamine D2 autoreceptors present in the midbrain dopamine neurons and the cascade of 
signaling processes activated by PPX ensued in the drastic reduction of DA firing rate with 
eventual complete shutdown of activity. Interestingly, the burst activity was also significantly 
attenuated whereas, some neurons didn’t show any burst effect; the ones that exhibited it was 
reduced as the dose of PPX approaches 0.05 mg/kg. Centrally, the burst activity is 
responsible for a large output of transmitter equivalent to the same number of impulses 
present at regular interlude at the same period (Gonon, 1988). Another electrophysiological 
study reported that PPX administered for 2 days in rats, altered the VTA DA neurons firing 
rate and burst activity by 40% reduction in firing from the baseline and that this alteration in 
firing rats was restored after chronic treatment for 14 days (Chernoloz et al., 2009b). Millan 
et al., (2000), also reported two types of dopamine firing which are, tonic and phasic patterns,  
and can be induced by PPX which is associated with an agonistic effect on either D2 or D3 
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receptors respectively. We discovered from our findings that most DA neurons from naïve 
rats exhibited total inhibition/sensitivity to PPX at a low dose (60µg/kg). More studies on 
acute PPX administration reveals an inhibition on the neuronal firing in the NAcc (Piercey, 
1998). Our finding on PPX as it relates to firing and burst activity attenuation is consistent 
with highlighted studies and further illustrated that low dose of PPX on naive rats abolishes 
desensitization process. In another series of electrophysiological study, we pre-treated rats 
(n=9) with once-weekly single intraperitoneal D-AMP 1 mg/kg injection for two weeks. 
Conversely, the DA neurons exhibited desensitization subsequent to low dose PPX 
administration (Fig. 13C, E). This raises the question of what mechanism can explain the D-
AMP effect on D2 autoreceptors. In animals pre-exposed to psychostimulant, the degree of 
sensitivity is principally dependent on the nature of the pretreatment frequency. Hence, 
sporadic treatment with fewer doses of drug induces more sensitization than persistent 
exposure to very large drug doses (Robinson and Becker, 1986b; Stewart and Badiani, 1993; 
Vanderschuren et al., 1997). We have previously highlighted the functional role of dopamine 
D2 autoreceptor located on the VTA dopaminergic neurons. The neuromodulatory roles such 
as dopamine neuronal firing, dopamine synthesis, and release through negative feedback 
mechanism as well as activation of signaling of GIRK pathway has been reported (Calipari et 
al., 2014b). Thus, dysfunctional D2 autoreceptors (Gorter et al., 2016; Keebaugh et al., 2017) 
associated with repeated D-AMP (once weekly for two weeks) led to abnormal dopamine 
activity in the VTA and NAc, this may be part of the basis for a drug-craving behavioural 
anomaly. Adopting the electrophysiological paradigm, we observed for the first time a 
profound influence of short time intermittent administration of D-AMP on VTA dopamine 
neuronal transmission.  
 Finally, on electrophysiological evaluation, we studied the potential correlation 
between VTA dopamine firing activity with behavioural phenotype of low as well as high 
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locomotor activity (Fig. 10B, 14). Although, the activity assessment method is limited in 
available sample size to precisely investigate correlation between behavioural and VTA DA 
firing activity. Behavioural modification in animals such as, hunger, emotion, motivation and 
sex drive, takes place both externally as well as an internal compensatory mechanism (Gorter 
et al., 2016; Keebaugh et al., 2017). The internalized behaviours are encrypted in diverse 
forms and are believed to be associated with neural activity in specific brain regions. 
Physiologically, voluntary events in a neuronal activity tend to exhibit momentous changes 
with or without external stimuli such as psychostimulant (Fox and Raichle, 2007). Here, we 
introduced an external stimulus D-AMP 1 mg/kg acute injection and reported a relative 
statistical significant association between low motor activity subjects with reduced VTA 
dopamine firing rate, as well as population activity and vice versa. We posit that a potential 
causal link exists between the behavioural traits that are DA-dependent and DA firing rate 
(Hamidovic et al., 2009). This may have a clinical implication on individualized medicine 
approach, based on varied unpredictable response to drug.  More studies in humans have 
provided more evidence to support this phenomenon that, genetic variability in DA receptor 
is associated with behavioural and impulsivity in D-AMP treated healthy individual. Besides, 
Aumann and Horne, (2012) postulate that firing activity of DA neurons in the SNc potentially 
regulates  DA gene expression. They concluded that neuronal activity in the brain controls 
DA behavioural phenotype, initiated from the SNc neurons. To some extent, our finding is in 
line with these studies, albeit, large samples are needed to appreciate and confirm the extent 
of this perceived association to give credence to our finding. In this chapter, we establish that 
DA receptors functionally regulate the activity of mesocorticolimbic and nigrostriatal 
pathways, performing a vital role in DA transmission. These studies have demonstrated that 
D-AMP administration in intermittent repeated doses modulate midbrain dopamine D2/D3 
receptor function and signaling. Interestingly, autoreceptors dysfunctionality may potentially 
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result in conformational changes of pre and postsynaptic D2/D3 receptors with direct impact 
on drug-craving associated behaviours. Our investigation on neural circuit’s impact of DA 
neuronal activity and interplay is censorious for understanding the neurochemical as well as 
the electrophysiological basis of diverse behavioural response. It was also important to report 
these data for better understanding of what will be presented later with GLP-1, insulin, and 
sucrose consumption studies. 
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Chapter II: Insulin modulation of dopamine 
signalling and dopamine-dependent behaviours 
 
II-I- Introduction 
 Insulin is primarily considered an important hormone for blood sugar homeostasis 
(Lerner and Porte, 1972; Seltzer et al., 1967). Beyond this early findings, Kleinridders et al., 
(2014), have demonstrated with the aid of quantitative real-time polymerase chain reaction 
(PCR) that its receptors are widely distributed throughout the brain regions in proportionality 
to the subtypes (Fig. 15). These receptors are activated by insulin in the brain to signal vital 
physiological processes such as, appetite regulation (Perry and Wang, 2012), lipid 
metabolism (Koch et al., 2008), control of body temperature (Sanchez-Alavez et al., 2011), 
maintenance of body weight and reproduction (Brüning et al., 2000), as well as vital energy 
homeostasis (Burks et al., 2000). Also, recent studies over the years have shown that insulin 
may be involved in the regulation of DA transmission (Caravaggio et al., 2015; Patel et al., 
2018a), DA gene expression and signalling (Mansur et al., 2018a), influence addictive 
behaviour (Dai et al., 2017; Daws et al., 2011), and is likely associated with pathology of 
neurodegenerative disorders (Calsolaro and Edison, 2015a). Insulin is suggested to have a 
profound effect on the activity of dopamine transporter (DAT) and drug that targets such site 
(Carvelli et al., 2002; Patterson et al., 1998). Thus, D-AMP, a psychostimulant and a classical 
candidate of a molecule that interacts with DAT activity, may potentially modulate insulin 
effect on DAT activity or vice versa. The investigation of pharmacological interaction 
between insulin and D-AMP may possibly help us in answering the question that is 
associated with the concept of drug-craving and various metabolic disorders emanating from 
insulin dysfunctionality. Owens et al., 2005, (2012), further demonstrated that disturbance to 
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DA haemostasis was exhibited when the rodent is made hypoglycaemic in the presence of 
streptozotocin. The study further implicates DAT clearance deficiency as a factor responsible 
for decreased responses in motor activity in  streptozotocin-induced hypoinsulinemic rats 
(Owens et al., 2005a, 2012). Previously in chapter I, we established the potential role of 
dopamine D2 receptor in modulating D-AMP-induced motor response (Fig. 11A), as well as 
the impact of D2 receptor agonist in enhancing DA uptake rate, a function of DAT. All these 
findings together suggest that D2 receptors can also modulate DAT activity. The vital role of 
D2 is further substantiated by the evidence that D2 receptors knockout mice significantly 
lowered dopamine clearance (Dickinson et al., 1999).  
 
Fig 15: Expression of IR, IGF-IR, IRS-1 and IRS-2 in the brain determined by 
quantitative real-time PCR (Kleinridders et al., 2014). Expression of IR, IGF-1R, IRS-1, 
and IRS-2 in the brain. The expressions of IR, IGF-1R, IRS-1, and IRS-2 were determined by 
q real-time PCR of brain regions dissected from male C57BL/6 mice. Data are expressed as 
the copy number per nanograms of RNA transcribed. Cb, cerebellum; CP, caudate putamen; 
Hpc, hippocampus; Hy, hypothalamus; NA, nucleus accumbens; NST, nucleus tractus 
solitaries; PFC, prefrontal cortex; RN, raphe nucleus; VTA, ventral tegmental area. 
 
The aim in this chapter was to study behavioural and neurochemical impacts of brain 
insulin level alteration, as well as how it impacts on D2 signalling.  We also investigated for 
the first time, by using a novel approach with diazoxide (a KATP channel activator inhibiting 
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insulin release) inducing a hypoinsulinemia model on rats. We investigated the consequential 
response to D-AMP-induced locomotor activity. Finally, we studied the electrophysiology of 
insulin on VTA dopamine neurons and PFC pyramidal neurons when administered either 
intravenously or through intracranial route in deeply anaesthetized rats. 
 
II-2- Materials and methods 
  
 II-2-A-Subjects 
  Please refer to paragraph II-2-A for detail information on animal conditions 
and regulatory protocol on a study involving rodents. 
II-2-B- Drugs  
  All drugs were purchased from Sigma (Sigma-Aldrich, UK), except for PPX 
in dose of 0.1 mg/kg given intraperitonially (i.p.) (Hellobio, UK), apomorphine hydrochloride 
(i.p.) (Tocris, UK), QNP in dose of 0.05 mg/kg (i.p.) (Tocris, UK). The drugs were dissolved 
into Krebs (release assays) and HEPES (uptake assays) buffers, as appropriate. The drugs 
were dissolved in distilled water or saline for studies involving behavioural and 
electrophysiological profiling. 
 
II-2-C- In vitro 3H-dopamine release assay 
  Please refer to paragraph I-2 for detailed experimental procedures. In this 
chapter, insulin 2µM and a powerful dopamine-releasing drug, D-AMP 10µM were 
investigated to determine their capacity to induce tritiated dopamine release on striatal brain 
slices. The interaction between the two drugs on postsynaptic for DA efflux was also 
investigated.  
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II-2-D-In vitro 3H-dopamine uptake assay 
  In these experiments, two methods were used to study [DA] uptake activity. 
 II-2-D1-In vitro direct measurement of 3[H]-dopamine uptake   
 Here, we studied 3[H]-dopamine uptake according to paragraph I-2 protocol. Please, 
refer to the earlier mentioned paragraph for detailed experimental procedures. However, 
molecular interaction between insulin 2µM and a dopamine D2/D3 agonist, QNP 125nM was 
investigated as well as the effect of each drug on direct dopamine uptake process.  
  
  
II-2-D2- Ex vivo kinetics of 3[H]-dopamine uptake  
  In this set of experiments, three groups of rats (n=5), one pre-treated with 
saline (0.8 ml/kg) or challenged with insulin (single i.p. injection 20µg/kg, a low dose) 
supplemented by 5% glucose to prevent hypoglycemia (Qinna and Badwan, 2015) or 
diazoxide (DZ) 150 mg/kg to impair insulin secretion. Blood glucose levels were monitored 
with a glucometer (Accu-Check viva). After 1 hr of treatment, the animals were sacrificed by 
cervical dislocation and the brains region of interest (striata) were then quickly removed and 
placed on an ice-cold platform for further dissection (see paragraph I-2 for full protocols). 
The homogenized tissue was pre-incubated for 5 mins at 370C with 3[H] DA and the kinetics 
of 3[H]-dopamine uptake was assayed in a total of 300 µl of uptake buffer. We then varied 
the concentration of 3[H] DA (5-80 nM) at each 5mins incubation period to determine the 
uptake rate per time. Protein level determined according to Bradford assay (Bradford, 1976). 
Apparent  Km, and Vmax values were calculated  by nonlinear least-square curve fitting of data 
using the algorithm described by Schreiner et al., (2011) assuming Michaelis-Menten kinetics 
and, where appropriate, competitive inhibition. Models for one and two enzyme systems were 
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fit, and the significance test described by Munson and Rodbard, (1980) was employed to 
choose the best model to describe the data. 
 
II-2-E- D-AMP and dopamine D2/D3 receptor agonist-induced behavioural studies 
Rats were transferred individually from their home cage to a test cage and then 
allowed to habituate for 30 min before the start of the experiment. Adult male Sprague-
Dawley rats were pretreated with saline (0.8ml/kg) or insulin 20µg/kg (5% glucose 
supplemented to prevent hypoglycaemia). The rats were later treated with single 
intraperitoneal injection 1mg/kg of d-amphetamine (D-AMP) or 0.1mg/kg of quinpirole 
(QNP). In another series of experiments, animals were pretreated with DZ 150 mg/kg, to 
prevent insulin secretion. Animals were then scored for behavioural locomotor parameters 
such as rearing (a dopamine-dependent motor manifestation), during 15-minute periods and 
up to a total of 60 minutes following the injection. Counting of yawning, pelvic grooming 
and pica eating behavioural traits were performed manually following QNP administration. 
Whenever possible, blood glucose levels were monitored with a glucometer (Accu-Check 
viva). 
 
II-2-F-In vivo extracellular single-unit electrophysiology 
 Please refer to paragraph I-4 for detailed protocol.  Recordings were done on both 
VTA DA neurons and pyramidal PFC neurons.  However, in this study our recordings in the 
midbrain DA neurons were carried out in three ways: 1) we acutely administered insulin 
while recording firing activity 2). We also injected the VTA region with insulin. In these 
experiments, the tip of a 5 µl Hamilton syringe was lowered into the VTA (5 mm posterior to 
bregma and 1.5 mm lateral to the midline, 7.8 mm below the cortical surface). Insulin (1.5 µg 
in 1.5 µl) or saline was slowly injected over a 3 min.  
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3). We also carried out experiments where insulin was administered through the recording 
electrode, by filling the electrode with insulin ( 100 µg/ml) in saline to allow for diffusion 
into the distinct brain region with a concurrent single unit recording (Marks et al., 1988). This 
method of administration of drugs through the recording electrode has worked previously in 
our laboratory, with different types of drugs, including some drugs with relatively high 
molecular weight. However, in these experiments the amount of drug that can diffuse through 
the recording electrode is uncertain.  We used this protocol to study the local effect of drug 
and to acquire electrophysiological information as well as recognition of cell populations at 
the site of local administration. 
 
II-2-G- Data analysis 
 Please refer to paragraphs II-2-G for a detailed method of analysis on each protocol. 
However, in uptake kinetics experiment all values are expressed as mean ± standard error of 
the mean (SEM). The mean Km and Vmax values (expressed in units of nM and pmol/mg/min, 
respectively) were obtained from the individual Km and Vmax values derived from each 
experiment using nonlinear regression analysis and a single-site model (GraphPad Prism 
version 3.0; San Diego, CA). Data were analyzed by two-way analysis of variance 
(ANOVA), followed by appropriate post-hoc tests. 
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II-3- Results 
 II-3-A- Insulin did not induce 3H-[DA] release on striatal slices 
  Administration of insulin at 2µM in the perfusion medium did not 
show any effect on basal 3H-[DA] efflux from striatal slices (Fig. 16A).  Also, insulin did not 
alter D-AMP-induced 3H-[DA] release (Fig. 16B). 
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Figure 16: Insulin effect on the release of striatal [DA] efflux. 
(A): Insulin 2µM did no induce a statistically significant change in 3H-[DA] efflux from 
striatal brain slices. (B): Insulin neither potentiates nor attenuates DAMP-induced striatal 
release. P>0.05 vs baseline, unpaired student's t-test, P>0.05, ***P<0.0001 vs. respective 
conditions. Neuman-Keuls, after significant one-way ANOVA. 
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II-3-B- Insulin modulates striatal synaptosomal 3H-[DA] uptake 
  II-3-B1- Insulin attenuates both baseline and QNP-induced 3H-[DA] 
 striatal uptake 
The striatal synaptosomes incubated with insulin 2 µM exhibited reduced 3H-[DA] uptake on 
both 5 mins and 30 mins pre-incubation period in the reaction medium. There was a 
significant (28%) inhibition after 30 min pre-incubation (F=6.126, df=29), which is more 
pronounced than after 5 min (F=4.151, df=9) (Fig. 17A and B). Interestingly, insulin also 
abolishes QNP-induced dopamine uptake (F (4, 70) =13.39) (Fig. 17C). Thus, dopamine 
transporter activity was simultaneously reduced in the presence of insulin. 
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Figure 17: Effect of insulin with quinpirole interaction on [DA] uptake transporter 
activity 
(A&B): Insulin 2µM significantly reduced [DA] uptake both in 5 mins and 30 mins 
incubation periods, unpaired student's t-test, * P<0.01, ***P<0.0001 vs baseline. 
(C) In the presence of insulin, quinpirole-induced [DA] uptake was significantly reduced, 
compared to control experiments performed in parallel. This is an indication of molecular 
interaction with QNP at uptake level and reduced dopamine transporter activity. 
###P<0.0001, *P<0.05, **P<0.001 vs baseline uptake, Neuman-Keuls, after significant 
ANOVA.       
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II-3-B2- Insulin modulates [DA] uptake kinetics on striatal synaptosomes 
In the control group, Michaelis-Menten's plot analysis of [DA] uptake kinetic 
parameters on striatal synaptosomes revealed a direct proportionality between 
concentrations (up to 40 nM) and the uptake velocity, as well as adequate saturation at 
80nM of [DA] (Fig. 18A). In the insulin-treated rats, Michaelis-Menten's plot analysis 
on striatal synaptosomes revealed that acute administration with insulin 2 µg/kg 
(supplemented with glucose 5%) in a single dose resulted in increase in Vmax with no 
apparent change in KM, which is a measure of affinity as compared with control group 
(Table 1). In another experiment with intraperitoneally administered DZ (KATP 
channel activator and an insulin release inhibitor), the Vmax also increased 
considerably.  
Vmax values for DAT-mediated uptake after. Data are means±s.e.m R
2 indicates 
goodness of fit (*P<0.05 vs. control, one-way ANOVA followed by Neuman-Keuls 
post hoc test. 
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II-3-C1- Presence of insulin and its inhibition by diazoxide modulate D-AMP-induced 
rearing activity  
  During  the  first  60  minutes  of  observation, following  administration of the 
dopamine-releasing agent D-Amphetamine (DAMP, 1 mg/kg ip), animals  that  were  pre-
treated  (15 min before the challenge) with insulin 20 µg/kg ip (supplemented with 5% ip. 
glucose administration to compensate for hypoglycaemia) did not show any more motor 
activity than the control group treated with D-AMP only, except during the first 15 mins of 
observation, where the insulin pre-treated group displayed more rearing activity (Fig. 19B). 
First, we investigated the glycaemic profile of DZ-treated rats for hyperglycaemic-inducing 
effect, through inhibition of insulin compared with control. The data showed a significant 
elevated (F=66.63, DFn=1, DFd=42) plasma glucose level than the control throughout the 3 
Kinetic
parameters
Control Insulin (20µg/kg) Diazoxide
(150mg/kg)
Km (nM) 43.7±15.82 34.45±11.11 26.6±4.117 
Vmax (pmol/mg/5min) 4.834±0.8730 37.49**±5.509 38.4**±4.81 
R2 0.9588 0.9609 0.9992
Table 1: Insulin and diazoxide effects on kinetic parameters in DAT-mediated 
uptake on striatal slices
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Fig 18: Michaelis-Menten plot for the determination of the Km and Vmax  DAT 
activity on [DA] uptake in control rats. 
n=5
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hours of glycaemic observation (Fig. 19A). However, during the first 60 minutes of  
observation following administration of DZ 150mg/kg ip, an insulin inhibitor, animals  that  
were  pre-treated  (15 min before the challenge)  displayed significantly less locomotor 
activity  (F (1, 42) =66.63) throughout the observation period (Fig. 19C). In fig. 19D, insulin 
pre-treated group did not show any alteration in locomotor activity except during the first 15 
mins of observation (F (6, 120) =9.5). We demonstrated evidence that the impact of insulin 
on motor activity was not due to it hypoglycaemic-induced effect as we prevented such effect 
with supplemented 5% glucose to a normoglycemic state. We also observed that n=value, for 
the control group (5) done during the series of experiment is not different from the entire 
control group pulled together (n=23). 
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Figure 19: Impact of insulin and diazoxide on D-AMP-induced motor activity 
(A): DZ treated rats exhibited consistent hyperglycaemic level likely due to insulin secretion 
inhibition throughout 3 hrs of observation, ***P<0.0001 vs. control at all times.  (B): Insulin 
20 µg/kg administered concurrently with glucose 5% (0.1 ml/kg) did not exhibit any 
significant alteration on glycaemic level. (C): In the presence of DZ, an inhibitor of insulin 
release, there was a significant reduction in locomotor activity, and pronounced statistical 
reduction during 30-45 and 45-60-mins periods. (D): Insulin 20 µg/kg pre-treated group did 
not show a significant change in locomotor activity throughout the observation period, except 
during first 15 mins of observation. $$$P<0.0001, *P<0.5, **P<0.001, ***P<0.0001 vs. 
respective control. Bonferroni post hoc tests after significant two-way repeated measures 
ANOVA. 
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II-3-C2- Insulin and diazoxide inhibit both QNP and PPX-induced behavioural effects 
As earlier indicated in the previous chapter, D2/D3 receptors induce classical 
behavioural traits such as yawning, pica eating, and pelvic grooming. A single dose of 
insulin 20 µg/kg pre-treatment supplemented with glucose, followed by QNP 0.1 
mg/kg shows significant reduced yawning activity (F (1, 32) =6.41) throughout the 
observation time compared with control (Fig. 20A). Similarly, significant reduced 
effects were also observed in pica eating (F (1, 24) =2.78) and pelvic grooming (F (1, 
24) =2) but, only during the first 30 mins (0-15 and 15-30 min periods, Fig. 20B &C). 
Interestingly, with PPX, a preferential dopamine D3 receptor agonist, 0.05 mg/kg, 
yawning (F (1, 32) =6.41) and pelvic grooming (F (1, 32) =4.65) effects were also 
significantly reduced in the insulin 20 µg/kg pre-treated groups compared to control 
(Fig. 21A, C). But apparent increase in pica eating than the control was demonstrated 
in rats pre-treated with insulin (Fig. 21B).  
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Figure 20: Impact of insulin on QNP-induced behavioural traits 
(A, B): Insulin 20 µg/kg pre-treated group significantly reduced pica eating and pelvic 
grooming activities induced by QNP during the 30-45, and the 0-15 mins observation 
periods, respectively. (C): On the other hand, there is a statistically significant difference in 
QNP-induced yawning activity throughout the observation period when compared with the 
control Bonferroni post-tests after significant two-way repeated measures ANOVA. 
**P<0.001, vs. respective control, ***P<0.0001 vs control at all times. 
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Figure 21: Impact of insulin on PPX-induced behavioural traits Insulin 20 µg/kg pre-
treated group significantly reduced yawning and pelvic grooming activities (A&C) during the 
observation period. However, in (B) insulin pre-treated group exhibited more pica eating 
activity than the control group, albeit not a significant increase. Significant two-way repeated 
measures ANOVA. *P<0.05 vs. control 
0 20 40 60 80
0
2
4
6
Vehicle (n=5)
PPX 0.05mg/kg (n=6)
PPX+Ins 20µg/kg (n=4)
(*)
Interval(Mins)
P
e
lv
ic
 g
ro
o
m
in
g
/6
0
m
in
s
0 20 40 60 80
0.0
0.5
1.0
1.5
2.0
2.5
Vehicle (n=5)
PPX 0.05mg/kg (n=6)
PPX+Ins 20µg/kg (n=4)
Interval(Mins)
N
u
m
b
e
r 
o
f 
b
it
e
s
/6
0
m
in
s
0 20 40 60 80
0
5
10
15
Vehicle (n=5)
PPX 0.05mg/kg (n=12)
PPX+Ins 20µg/kg (n=4)
Interval(Mins)
N
u
m
b
e
r 
o
f 
y
a
w
n
s
 i
n
 6
0
m
in
s
(*)
A
B
C
80 
 
II-3-D1- Insulin modulates both pyramidal and DA neurons firing activities 
  First, in the PFC and VTA, we investigated the effect of DZ on the firing 
activity of neurons. DZ in these two brain regions did not alter the firing activities on both the 
pyramidal and VTA DA neurons. In the prefrontal cortex, intravenous administration of 
insulin 20 µg/kg does not affect the firing activity of PFC pyramidal neurons. However, 
following an additional dose of 20 µg/kg; the firing activity slightly but significantly 
increased (Fig. 22A).  Three pyramidal neurons out of the seven tested had their firing rate 
increasing by more than 40% from baseline after a cumulative dose of 40 µg/kg. Similar 
finding has been reported by Zhou et al., (2017).  On the other hand, in the VTA intravenous 
insulin had a slight decreasing effect on the firing rate of dopamine neurons (Fig. 22C). 
However, this was significant only at the high cumulative dose of 60 µg/kg.). 
 
 
 
 
 
 
Figure 22: Electrophysiological effects of intravenously administered insulin on 
pyramidal prefrontal cortex neurons and VTA dopamine neurons  
(A): Firing rate histogram of a pyramidal PFC neuron showing progressive activation upon 
administration of 3 subsequent doses of insulin (20 µg/kg, iv.) (B): Mean firing rates of PFC 
neurons before and after the administration of 2 doses of insulin (20 µg/kg, iv.). Neurons 
show a significant level of activation following the cumulative administration of insulin of 40 
µg/kg (iv.). *P<0.03, vs baseline level, Newman-Keuls test after significant repeated measure 
one-way ANOVA. (C): In the VTA insulin given intravenously slightly but significantly 
reduced VTA dopamine neurons firing activity, but only at the highest cumulative dose tested 
(60 µg/kg, iv.). *P<0.03, vs baseline level, Newman-Keuls test after significant repeated 
measure one-way ANOVA.  
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II-3-D2- Insulin diffusion in brain progressively modulates VTA dopamine 
population firing rate 
  In these experiments, the recording electrodes were filled with insulin (final 
concentration 100 µg/ml) and lowered into the VTA for the recording of dopamine neurons. 
It is anticipated that during the recording the insulin solution is allowed to diffuse through the 
recording electrode into the VTA nearby the recorded neurons. In our laboratory, this method 
of administration of products directly to the neuron tested has proven to be efficient (Gronier, 
2011a). Although the amount of product applied to the neurons cannot be predicted and 
diffusion efficiency can vary from one electrode to one another. Whenever possible, the 
dopamine neurons were recorded during two subsequent periods of 7 min and firing activity 
between period 1 and 2 was compared assuming that insulin will progressively diffuse 
through the electrode and that neurons will be exposed to insulin for longer in the second 
period of the recording. Firing activity of dopamine neurons recorded this way was not 
significantly different than the firing activity of a control population of neurons (though it 
tends to be lower, p<0.2). However, during the second period of the recording, the mean 
firing activity became lower than during the early period of the recording and lower than in 
the control (Fig. 23A &B).  
II-3-D3-Intra-VTA administration of insulin   
Previous data from our laboratory has shown that administration of saline (1-2 µl) within the 
VTA did not change the electrophysiological characteristics of the dopamine neurons 
(Gronier, 2008). This indicates that the insertion of the Hamilton syringe needle does not 
induce significant damage in this structure. We have confirmed this result on a small group of 
neurons (n=7) but used our main control population for comparison. Figure 24 shows that 
neurons recorded at least 40 min after the administration of insulin (1.5 µg) into the VTA 
region displayed a significantly lower baseline and lower burst activity than in the control 
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population. Interestingly the proportion of non-bursting neurons was particularly high in the 
treated group (12/16, 75% of neurons) compared to the control group (8/43, 18%). 
 
 
 
 
 
 
 
 
Figure 23: Population firing activity of intra VTA-infused insulin on DA neurons 
(A): Firing rate histograms of a VTA dopamine neuron recorded with an electrode filled with 
insulin (100 µg/ml in saline). This particular neuron displayed a large decrease in firing 
activity during the recording period. 
(B): The mean firing activity of VTA dopamine neurons recorded with an electrode filled 
with insulin decreased significantly during the later period of the recording (7-15 min), 
during that time the firing is also significantly lower than the mean firing activity of VTA 
dopamine neurons recorded in normal condition (with saline-filled electrodes). Note that in 
control condition the firing rate of dopamine neurons do not decrease with time.  *P<0.02 
compared to respective firing rate during the early period of the recording (paired Student's t-
test) and compared to controls (unpaired t-test). 
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Figure 24: Individual electrophysiological characteristics of intra VTA insulin 
Firing rate and burst firing of VTA dopamine neurons rats (n=4) that were administered 
insulin (1.5 µg) within the VTA at least 40 min before and in control animals (n=6). Both 
firing and burst activities were significantly lower than control values. *p<0.03, unpaired 
Student’s t-test. 
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II-4-Discussion 
 Systemic peptides such as insulin, glucagon–like peptide (GLP-1), leptin and ghrelin 
can modify feeding habit via regulation of reward pathways (Figlewicz and Benoit, 2009). In 
this study, our neurochemical data reveals that insulin possibly does not have a pronounced 
effect on basal and D-AMP-stimulated striatal [DA] release (Fig. 16A, B). However, we 
reported that insulin may interact with dopamine uptake processes by causing a reduction in 
[DA] uptake via DAT clearance in our in vitro study on striatal synaptosomes (Fig. 17A, B, 
and C).  Our ex vivo kinetic study indicates that the kinetic parameters of the DAT (Vmax and 
Km) can be affected by insulin. A supplementation of insulin (administered 1 hr before 
animal sacrifice) seems to slightly reduce the KM of the transporter. Therefore, it may 
increase its affinity for dopamine transport velocity when dopamine concentration is within 
its physiological range. However, a presumed deficiency of insulin in the brain caused by the 
blockade of its peripheral secretion (diazoxide acting on the pancreatic β-cells), seems to 
disturb more dramatically the activity of the transporter reducing considerably its affinity for 
dopamine. Therefore, the presence of insulin may be required in the synapse to stabilize the 
activity of the presynaptic transport of dopamine. It is not known whether this can be caused 
by a direct or indirect interaction between dopamine transporter and insulin receptor. As 
shown in the literature, insulin can represent a reward indicator, as well as function in the 
satiety signaling process. Previous proof has indicated that insulin can modulate DAT activity 
via an increased dopamine uptake (Schoffelmeer et al., 2011a; Williams et al., 2007a). 
However, there are contrasting studies that have shown that insulin role in the striatum is 
quite complicated. While, Schoffelmeer et al., (2011b) reported a decreased in electrically 
evoked release of 3[H]DA from the striatum, another finding by Mebel et al., (2012) 
demonstrated that in the VTA there was a pronounced effect of insulin on dopamine uptake 
resulting in decrease dopamine efflux by fast-scan cyclic voltammetry method. Stouffer et al., 
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(2015) however, discovered through cyclic voltammetry method that insulin magnifies 
striatal DA release in a nicotinic acetylcholine receptor-dependent manner by facilitating 
cholinergic excitability through insulin receptors. From all these controversial studies, one 
wonders from our data the reason for the paradoxical effect of insulin on 3H[DA] release and 
uptake and possible desensitization of insulin receptors or downregulation in signaling 
pathways may be potentially implicated. Furthermore, insulin receptors experience fast 
endocytosis and breakdown after binding to peripheral tissue leading to neuronal 
desensitization of insulin receptors after exposure to supra-physiological concentration 
(Anthony et al., 2006; Mayer and Belsham, 2010; Schulingkamp et al., 2000). There are 
differences in protocols deployed from all the studies mentioned, as well as the methods used 
in our studies, and this could contribute to regional discrepancies in insulin activity. In some 
studies, it is hypothesized that  insulin receptors stimulation induced an increase in surface 
expression and activity of DAT in the rat striatum, by facilitating dopamine reuptake via 
phosphatidylinositol 3-kinase (P13K)-dependent process (Carvelli et al., 2002; Garcia et al., 
2005; Lute et al., 2008a). Phosphatidylinositol 3-kinases are a group of enzymes that regulate 
downstream intracellular signaling via binding to pleckstrin domains of protein kinase B 
(PKB) and phosphoinositide-dependent protein kinase (PDK) to cause modulation of 
phosphorylation of PDK (Shepherd et al., 1998). However, PI3K has assumed new roles in 
dopamine signaling process and implicated in multiple transduction of dopamine-induced 
control of gene expression, long-term striatal neuronal adaptation (Brami-Cherrier et al., 
2002) as well as dopamine D2 receptors regulation in addition to cyclic adenosine 
monophosphate  (cAMP) pathways (Beaulieu et al., 2011). Our finding is consistent with 
these studies, having demonstrated an increased velocity above control following insulin 
administration. More data from our studies on radiometric uptake assay reveals that insulin 
receptors stimulation, modulate dopamine D2 receptors which in turns contribute to the 
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regulation of DAT activity in the striatum (Fig. 17C). Mayfield and Zahniser, (2001) reported 
that dopamine D2 receptor stimulation can facilitate surface expression and functional activity 
of DAT of Xenopus oocytes. Another interesting data has linked dopamine (D1/D2) receptors 
activation with cognitive enhancement (Mehta and Riedel, 2006), as well as suggesting a 
correlation between insulin administration and cognitive performance (Strachan, 2005a). 
Although, there is a disparity between data from animals and human studies, it is still 
plausible, that cognitive enhancing effect of insulin is partly due to its ability to modulate 
dopamine neurotransmission through the uptake process. Besides, when D2 receptor agonist 
QNP was added to the reaction mix of striatal synaptosomes there was a significant increase 
in the velocity of [DA] uptake as in our study (Meiergerd et al., 1993b). In both studies, the 
effects were inhibited by dopamine D2 blocker sulpiride, a study in agreement with D2 
receptor able to modulate DAT function and cell surface expression (Meiergerd et al., 1993b; 
Mayfield and Zahniser, 2001). We have demonstrated (for the first time) through in vitro 
radiometric assay an inhibitory effect of insulin on quinpirole-induced 3[H]- [DA] uptake; a 
mechanism that is mediated by D2 dopamine receptor. Whether this indicates that dopamine 
D2 and insulin receptors can negatively (directly or indirectly) interact would be an 
interesting question to address. Data presented on behavioural studies further corroborate 
these neurochemical findings. However, we found that insulin pretreatment did not have a 
significant effect on d-amphetamine-induced locomotor activity when compared with the 
control. Furthermore, more locomotor activity was exhibited during the first 15 mins of 
observation in insulin pretreated group. Previous studies on the role of insulin in the 
behavioural manifestations of organic reinforcers and substances of abuse show that, insulin 
given in acute dose facilitates clearance of dopamine by enhancing the cell surface expression 
of DAT in the dopamine nerve endings (Figlewicz and Benoit, 2009; Lute et al., 2008a; 
Owens et al., 2005a; Williams et al., 2007b). Furthermore, it has been demonstrated that DAT 
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is the principal target for psychostimulant such as d-amphetamine (Rothman and Baumann, 
2003), insulin receptors activation might probably play a key role in influencing cognitive 
and motivational functions of D-AMP (Giros et al., 1996). More homeostatic role of insulin 
in neurotransmission revealed that insulin receptors activation through activation of insulin 
receptors (IRS-2)/phosphatidylinositol 3-kinase (PI3K) pathway, maintains dopamine 
transporter function in the dopamine nerve endings, which is necessary for DAMP to 
facilitate dopamine neurotransmission (Khoshbouei et al., 2004; Lute et al., 2008a; Williams 
et al., 2007c). Therefore, our data indicate that insulin pre-treatment may worsen D-AMP 
effect  at least in the first 15 minutes of its administration. Insulin also reduced DA uptake 
through attenuation of DAT activity to enhance the synaptic output of DA. In the presence of 
D-AMP, this effect was initially potentiated but later faded out. The insulin effect on D-
AMP-induced motor activity is more of modulatory role rather than direct impact on uptake 
and release. A negative interaction with dopamine D2 autoreceptor, as we have found, may 
slow down the negative control of dopamine release exerted by these receptors and in turn 
further increase DA release. 
In another series of behavioural studies, we introduced diazoxide 150mg/kg (a drug 
preventing insulin release) for the first time to evaluate the effect of an absence of insulin 
hence; we made the rats acutely hypoinsulinemic. Our finding reveals a marked reduction of 
locomotor activity in DZ-pretreated group throughout the observation period. Previous 
studies have adopted the use of streptozocin to induce hypoinsulinemia or render the animal 
diabetic (Marshall, 1978; Owens et al., 2005a). In experimentally diabetic animals, there is a 
reduction of locomotor activity induced by D-AMP via insulin- mediated DAT activity in the 
striatum (Williams et al., 2007b). It has also been reported that insulin receptor knockout 
mice (NIRKO) exhibited insulin resistance causing alteration in dopamine turn over as well 
as behavioural disorders (Kleinridders et al., 2015b). Interestingly, other studies have 
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demonstrated that streptozocin-induced hypoinsulinemia reduced the dopamine-releasing 
effect of D-AMP via the blockage of PI3K signaling of InRs and attenuation of surface 
expression of dopamine transporter activity in the striatum (Lute et al., 2008b). It is possible 
also that change in DA clearance in DZ‐treated rats are due, at least in part, to hyperglycemia 
resulting from insulin inhibition. However, according to our glycaemia data (Fig. 19A), it is 
unlikely that glucose in the brain could be in a concentration high enough to interact directly 
with the dopamine transporter. All together, these studies suggest that behavioural effects of 
amphetamine mediated by striatal DA release maybe insulin-dependent through DAT 
regulation. We further tested the effect of insulin status on D2/D3 dopamine agonists mediated 
behavioural traits such as; yawning, pica eating and pelvic grooming. Data from this study 
indicate that alteration in circulating insulin could significantly affect the behavioural 
activities of molecules acting on dopamine receptors. Our results also demonstrate that the 
activity of dopamine transporter and D2/D3 receptors is distinctively influenced by insulin 
status in rats. Quinpirole and PPX are D2-like family receptor  agonists, with different affinity 
for D2 and D3  receptor subtypes respectively (Kebabian et al., 1997). The main finding in our 
study is that insulin significantly reduced quinpirole and pramipexole-induced yawning, 
penile grooming and pica eating. Altszuler et al., (1977) earlier reported that DZ 
hyperglycemia is not mainly due to reduced insulin secretion, but may be directly linked to 
enhanced production of glucose and subsequent blockage of glucose uptake. Therefore, 
reduced behavioural sensitivity in DZ-treated rats compared with the insulin-treated group 
may be due to the differential level of glucose homeostasis that influences dopamine 
receptors density and signaling processes (Abbracchio et al., 1989; Lozovsky et al., 1981). 
We cannot exclude that the behavioural effect caused by lack of insulin is also due to an 
increase in glucose concentration. However, intracerebral glucose concentration is not 
regulated in the same way as peripheral glucose concentration and is much lower, suggesting 
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that the impact of a high concentration of glucose in the plasma will be possibly less 
significant in the brain. Albeit, an adequate concentration of glucose in the brain is of course 
absolutely essential for brain function. Also, from our data glycaemia is only increased by 2-3 
times and it is not sure that it will be enough to cause important neurochemical alteration. 
We also hypothesize that the near deficit in yawning, pica eating and pelvic grooming 
observed in the two groups might express reduced sensitivity in both receptor sub-types. 
Consequently, reduction in behavioural effects of D2/D3 receptor in DZ-treated rats might 
confirm the alteration in the dopaminergic transmission that takes place when insulin status is 
altered. We infer from this study, that changes in insulin and glucose status affect sensitivity 
to behavioural effects of dopaminergic drugs (Boucher et al., 2014; Caravaggio et al., 2015). 
The results also emphasize the vital role of insulin in modulating dopamine transmission, as 
well as understanding the comorbidity of eating disorders and addiction. Apparently, at the 
molecular level, insulin receptor signaling interferes adversely with dopamine receptor 
signaling and potentially amplifies action potential-DA dependent transmission in the 
mesolimbic DA pathway. 
Our in vivo electrophysiological studies provide new information on the impact of 
insulin on the electrical activity of pyramidal neurons in the prefrontal cortex (PFC) as well 
as the dopamine neurons within the ventral tegmental area. First, we tested how intravenously 
injected insulin in anaesthetized rats modulates pyramidal neurons in the PFC. We 
demonstrate that insulin via i.v route slightly increased the excitatory effect of these neurons 
(Fig. 22A, B). Although the effect is very modest, some neurons appear to be sensitive to 
insulin. This might be as a result of insulin differential time-dependent process in crossing the 
blood-brain barrier (Banks and Kastin, 1998; Banks et al., 1997b). Hence, this physiological 
barrier prevents an optimum concentration of insulin from reaching the brain to activate 
insulin receptors. In support of this hypothesis, Csajbók and Tamás, (2016) propose that the 
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rate of pancreatic insulin transportation into the cerebrospinal fluid is much slower than the 
operating speed of neural networks. This leads to a slow supply of insulin to the brain by the 
pancreatic β-cell of the islet of Langerhans albeit; the neuronal insulin released locally in the 
brain provides more rapid means of neuromodulatory effect on the neural circuit. As a result, 
at any given time the plasma insulin concentration is usually higher than that in cerebrospinal 
fluid (Strubbe et al., 1988; Wallum et al., 1987). Zhou et al., (2017) recently demonstrated 
that locally administered insulin in the anterior piriform cortex (APC) increase the excitation 
of pyramidal neurons and resulted in a negative feedback inhibition of synaptic transmission 
performed on slice recordings. Data from experimental animals as well as epidemiological 
studies in humans suggest a biological correlate between insulin and cognitive performance 
(Strachan, 2005b). In addition, findings from (Reger et al., 2006; Shemesh et al., 2012), have 
revealed that intranasal insulin administration provides a therapeutic advantage in 
Alzheimer’s patient by aiding memory performance. Since most of the excitatory inputs 
received by the pyramidal cells are glutamatergic, we can suggest that insulin effect on the 
pyramidal neurons potentially results in cognitive enhancement. 
 Since insulin is associated with cognitive and motivational processes which are linked 
with dopamine transmission, as well as insulin receptors activation (Labouèbe et al., 2013a); 
we tested this drug on VTA dopamine neurons' firing activity. Similar to PFC recordings, 
insulin on VTA dopamine neurons via intravenous injection did not show a significant 
change in the firing activity of the neurons (Fig. 22C), albeit, there was a modest decrease 
with high doses of insulin. High dose of insulin caused a reduction in VTA DA activity and 
through indirect activation of PFC pyramidal neuron this may enhance cognition. Our studies 
on insulin local administration through intra-VTA revealed a significant reduction in 
population firing activity when compared with the baseline. The data in this study suggested 
a mechanism by which insulin modulates dopamine transmission in the mesolimbic pathway. 
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Labouèbe et al., (2013) further reports that insulin induced a long-term depression (LTD) of 
excitatory postsynaptic currents released as a result of VTA dopamine neurons in mice's brain 
slices. This neuroadaptive mechanism (LTD) represents synaptic plasticity in the brain and is 
suggested to be associated with learning, memory retrieving and storage as well as 
information task. More importantly, in an in vitro study, long-lasting inhibition on VTA 
dopamine neurons is thought to be mediated by α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR) excitatory synaptic transmission. Insulin-
enhanced LTD has also been reported in the cerebellum (Man et al., 2000) and hippocampus 
(Wang and Linden, 2000). In addition to the significant reduction in firing activity following 
intra-VTA administration of insulin, we also report that the burst activity was significantly 
attenuated when compared with controlled animals. Findings from Labouèbe et al., (2013b) 
revealed that insulin in the VTA attenuates excitatory synaptic transmission and reduces 
burst activity of DA neurons. Together with all the studies, our findings and other articles 
highlighted show the vital connection between the functions of insulin and 
neurotransmission. 
 In conclusion, our behavioural data shows that insulin remarkably impairs dopamine-
dependent behaviours induced by D2/D3 agonist. We infer a possible correlation between 
behavioural anomalies and suboptimal brain’s insulin level, as also evident by the reduced 
locomotor effect to D-AMP following administration of DZ, an insulin release inhibiting 
agent. The fact that insulin weakens QNP and PPX-induced behavioural and neurochemical 
effects (dopamine uptake) suggest a potential interaction with D2 /D3 receptor signaling. A 
significant inhibitory effect on VTA dopamine neurons by insulin was observed when locally 
administered. 
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Chapter III- Electrophysiological and 
neurochemical effects of anti-diabetic 
sulphonylurea tolbutamide in the rat’ ventral 
tegmental area and prefrontal cortex 
 
III-1-Introduction 
 Tolbutamide is an orally administered sulphonylureas, used in the management of 
non-insulin-dependent diabetes mellitus (Fulton and Bell, 1957; O’donovan, 1959) and as an 
adjuvant therapeutic agent in insulin-dependent diabetes mellitus (Fabrykant and Ashe, 1959; 
Pontiroli et al., 1984). This class of drug acts on the sulphonylureas receptors through 
blockage of potassium adenosine triphosphate (ATP-regulated K+-) channels to release 
insulin from pancreatic β-cell (Liss et al., 1999). In the presence of diazoxide, a KATP 
channels opener, the signalling process is reversed as the propagation of action potential 
initiation is shut down resulting in inhibition of insulin secretion (Fig. 25). Anatomically, 
Katp channels has on it sulphonylurea receptors, these receptors (SUR) are activated by TBT 
leading to blockage of Katp, this action is reversed by DZ. Also, some studies have shown 
the important modulatory effect of the channels on the excitability of substantia nigra neurons 
(Peltier and Vecchio, 1961; Röper and Ashcroft, 1995; Schiemann et al., 2012a) and 
dopaminergic midbrain neurons (Liss et al., 1999). Interestingly, Liss et al., (1999) further 
revealed that dopaminergic substantia nigra (SN) neurons express K-ATP  channels subtypes 
with different sulphonylurea-sensitive receptors. These channels are configured in pore-
forming subunits namely, Kir6.1 and Kir6.2 as well as a sizeable supplementary subunit, the 
sulfonylurea receptor (SUR1, SUR2A, and SUR2B) (Tinker et al., 2018). Thus, the Kir6.0 
series is part of the inwardly rectifying member of potassium channels (KATP) while; the SUR 
is part of the adenosine triphosphate (ATP)-binding class of proteins. 
93 
 
 
 
 
 
Fig. 25: Model of KATP channels modulation of insulin pancreatic beta-cell signalling 
(Babenko et al., 1998) 
 
 
It was also reported that ATP responding KATP channels are termed as such, due to capacity to 
open when cellular ATP amount drops. This results in membrane hyperpolarization and 
hence relates cellular metabolism and neuronal excitability (Tinker et al., 2018). More in 
vitro studies demonstrate that activation of these channels differentially enhance degeneration 
of SN dopamine neurons (the hallmark of Parkinson disease), but not VTA dopamine neurons 
(Liss et al., 2005). The mechanism for this selective harmful effect on SN DA neurons was 
reported to be due to a process of KATP (Kir6.2) genetic mutation that led to a selective rescue 
of SN (apoptosis), but not in VTA DA neurons (Liss et al., 2005). In the pancreatic ß-cells, in 
vitro (Fridlyand et al., 2010a) and in vivo (Gomis and Valdeolmillos, 1998a) studies show 
that KATP channel opening enhances burst firing activity.  
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Nevertheless, there is very little documented data about the presence of these 
receptors, as well as their modulatory roles in the ventral tegmental area (VTA) and 
prefrontal cortex (PFC), two important brain areas involved in the control of our emotion. In 
the present study, we have investigated whether this drug can modulate neuronal activity in 
VTA and PFC using in vivo extracellular single-unit recordings, in anaesthetised rats. We 
also examined in vitro, the effects of this drug on dopamine transporter activity using 
striatum synaptosomes, as well as performed qualitative estimation of Kir6.2 channels 
distribution in specific brain regions such as PFC, striatum and the midbrain through the use 
of western blot technique. 
 
III-2- Materials and methods 
 III-2-A-Subjects 
  Please refer to paragraph I-2-A for detail information on animal conditions 
and regulatory protocol on a study involving rodents. 
  
III-2-B- In vivo extracellular single-unit electrophysiology 
  Please refer to chapter I for a description of electrophysiological experiments. 
All recordings in the ventral tegmental area (anteroposterior -4.5 to -5.5 mm to Bregma, 
lateral 0.3-1.2 mm, 7.2-9.5 mm below the cortical surface) were made in chloral hydrate (400 
mg/kg) anaesthetised rats. Dopamine neurons were identified according to criteria 
summarised by (Ungless and Grace, 2012b). Only presumed dopaminergic neurons generally 
presenting a notch in the rising phase, a prominent negative compound and a time greater 
than 1 ms, from the start of the depolarization to the end of the repolarisation, were selected 
in our study. We also tested TBT on few identified non-dopamine neurons in the midbrain 
that did not fulfilled VTA dopamine neurons criteria (main criteria was action potentials (AP) 
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duration < 0.9 ms calculated from the spike propagation to the negative peak phase of the 
AP), as well as, when possible a lack of inhibition, or even an activation, of the neurons by 
systemic administration of low dose dopamine D2 agonist (25 µg/kg i.v apomorphine) 
(Ungless and Grace, 2012a). Urethane (1.5g/kg) anaesthetized rats were used for recording 
pyramidal neurons in the prefrontal cortex (PFC, anteroposterior 2.5 to 3.5 mm to Bregma, 
lateral 0.3-1.7 mm, 1.5-5.5 mm below the cortical surface). Presumed pyramidal PFC neurons 
were identified according to previous electrophysiological criteria (Gronier, 2011b; Wang et 
al., 2011). A broad action potential (>1 ms), with a biphasic or triphasic large waveform 
action potential, starting with a positive inflection, a relatively slow firing rate (1-50 
spikes/10 sec) and an irregular firing pattern, often with burst activities Outputs from the 
electrode were sent to a Neurolog AC pre-amplifier and amplifiers (Digitimer, UK). In some 
of the in vivo experiments involving tolbutamide, small volumes of a 5 % glucose solution 
were administered to prevent hypoglycaemia. However, this procedure was found to be 
unnecessary as we found that anaesthetic condition leads to a permanent state of 
hyperglycaemia, totally insensitive to insulin or insulin secretagogues like sulphonylurea 
(indicate if you have a figure showing that). Blood glucose levels were monitored with Accu-
Check glucometer. Signals were filtered and sent to an audio amplifier, a Tektronix 2201 
digital storage oscilloscope, and a computer running Spike 2, for data capture and analysis. 
Please refer to paragraph I-2- for detail information on animal conditions and regulatory 
protocol on a study involving rodents. 
III-2-C- 3[H] Dopamine uptake studies by striatal synaptosomes 
  Striata were isolated and used to prepare  synaptosomes according to (Dunkley 
et al., 2008) with minor modifications as indicated in the use of not more than 5 strokes 
during homogenization of synaptosomes. Please, refer to chapter I for detail description of 
radiometric uptake protocols. Dopamine uptake was assayed using [3H] dopamine, 10 nM) 
96 
 
and synaptosomes were incubated with tolbutamide 30 µM or diazoxide 100 µM in a total 
volume of 400 µl for 30 min at 37°C. Non-specific dopamine uptake was measured in the 
presence of 10 μM methylphenidate (dopamine uptake inhibitor). Dopamine uptake was 
stopped by addition of 3 ml ice-cold Krebs–Ringer buffer. The suspension was immediately 
filtered under vacuum through Whatman GF/B filters. Radioactivity was determined by 
liquid scintillation spectrometry. Specific [3H] dopamine uptake was defined as the difference 
between dopamine accumulated at 37°C in the presence and absence of methylphenidate. 
III-2-D- Western blot studies on Kir6.2 channel expression in specific brain regions 
 Naïve rats (n=5) were administered an overdose of chloral hydrate followed 
by rapid decapitation. The brain tissues were immediately dissected on an ice-cold platform 
and before being immersed in liquid nitrogen. Tissues were then stored at -80oC until further 
analysis. The Western blot technique is employed for the detection of specific protein 
molecules from among a complex mixture of proteins. These mixtures may include all the 
proteins associated with a particular cell type or tissue. Western blots (WB) are used in 
evaluating protein expression or for assessing the size of a protein of interest (Kurien and 
Scofield, 2015; Mahmood and Yang, 2012a). In this chapter, the western blot technique was 
used to qualitatively evaluate the proportion of Kir6.2 protein expression in specific brain 
regions such as PFC, striatum and midbrain (containing the VTA). The first major step in a 
WB is sample preparation, where samples are mixed with a detergent, usually sodium 
dodecyl sulphate (SDS), which unfolds the proteins in the sample into linear strands and then 
coats them with a net negative charge (Kurien and Scofield, 2006; Mahmood and Yang, 
2012b). The protein molecules are then separated according to their sizes via gel 
electrophoresis. After separation, the proteins on the gel are transferred onto a blotting 
membrane (e.g. nitrocellulose membrane). Following a successful protein transfer, the 
nitrocellulose membrane would carry all of the protein bands originally seen on the gels. The 
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membrane then goes through a treatment process called ‘blocking’ (carried out using non-fat 
dry milk or bovine serum albumin), which prevents the occurrence of any non-specific 
reactions. To detect a specific protein from the protein mixture on the membrane, the 
membrane is incubated with a primary antibody that specifically binds to the target protein. 
After primary antibody incubation, any unbound antibody is washed off with a buffer (e.g. 
using a tris buffered saline with tween i.e. TBST buffer). The membrane is incubated again 
but this time with a secondary antibody that recognizes and binds specifically to the primary 
antibody (Fig. 27). The secondary antibody used in this thesis was linked with a reporter 
enzyme (e.g. HRP i.e. horseradish peroxidase) that produces colour or light, permitting it to 
be detected, imaged and quantified (Kurien and Scofield, 2006; Mahmood and Yang, 2012b). 
Through these processes, therefore, the Western blot technique allows the detection and 
quantification of target proteins from among a complex mixture of proteins.  
 
Figure 26: The primary and secondary antibody complex in Western blotting. 
The primary antibody binds to the target protein and then a secondary antibody linked with a 
reporter gene (e.g. HRP – horseradish peroxidase) then binds to the primary antibody. This 
enzymatic complex can then be detected upon addition of chemiluminescence substrates. 
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Preparation of brain samples 
A 1:1000 dilution of protease inhibitor and RIPA lysis buffer (Cocktail SIGMA) mixture was 
prepared. 500 µl of this mixture was added to each of the dissected brain regions of interests 
namely: frontal cortex, striatum and the midbrain. The tissue samples were then homogenised 
using Polytron PT318 (Kinematica, Switzerland) and then centrifuged for 10 mins at 13,000 
g and 4ºC using a benchtop temperature-regulated centrifuge (Sorvall Legend Micro 17R, 
Thermo Scientific, UK). The supernatant was extracted and 100 µl of the extract added to 
100 µl of 2x electrophoresis buffer (5% β-2-mercaptoethanol, 20% glycerol, 0.5 M Tris-HCl 
of pH 6.8, 0.006% w/v bromophenol blue and 10% sodium dodecyl sulphate). The resultant 
mixture was heated at 90ºC for about 3 mins and then stored at -80ºC for later use. The 
remaining supernatants were used in estimating the concentrations of the total proteins using 
Bradford assay kit (Sigma Aldrich, UK), which allowed for equal protein concentrations (20 
µg/µl) of the brain samples to be loaded. According to Lambert-Beer's law, the Bradford 
assay curve should produce a straight line curve. In practice, you may get a curve at high 
protein amounts. Disregard the curved data and also any data points that are clearly outliers. 
Then we use linear regression to calculate the slopes b of the lines, we make sure 0 µg 
standard was included and test for any signal produced by the buffer 
Estimation of brain tissue protein concentration 
A standard protein curve was generated from the Bradford assay by diluting 1.0 mg/ml of 
bovine serum albumin (BSA) in distilled water to yield a range of concentrations from 0 - 1 
mg/ml at intervals of 0.1 mg/ml. The protein standards were made in duplicate. From the 1.0 
mg/ml BSA stock, the standards were prepared as shown below: 
 BSA stock (100 µl)  1.0 mg/ml 
 90 µl stock + 10 µl diluent 0.9 mg/ml   
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 80 µl stock + 20 µl diluent 0.8 mg/ml   
 70 µl stock + 30 µl diluent 0.7 mg/ml   
 60 µl stock + 40 µl diluent 0.6 mg/ml   
 50 µl stock + 50 µl diluent 0.5 mg/ml   
 40 µl stock + 60 µl diluent 0.4 mg/ml   
 30 µl stock + 70 µl diluent 0.3 mg/ml   
 20 µl stock + 80 µl diluent 0.2 mg/ml 
 10 µl stock + 90 µl diluent 0.1 mg/ml 
 0 µl stock + 100 µl diluent 0.0 mg/ml 
Along with the protein standards, tissue homogenates were also diluted 1 in 8 with distilled 
water and loaded into a 96-well plate (Multiwell plate, polystyrene 96-well, Fisher Scientific, 
UK). 200 µl of Bradford reagent (Sigma-Aldrich, UK) was then added to each well. The 96-
well plate was mixed gently, covered with a foil and incubated at 37C for 30 mins. 
Following incubation, the plate was allowed to cool for 10 mins, mixed gently and the foil 
removed before being placed in a microplate reader (uQuantTM, BioTek, USA) set at 595 nm. 
Before the calculation of the concentration (µg/µl) of protein in each sample, the standard 
curves were checked for outliers.  
SDS-PAGE electrophoresis 
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
using the BIO-RAD Mini-Protean system. Glass plates (0.75 mm) along with its spacer plates 
(BIO-RAD, UK) were mounted in support cassettes. Before sealing the cassettes, the lower 
borders of both the glass plates and their spacers were checked to ensure correct alignment. 
The gel cassettes were then clamped against a casting frame, which allowed a level pouring 
of gels. To maximise the resolution of protein molecules, a discontinuous SDS-PAGE system 
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was employed. Both the stacking and the separation (resolving) gels were prepared with 
standard acrylamide gel reagents using concentrations estimated from the Chang Bioscience 
website (http://www.changbioscience.com/calculator/sdspage.html). A 10 ml of 12% 
separation gel (for 10 – 200 kDa proteins) was prepared as follows: 
 30% Polyacrylamide    4.0 ml 
 1.5 M Tris-base (pH 8.8)   2.5 ml 
 10% Ammonium persulphate   0.1 ml 
 10% SDS     0.1 ml 
 TEMED (tetramethylethylenediamine) 0.004 ml 
 Distilled water    3.3 ml 
 
 
A 5 ml of 5% stacking gel was also prepared as follows: 
 30% Polyacrylamide    0.85 ml 
 1.0 M Tris-base (pH 6.8)   0.63 ml 
 10% Ammonium per sulphate  0.05 ml 
 10% SDS     0.05 ml 
 TEMED     0.005 ml 
 Distilled water    3.4 ml 
The prepared separating gel solution was gently inverted two or three times and then 
dispensed into the space between the mounted glass plate and the spacer plate of the gel 
cassettes. To ensure a smooth surface, a small layer of isopropanol was placed at the top of 
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the separating gel and left for 30 mins to polymerise. After polymerisation, the isopropanol 
was decanted and the stacking gel solution was prepared and poured on top of the separating 
gel. A 15-well comb (3 mm x 10 mm, BIO-RAD, UK) was then inserted gently in the gel, 
refilled and left for an hour to polymerise. Subsequently, the wells were thoroughly rinsed 
with distilled water to remove excess polymerised acrylamide. The gels were then connected 
to the electrophoresis tank and then filled with 1x running buffer prepared from a 10x stock. 
A litre of the 10x running buffer stock was prepared as follows: 
 Tris-base   30.3 g    25 mM 
 Glycine   144 g    250 mM 
 SDS    10 g    1% 
 Distilled water  up to 1000 ml 
Equal concentrations (20 µg/µl) of each tissue sample were loaded into the wells. The first 
and the last wells contained 2 µl of all blue precision protein standard (BIO-RAD, UK) and 2 
µl of 2x electrophoresis buffer (negative control), respectively. The standard protein aided in 
the later estimation of the molecular weight range of the proteins of interest. Before loading, 
all the samples were denatured at 90C for 3 mins. The samples were initially run at 120 V 
for 15 mins to allow sample passage through the stacking gel followed by 100 V for 45 mins. 
The bromophenol blue tracking dye present in the electrophoresis (loading) buffer and/or the 
all blue standard protein marker allowed the visualization of protein movement in the gel.  
Protein transfer 
The separated proteins were transferred from the gels onto a ProtranTM nitrocellulose 
membrane (GE Healthcare, UK) via a transfer sandwich and an electroblotter. The transfer 
sandwich consisted of two pieces of white scotch-brite pads (200 mm x 160 mm, BIO-RAD, 
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UK), two pieces of 3 mm Whatman filter papers (Fisher Scientific, UK) and a piece of 
nitrocellulose membrane. The transfer sandwich was arranged as follows:  
 
 Scotch-brite pad 
 Whatman filter paper 
 Gel 
 Nitrocellulose membrane 
 Whatman filter paper 
 Scotchbrite pad 
The black side of the transfer cassette was placed on the workbench and each element in the 
transfer sandwich was soaked in a transfer buffer, and then stacked on the cassette with air 
bubbles being dispelled at each stage by rolling sterile glass pipette over the sandwich. The 
cassette was then sealed and inserted into a Mini trans-blot tank (BIO-RAD, UK), while 
taking note of the colour codes (red for red). The transfer tank was filled with cold (4C) 
transfer buffer. One litre of 1x transfer buffer (pH 9.2) was prepared as follows: 
 Tris-base   5.82 g    48 mM 
 Glycine   2.93 g    39 mM 
 Methanol   200 ml    20% 
 Distilled water  up to 1000 ml 
The transfer set up was then run at 100 V for 1 h. Following the transfer procedure, the 
nitrocellulose membranes were stained a Ponceau S dye to allow an estimation of transfer 
efficiency. The nitrocellulose membranes were immersed in the Ponceau S dye and left on a 
shaker for 5 mins. After staining, the nitrocellulose membranes were placed in a destaining 
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solution (5% glacial acetic acid) and left on the shaker for 5 mins. The destaining solution 
was changed 3-5 times until clear bands with almost no pink background were obtained. A 
0.1% (x/v) Ponceau S dye in 1% (v/v) acetic acid was made as follows:  
 Ponceau S dye    0.033 g 
 Glacial acetic acid   0.3 ml 
 Distilled water   up to 30 ml 
Dissolving 5 ml of the 100% glacial acetic acid in 95 ml distilled water also yielded a 100 ml 
of 5% glacial acetic acid.  
 
Immunoblotting 
Following Ponceau staining, a 10x TBS stock was (24 g Tris-base, 88 g NaCl, distilled water 
up to 1000 ml, pH 7.6) prepared. The membranes were blocked with 3% (w/v) non-fat dried 
milk in 1x TBST (0.1% Tween 20 in 1x TBST; blocking buffer) for 1 h at room temperature 
to prevent non-specific antibody binding. The 3% non-fat dried milk blocking buffer was 
observed to produce better quality bands with less background compared to 5% non-fat dried 
milk buffer. Primary antibodies were incubated overnight at 4C in blocking buffer. 
Appropriate dilution ratio was used according to manufacturer’s specifications (anti-
potassium channel Kir6.2 antibody, 1:200, and predicted molecular weight, 44kDa). 
Following overnight exposure to the appropriate primary antibodies, the membranes were 
washed three times with 1x TBST for 5 mins each time, to wash off unbound antibody. The 
membranes were then incubated with the relevant secondary antibody in blocking buffer. In 
accordance with the enhanced chemiluminescence (ECL) system (Amersham Biosciences, 
UK), the secondary antibodies (bs-0295G-HRP 1:2000) used was linked to the detection 
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enzyme, horseradish peroxidase (HRP). After secondary antibody binding, the membranes 
were again washed three times with 1x TBST for 5 mins each. Following the last wash, the 
membranes were developed via the ECL plus detection kit (Amersham Biosciences, UK), 
which allows the emission of light produced in a multistep reaction in which peroxidase 
catalyses the oxidation of luminol. In this procedure, the nitrocellulose membranes were 
incubated with ECL reagent A (luminol), and reagent B (peroxide) for 5 mins (1:1 dilution). 
After the 5 mins exposure, excess ECL reagents were poured off and the membrane was 
sealed in a plastic wrap (Saran™ film). The image analysis was carried out by capturing the 
membrane images on the blot using a CCD-camera-based imager ChemiDoc MP (Bio-Rad). 
 
Membrane stripping and reprobing 
For all experiments, the nitrocellulose membranes were stripped following film development. 
Stripping allowed for the removal of the primary and secondary antibodies from the 
membranes. The membranes were then re-probed with the rat anti-β-actin monoclonal IgG1 
primary antibody. The β-actin protein was used as a control for the amount of protein loaded 
into each well. A mild stripping buffer (containing 15 g glycine, 1 g SDS, 10 ml Tween20, 
distilled water up to 1000 ml, pH 2.2) was prepared. The membranes were washed twice with 
stripping buffer for 10 mins each at room temperature. The membranes were then washed 
twice with 1x PBS for 10 mins each, followed by a 5 mins wash with TBST. A 10x PBS 
stock solution was prepared as follows: 
 NaCl     80.0 g 
 KCl     2.0 g 
 KH2PO4    2.4 g 
 Na2HPO4    14.4 g 
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 Distilled water   up to 1 L 
 pH     7.4 
The membranes were then blocked for 1 h with 3% non-fat dried milk blocking buffer, after 
which the immunoblotting protocol was repeated with anti-β-actin primary antibody and an 
anti-rat secondary antibody.   
III-2-E-Drugs 
  All drugs and antibodies were purchased from Abcam (Biotechnology 
company, UK), except, tolbutamide (Sigma-Aldrich, UK), primary antibody (anti-potassium 
channel Kir6.2, Sigma-Aldrich, UK in 1:200 dilution) and secondary antibody (bs-0295G-
HRP, Bioss antibodies UK), The drugs were dissolved into Krebs (release assays) and 
HEPES (uptake) buffers, as appropriate. However, the drugs were dissolved in dist illed water 
or saline for electrophysiological studies. 
 
IV-2-F-Statistical analysis 
  All results are expressed as the mean +/- SEM. Changes were considered 
significant if p<0.05. This was assessed by using one or two-way ANOVA tests followed by 
Neuman-Keuls or Bonferroni posthoc tests (as appropriate), Student's t-tests and Chi-square, 
where appropriate. Kir6.2 channel protein quantifications were analyzed using ImageJ 
software following visual membrane images captured by CCD-camera-based imager 
ChemiDoc MP (Bio-Rad). The expression of each protein was normalized to the 
housekeeping protein β-actin. Data were expressed as a percentage of the control group 
(saline, mean±standard error of the mean). 
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III-3- Results 
 III-3-C1- Tolbutamide biphasically alters VTA dopamine neurons' firing activity 
 In the VTA, the insulin secretagogue tolbutamide (TBT, 20 and 40mg/kg, iv) induced 
biphasic effects on the basal activity of most of the dopamine neurons tested (Fig. 25A, C) 
large inhibition (up to 100%) during a relatively short period (1-3 min), caused by 
hyperpolarization, followed by a long-lasting statistical (F (3, 37)=14.84) significant 
excitatory effect (up to 40% of the baseline activity). Such an increase in neuronal 
excitability was slightly associated with alteration in the pattern of burst activity in some 
neurons (Fig. 27B). The proportion of neurons that responded to TBT and saline 
administration via activation or inhibition was analysed (Fig. 27D). We also noted that there 
is no significant decrease in glycaemia with anaesthetized animals after the administration of 
SU, as glycaemia has skyrocketed due to the presence of the anaesthetic. 
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Figure 27: VTA dopamine electrophysiological recording during tolbutamide acute 
treatment 
(A): TBT (20 and 40 mg/kg) biphasically altered the firing activity of DA neurons compared 
to baseline, first by brief inhibtion (1-3 mins) and followed by significant activation. (B): The 
burst activities were enhanced in most neurons tested with TBT. (C): TBT (20 and 40 mg/kg) 
dose-dependently increased the firing rate of DA neurons after the inhibitory phase. (D): 
Comparison between the two treatments, using Chi-square followed by Fisher’s exact post 
hoc test. **P<0.01, **P<0.01 vs. baseline, Newman–Keuls after significant ANOVA. 
##P=0.0045, Fisher’s exact test after significant Chi-square analysis.  
III-3-C2-Tolbutamide monophasically alters VTA non-DA neurons' firing activity 
TBT (20 and 40 mg/kg, i.v) induced generally a monophasic excitatory effect on the 
non-DA VTA cell (Fig. 28B, C). Fig. 28A shows neurons with no alteration in firing rate. 
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Statistical analysis of neuronal responses (inhibition, excitation and no effect) between saline 
and acute TBT administration (Fig. 28D). 
 
 
Figure 28: Midbrain non-DA electrophysiological recording during acute TBT 
administration 
(A): TBT (20 and 40 mg/kg) did not alter the firing activity of this non-dopaminergic neurons 
(identified from established criteria) (B, C): Another non-DA cell exhibited a monophasic 
activation of the firing rate upon administration of TBT and apomorphine 10 µg/kg further 
increased its firing activity. This is a typical excitatory effect of apomorphine on non-
dopaminergic neurons. (D): Proportion of TBT treated non-DA neurons responses (excitatory 
or inhibitory from more than 20% of basal firing activity. #P<0.001, *P<0.05 vs. baseline 
firing; ##P=0.0021, Fisher’s exact test after significant Chi-square analysis.  
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III-3-C3-Tolbutamide increases PFC pyramidal neurons' firing activity 
  In the PFC, tolbutamide (TBT, 20 and 40 mg/kg, iv) acute administration 
dose-dependently and significantly increased the firing activity of most of the PFC neurons 
tested (about 75%) but, more usually, in a monophasic way (Fig. 29A, B), than in the 
biphasic pattern. Figure 29E, F show that the proportion of neurons showing increased firing 
activity following TBT is significantly higher than the proportion of neurons showing 
reduced and no effects. Effect of saline on PFC neurons displayed 76% of no response and 
about 15% of the neurons manifested an increase in firing activity (Fig. 29D, F). We also 
observed a biphasic neuronal firing in only about 10 % of the pyramidal neurons (Fig. 29C). 
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Figure 29: PFC electrophysiological recording during tolbutamide acute treatment 
(A, B): TBT (20 and40 mg/kg) significantly increased firing activity on pyramidal neurons 
compared to the baseline firing rate **P<0.001 vs. baseline firing, followed by Newman–
Keuls after significant ANOVA. (C): In few a neurons (about 10%), TBT administration 
induced biphasic effect similar to VTA DA neurons firing (see figure 27).  (D, E): Proportion 
of electrophysiological responses (no response, increase, decrease) of PFC neurons to the 
administration of TBT or to administering saline. (F): The proportion of TBT treated 
pyramidal neurons responses (excitatory or inhibitory from more than 15% of basal firing 
activity.*P<0.05 vs. baseline firing, Chi-square analysis. #P=0.013  
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III-3-D1-TBT and DZ reduce synaptosomal3 [H] DA uptake to enhance the release 
  TBT (30µM) shows a significant reduction (t=2.655 df=10) in striatal 3[H] DA 
uptake compared to the baseline control uptake (Fig. 30A). Similarly, in (Fig. 30B), we 
observed a paradoxical significant drastic reduction in 3[H] DA uptake with 100µM DZ 
(t=3.361 df=16) an effect similar to TBT. The reduction with TBT was further significantly 
enhanced (F (2, 15) =92.56) in the presence of DZ (100µM), a KATP channels opener (Fig. 
30C).  
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Figure 30: Striatal synaptosomal 3[H] DA uptake of TBT and diazoxide 
TBT (30µM) and DZ (100µM) showed a statistical significant reduction in 3[H] DA uptake 
after 30 mins incubation period *P<0.05, and **P<0.01 respectively, Student's t-test (A, 
B).C: In the presence of diazoxide (DZ) 100µM, TBT inhibition on DA uptake was 
statistically enhanced. **P<0.01, ***P<0.0001 vs. control, ANOVA followed by Newman–
Keuls after significant one-way ANOVA. 
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III-3-D2- High strength glucose dose-dependently reduces synaptosomal 3[H]DA uptake 
 Effect of metabolic change (varying degree of glucose level) on striatal 3[H]DA 
uptake was carried out. We aimed at testing the hypothesis that metabolic alteration may 
modulate dopaminergic transmission in the mesolimbic circuits (Narayanan et al., 2010). 
When the incubation medium for dopamine uptake was enriched to 40 mM, there was no 
alteration in striatal 3[H] DA uptake when compared to the control (Fig. 31A). However, at 
80mM of glucose concentration, striatal synaptosome 3[H] DA uptake significantly (F=1.021, 
DFn=11, DFd=8) increased slowly in response to this dramatic change (Fig. 31B). The buffer 
that had a low concentration of glucose showed no changes in striatal 3[H] DA uptake when 
compared with the control (Fig. 31C). 
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Figure 31: Striatal synaptosomal 3[H] DA uptake of Glucose  
(A): Glucose (40mM) did not show any alteration in 3[H] DA uptake after 30mins incubation 
period P=0.6721, Student's t-test (B): Glucose (80mM) showed a statistically significant 
reduction in 3[H] DA uptake after 30mins incubation period *P<0.05, Student's t-test. (C): In 
the presence of low glucose concentration about 3-4mM there was no alteration in 3[H] DA 
uptake at any point in time. 
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III-3-E- Protein expression of Kir6.2 channel on specific brain regions 
 This experiment aimed to investigate the presence of Kir6.2/KATP channels, 
and its proportion in the brain regions (PFC, striatum and midbrain) of interest. Since, our 
electrophysiology study has revealed that neurons containing Kir6.2/KATP channel in the PFC 
and VTA were activated by TBT, which may suggest the functions of the channels in 
mediating cognitive and reward processes. Our qualitative western blot results indicate that 
Kir6.2 channel was distributed in the three brain regions in seemly equal amount. Fig. 32A, 
B, C are the locations distribution of Kir6.2 channels in the PFC, striatum and VTA 
respectively. Fig. 32D illustrates representative blots from different brain regions namely, 
PFC, striatum and the VTA.  
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Figure 32: Kir6.2 channels distribution in the PFC, striatum and the midbrain 
(A): Kir6.2 channels distribution in the PFC (B): Kir6.2 channels distribution in the striatum 
(C): Kir6.2 channels distribution in the midbrain containing the VTA (D): Western blots 
distribution of Kir6.2 channels in the three brain regions. There is limitation to western blot 
technique due to lack of spatial distribution of the protein. 
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III-4- Discussion 
 KATP channels are abundantly present in many sensitive tissues and act as a regulator 
of metabolically associated excitation of neurons, as well as control of energy homeostasis 
(Nichols, 2006). These channels are metabolic sensitive to ATP intracellular changes which 
are, at least in part modulated by glucose or lactic acid metabolism; thus, when the cells are 
in energy surplus the channels can be inactivated (Cota et al., 2007), which can promote 
depolarization and cell activation. Briefly, we evaluate the presence of Kir6.2 channel in all 
the three brain regions (PFC, striatum and midbrain). Our data demonstrated the presence of 
Kir6.2 channels in all the three regions, although, we did not quantify the level in each of the 
region (Fig. 32). To support our findings, previous studies have also demonstrated  Kir6.2 
channel expression  in the cortex and hippocampus (Héron-Milhavet et al., 2004; Moriguchi 
et al., 2018), striatum (Patel et al., 2011; Shi et al., 2008) and in the SN (Schiemann et al., 
2012b). Here, we provide a pilot finding of the expression of Kir6.2 in the midbrain. The 
VTA, part of the mesolimbic system, is concerned with reward as well as motivation hence, 
our data shows that manipulation of  KATP/Kir6.2 channels may alter the electrical response 
of VTA DA neurons which can impact on reward (Ranaldi, 2014).  Thus, our data showed 
that VTA dopamine neurons are sensitive to metabolic status. VTA neurons are important 
targets for metabolic hormones such as leptin, glucagon-like peptide-1, ghrelin and insulin. 
Insulin receptors are located on dopamine neurons in the ventral tegmental area (VTA) hence, 
any change in the level of this hormone affects the VTA neuron firing activity. In the 
presence of anesthetic with saline administration as control, we did not notice any alteration 
in the firing rate of the VTA DA neurons. However, in the presence of TBT, marked 
alteration beginning with inhibition and followed by excitation were noticed resulting from 
Katp/Kir6.2 channels blockage. The significance of this remains to be established. The results 
presented show that most VTA dopamine neurons responded to TBT acute administration 
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generally with inhibition followed by excitation of electrical activity (Fig. 27A). There is now 
evidence for a possible positive association between nigral dopaminergic neuronal loss, a 
pathological basis of Parkinson disease (Dauer and Przedborski, 2003; Shimohama et al., 
2003), and KATP channels activation in particular from studies in 6-hydroxydopamine (6-
OHDA) treated rats (Piri et al., 2017a). Electrophysiological studies on substantial nigra (SN) 
dopamine neurons revealed that KATP channels present in SN DA neurons may be involved in 
the regulation of burst activity as a genetic depletion of the Kir6.2/KATP channels in mice 
significantly reduced the burst activity of SNC neurons (Schiemann et al., 2012b). Recent 
papers suggest a potential use of Kir6.2/KATP channels  blockers for the management of 
Parkinson disease (Zeng et al., 2008; Du et al., 2018; Han et al., 2018). According to some 
studies blocking the K-ATP channel can slow down neurodegeneration, by a mechanism that 
needs to be elucidated (Peltier and Vecchio, 1961). Interestingly, Kir6.2 inhibitors reversed 
the hyperpolarizing effect caused by reactive oxygen species (ROS) in particular hydrogen 
peroxide, which is a potent channel opener (Avshalumov et al., 2003). In simplified term, it is 
suggested that in a condition of stress the closing of this channel on the dopamine cells may 
play a role to prevent the cell to fall in an inactive state leading to cell death (Santos et al., 
2019). Similarly, burst-stimulating discharge effect has also been reported by Fridlyand et al., 
2010b; Gomis and Valdeolmillos, (1998b) on pancreatic β-cells. Accordingly, these channels 
add to the traditional mechanisms of burst regulation for dopamine neurons. We have for the 
first time demonstrated the effect of the KATP channels blockage on VTA dopamine neurons. 
We also report a biphasic effect starting as a near-complete inhibition during a relatively 
short period (1-3 min), associated with hyperpolarization, and followed by a long-lasting 
excitatory effect (up to 40% of the baseline activity). Here, we hypothesize that initial 
inhibitory effect caused by neuronal hyperpolarization was due to activation of GABA 
interneurons which are the main inhibitory neurons in the VTA. Activation of GABA spiny 
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neurons, possibly triggered by TBT, in the NAc may also relay powerful GABA modulatory 
innervations to the VTA. This was followed by stimulation of DA neurons with rapid 
depolarizing firing activity. Though being a hydrophobic molecule, TBT is an insulin 
secretagogue, KATP channels blocker and there is a direct connection between electrical 
discharge activity (Atwater et al., 1980) and exocytotic insulin release (Gilon et al., 1993). A 
body of literature has also demonstrated that TBT possesses a low brain distribution 
pharmacokinetic property, which has been attributed to P-glycoprotein-efflux transport 
system (Takanaga et al., 1998),  as well as pH and membrane /potential –dependent transport 
efflux processes (Koyabu et al., 2004). Given this background, we utilized an escalated 
dosage of TBT at relatively high doses to allow for adequate concentration in the brain. 
Another recent finding from our laboratory on memantine, a drug used in the clinical 
management of moderate to severe Alzheimer's disease exhibited a dose-dependent activation 
of pyramidal neurons on PFC (unpublished). Our new report further demonstrated that 
activation of pyramidal neurons in the PFC is associated with cognitive enhancement. This 
possibly explains reason TBT alleviates cognitive impairment in a patient with a neurological 
disorder, an effect due to Kir6.2 blockage and pyramidal neurons in the PFC (Slingerland et 
al., 2008). This finding further suggests that TBT is possibly acting directly on the brain via 
Kir6.2/KATP channels inhibition and SUR1 activation. 
Our findings on radiometric 3[H] DA uptake assay revealed a significant reduction in 
dopamine uptake with TBT tested on striatal synaptosomes. An effect that potentially 
increases dopamine output in the postsynaptic terminals through the inhibition of DAT. The 
data described from this experiment shows that KATP channels can modulate striatal dopamine 
uptake, associated with DAT activity regulation under a non-pathological condition. Thus, it 
can be that TBT has some affinity for the dopamine transporter. Essentially, KATP channels in 
the brain are in the closed state under normal physiological condition and have been 
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implicated in ischemic brain injury, providing a  neuroprotective function (al; Ben-Ari et al., 
1990). These channels are also responsible for maintenance of glucose homeostasis via 
metabolic sensitivity in the hypothalamic region of the brain (Ashford et al., 1990; Routh, 
2002) and modulation of vagal neuronal activity (Trapp et al., 1994b), as well as controlling 
the functional effect of respiratory neurones (Pierrefiche et al., 1996). The present 
investigations demonstrated the regulatory role of KATP channels in striatal synaptosomes that 
demands DAT as a principal regulatory transmembrane agent. Interestingly, there is general 
credence that activation of KATP channels in an ischemic event possesses neuroprotective 
effects by prompting depletion in energy utilization (Fujimura et al., 1997). It follows that 
opening of KATP channels causes hyperpolarization of the neurons and subsequently 
equilibrates the resting membrane potential in ischemic condition, particularly in an energy- 
deficient system when adenosine triphosphate (ATP) is reduced to adenosine 
diphosphate  (ADP) (Sun et al., 2006; Yamada et al., 2001). However, recent evidence has 
contradicted the use of sulphonylureas in the management of cerebrovascular disorder as a 
compromising agent to achieve neuroprotection (Liu et al., 2016). The studies further 
explained that tolbutamide induces neuronal injury by stimulating oxygen-glucose 
deprivation (OGD) and persistent middle cerebral artery occlusion (MCAO). Whereas, the 
opening of these channels by diazoxide lowered the effects of both neuronal injuries (Liu et 
al., 2016). Liu et al., (2016)  findings revealed that closing the Kir6.2/KATP channel by TBT 
enhanced the neuronal trauma caused by oxygen-glucose deficiency (OGD) and enduring 
middle cerebral artery occlusion (MCAO). Thus, they postulated that Kir6.2/KATP activation 
by DZ reduced OGD and MCAO in diabetic-induced mice through streptozotocin treatment. 
Another recent contrasting study has demonstrated the anti-Parkinson effect of KATP channels 
blocker in 6-hydroxydopamine –induced rat model of Parkinson (Piri et al., 2017b). Thus, 
may prevent the neuron to die as in Parkinson disorder in which there is a shortage of ATP 
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from mitochondria, which leads to the constant opening of the channel, the neuron may 
become silent and start dying more quickly. Interestingly, DZ a KATP channels activator 
exhibited a more pronounced striatal 3[H] DA uptake reduction; an effect possibly expected 
to be reversed in this condition. This implies from our results that both drugs TBT and DZ 
may exhibit some specific similar effect on striatal synaptosomes by inducing a reduction of 
3[H] DA uptakes. This is in variance with a study that demonstrated an antagonistic effect of 
DZ on glucose-induced (Kr6.2/KATP channels blocking) dopamine release from 
pheochromocytoma-12 cells (PC-12) (Koshimura et al., 2003). In addition, paradoxical effect 
of DZ has been reported due to its non-specific action (Schikman , et al 1978). We also tested 
the effect of high concentration of glucose on DAT activity. We show that, at a glucose 
concentration of 80 mM which is an escalating dose, typical of a patient in a diabetic coma, 
the DAT activity was significantly inhibited which resulted in a reduction in 3[H] DA uptake. 
Conversely, in the absence of glucose, the uptake process was aborted, indicating that glucose 
is primarily responsible for energy transport in the neuronal transmission. However, more 
recent studies have shown that other metabolic substrates such as lactate (Riske et al., 2017), 
pyruvate (Koivisto et al., 2016) as well as glutamate (Fendt and Verstreken, 2017) are  also 
responsible for fueling of mitochondrial metabolism in the brain function. These findings enhanced 
the probability that the presence of glucose regulates neurotransmitter uptake in  neuronal 
cells which represent similar activity in pancreatic β-cells of the islet of Langerhans (Taylor 
et al., 1999). Thus, glucose in high concentration (80mM) stimulated membrane 
depolarization, which signals the voltage-gated Ca2+ channels to trigger exocytotic dopamine 
release via DAT inhibition (Fridlyand et al., 2013; Han et al., 2018b; Komatsu et al., 2013). 
From all the neurochemical studies, our collective findings show that TBT and glucose can 
modulate KATP channels and bring about membrane depolarization via action on DAT to 
cause reduced striatal 3[H] DA uptake. Since DAT activity has been known to be widely 
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dependent on the degree of ATP as well as sodium and potassium slopes, we hypothesize that 
TBT, DZ and glucose modulate KATP channels by inhibiting DAT activity which results into 
increase in extracellular dopamine levels. 
 In conclusion, TBT at high dose induced a biphasic effect on the dopamine neurons, 
an effect plausibly mediated by KATP channels blockage through sulphonylurea receptors 
activation. We also infer that period of inhibition (hyperpolarization) may be due to GABA 
interneurons or as possible negative feedback from activated accumbens neurons which send 
strong GABA inhibitory innervations to VTA. Interestingly, TBT activatory effect on 
pyramidal neurons of the PFC may indicate it could exert a positive effect on cognition and 
memory due to its ability to activate glutamatergic neurons on the PFC. Such an effect may 
not occur immediately in treated diabetic patients due to the relatively poor brain 
penetrability of the drug. The neurochemical studies show evidence of a significant reduction 
in specific dopamine uptake with TBT, DZ and glucose; these indicate a possible interaction 
of the drugs with dopamine neurotransmission (uptake or release) which may further be 
linked with reward processes (Sidló et al., 2008).  
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Chapter IV-Activation of glucagon-like 
receptor-1 modulates dopaminergic and 
glutamatergic transmission in rats’ brain 
regions 
 
IV-1- Introduction 
Glucagon-like peptide-1 (GLP-1) is an endogenous insulin-producing gut hormone 
belonging to the incretin family (Calsolaro and Edison, 2015b). It is released by endocrine L- 
cells after feeding, stimulates insulin secretion and biosynthesis, prevents glucagon release as 
well as extends gastric fullness by reducing gastric emptying (Drucker, 2003a, 2003b). 
However, GLP-1 is not only essential metabolic hormones (Bae and Song, 2017), but can 
also modulate important brain function unrelated to feeding behaviour (Cabou and Burcelin, 
2011). Different evidence suggests that these peptides can affect cognition (Abdelwahed et 
al., 2018; Gault et al., 2010a), motivation (Alhadeff and Grill, 2014; Alhadeff et al., 2014), 
addictive behaviour, as well as neuronal survival (Liu et al., 2015; Salcedo et al., 2012; 
Sharma et al., 2014). As a result of this neuromodulatory effect, GLP-1Rs have been 
identified in the cortex and hippocampus (Rebosio et al., 2018), hypothalamus (Liu et al., 
2017), nucleus accumbens (Hernandez et al., 2019), as well as in VTA (Göke et al., 1995), 
where they perform devised neurophysiologic functions. Evidence has emerged that rodents 
that have their cortical and hippocampal GLP-1R deleted display impairment in a cognitive 
task, while amplification of GLP-1 in the hippocampus increased learning and working 
memory (Abbas et al., 2009; During et al., 2003a). In Abbas et al., (2009) findings, GLP-1  
was administered intracerebroventricularly (i.c.v.), but not peripherally to elicit memory- 
enhancing effect in mice. Also, through genetic manipulation GLP-1R-deleted mice exhibited 
a phenotype characterised by learning deficiency and this was reversed subsequently to 
hippocampal GLP-1R gene transfer. Exendin-4 (Ex-4), a GLP-1, dipeptidyl peptidase-4 
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(DPP-IV)-resistant (Simonsen et al., 2006) and clinically used drug in the management of 
type 2 diabetes mellitus, as well as geniposide (GPO), a new putative GLP-1 agonist of plant 
origin (Rebosio et al., 2018), were the typical GLP-1agents studied in this chapter. GPO is an 
iridoid as well as found as secoiridoids (secondary metabolite), it has been extensively 
explored in the management of Alzheimer’s and Parkinson disorders. Generally, plants 
iridoids of glycoside origin such as GPO, harpagoside and loganin have been shown to have 
pronounced neuroprotective effect on both Alzheimer’s and Parkinson disorders (Dinda et al., 
2019). 
 In the present study, we examined if the two GLP-1 agonists (Ex-4 and GPO) can 
affect some dopamine-dependent behaviours such as the ones we presented in chapter I. 
Following the behavioural investigations, we tested the effect of acute treatment of Ex-4 on 
specific protein expression such as, dopamine transporter (DAT) and GLP-1R, subsequent to 
D-AMP-induced motor activity with the aid of western blot technique. In another series of 
behavioural experiments, we also assessed, if chronically administered Ex-4 influences 
cognitive function in PCP treated rats, through the object recognition test (ORT) as well as 
the peptide acute effect on phencyclidine-induced hyperlocomotion activity. In addition, we 
investigated the role of neurochemical processes of radiometric release and uptake assays on 
3[H] dopamine when GLP-1R is activated.  Finally, we have examined in rats whether the 
stable glucagon-like-peptide-1 receptor agonists Ex-4 or GPO can affect the electrical activity 
of dopamine neurons in the VTA and of pyramidal neurons in the PFC, using single-unit 
activity electrophysiology recording techniques. 
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IV-2- Materials and methods  
 IV-2-A-Subjects 
  Please refer to paragraph I-2-A for detail information on animal conditions 
and regulatory protocol on a study involving rodents. 
 
 IV-2-B- In vitro 3[H]-dopamine and serotonin release assays 
  Please refer to paragraph I-2 for detailed experimental procedures. In addition, 
AMPA effect was studied on 3H [DA] release following the same protocol in paragraph I-2. 
The effect of Ex-4 and GPO are studied on baseline [DA] release, as well as if these peptides 
influence D-AMP-induced 3[H] DA efflux at the postsynaptic terminal of striatal brain slices.  
 
 IV-2-C-In vitro 3[H]-dopamine uptake assay 
  Please refer to paragraphs I-2 for direct uptake assay protocol. In another 
series of experiments, 5-HT uptake was assessed in the PFC as well as uptake interaction of 
GLP-1 with a D2/D3 dopamine agonist in striatal synaptosome. For detailed experimental 
procedures, paragraph II-2-C2 discusses uptake kinetics for KM/Vmax determination 
following intraperitoneal injection of the tested drugs. In this chapter, we studied Ex-4 and 
GPO effects on radiometric uptake parameters. 
  
IV-2-D- Behavioural paradigm 
  Three major behavioural protocols were employed to ascertain the effect of 
Ex-4 and GPO on various behavioural traits. The experiments are object recognition test, 
PCP-induced hyperlocomotion activity and dopamine drug-induced behavioural traits 
assessments.  
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IV-2-D1- Novel object recognition (NOR) test  
  The experiment was carried out according to Broadbent et al., (2010) with 
little modifications in an open field circular box measuring 70 cm in diameter and 58 cm in 
height. The materials consisted of aluminium tin or plastic objects that varied in colour and 
size measuring, width=6.2–7.5 cm; height = 10–13 cm (Fig. 33). The objects were securely 
attached to the floor and separated 7 cm apart. The testing session was recorded manually 
under bright fluorescent lighting for effective illumination of the circular open field. Two 
groups of rats in each category of duration of treatment (n=4), control (0.8 ml/kg saline) and 
treated (ip Ex-4 5µg/kg) given in acute (24hr.), sub-chronic (5days) and chronic doses (2 
weeks). They were acclimatized to the experiment room and the circular open field for two 
consecutive days before the testing (40 min in the experiment room and 5 min to explore the 
empty open field). In another series of experiments, rats were pre-treated with saline 
(0.8ml/kg) or Ex-4 (5µg/kg) and then treated with single i.p. injection 5 mg/kg of 
phencyclidine after the habituation period. 
 
Figure 33: Images of materials used in object recognition model 
The two identical objects represent the familiar objects placed about 7 cm apart during the 
training sessions, while one of the familiar objects is replaced during the test day by the novel 
object. 
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Object familiarization training 
Rats were exposed for a period 4 days familiarization with the two identical objects (three 
exposures each day). Each animal was habituated to the testing room for 45 min and later 
placed in the empty open field for 1 min on each testing day. The rat is removed afterwards 
followed by centrally placing the two identical objects at 7 cm apart. The rat is then returned 
into the open field and allowed to explore for a period of 5 mins. As soon as all the rats in the 
group were familiarized with the two objects, the same protocol was repeated two more times 
on the same day (maximum interval of 60 min ensured between daily exposures). The two 
identical objects were repeatedly exposed to the rats for a period of 4 days. 
Novel objects recognition (NOR) test 
Memory testing started after 5 days of a washout for chronic study and immediately for an acute 
experiment. First, each rat was reacclimatized to the empty open field for a period of 1 min. The rat 
was subsequently removed and later placed in the open field to explore two objects (one new/novel 
object and a duplicate of the familiarized object) for a period of 5 mins. The exploration of the objects 
was scored manually when the rat's nose was about 1 cm away from the object and the whiskers were 
in motion according to Clark et al., (2000). It is noteworthy to know that exploration of objects was 
not considered an effective experimental scoring when the animal rears in an upright scrambling 
position on the object with the nose facing up. Proclivity for the novel object was demonstrated as the 
% time that the animal spent exploring the novel object compared to the familiar object. The 
preference for a novel object means that image of the familiar object still exists in 
animals' memory hence, the higher the % the more the memory for familiar object for 
discrimination. 
  
IV-2-D2- PCP-induced hyperlocomotion studies 
  Rats were transferred individually from their home cages to the test open-field 
arena and then allowed to habituate for 30 min before the start of the experiment. First, we 
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tested the effect of acute Ex-4 (5 µg/kg) on basal motor activity of the rats, whether the drug 
on its own affects the normal basal horizontal movement of the subjects (assessed by number 
of times the rat walks a distance of 10 cm). Adult male Sprague-Dawley rats were treated 
with either Ex-4 (5µg/kg) or saline (0.8ml/kg). In another series of experiment, rats were pre-
treated with either saline (0.8ml/kg) or Ex-4 (5µg/kg) and later treated with single 
intraperitoneal injection 10 mg/kg of PCP. The circular open field arena was divided and 
marked into 4 quadrants, and animals were then scored for behavioural locomotor activity 
such as running across (based on the number of the quadrant that was crossed over by the rat) 
and stereotypic head-shaking traits, during 15-minutes time periods and up to 60 minutes 
following the administration. 
  
IV-2-D3- D-AMP and DA D2/D3 receptor agonist-induced behavioural studies 
  Please, refer to paragraph II-2-D for detailed behavioural protocols. In this 
study, Ex-4 (5µg/kg) and GPO (40mg/kg) were acutely (24hr) and sub-chronically (1 week) 
tested on D-AMP-induced locomotor activity, as well as dopamine D2/D3 agonist-induced 
yawning, pica eating and pelvic grooming in male adult Sprague-Dawley rats. In another 
series of experiment, we investigated the role of 30µg/kg of Ex-9 (a GLP-1 antagonist) on 
both D-AMP induced locomotors effect, as well as in the presence of Ex-4 agonist for 
possible pharmacological interaction at the receptor site.  
 
 
IV-2-E- Western blot studies on DAT and GLP-1 protein expression 
 Following the last behavioural experiments (paragraph IV-2-D3), brain tissues were 
immediately dissected on an ice-cold platform and before being immersed in liquid nitrogen. 
Tissues were then stored at -80oC until further analysis. Western blot technique was 
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deployed, according to paragraph III-2-D for the detection of specific protein molecules from 
among a complex mixture of proteins and how these proteins were altered by acute treatment 
with D-AMP 1 mg/kg or Ex-4 5 µg/kg+D-AMP 1 mg/kg. Appropriate dilution ratio was used 
according to manufacturer’s specifications (DAT 1:1000, β-actin 1:1000 and GLP-1 1:500). 
Following overnight exposure to the appropriate primary antibodies, (the membranes were 
washed three times with 1x TBST for 5 mins each time, to wash off unbound antibody.  
IV-2-E-In vivo extracellular single-unit electrophysiology recording 
  Please refer to paragraph I-4 for detailed protocol. Recordings were done on 
both VTA DA neurons and pyramidal PFC neurons.  However, in this study Ex-4 5µg/kg and 
GPO 40mg/kg were investigated. At a point, we investigated the potential activatory or 
inhibitory effect of Ex-4, 5µg/kg combined with insulin 20µg/kg on the cell bodies of DA 
neurons following an intravenous administration. Next, we assessed the effect of Ex-4 when 
administered directly into the brain region of interest (VTA) through the use of Hamilton’s 
syringe filled with the peptide and allowed to diffuse for up to an hour before extracellular 
recording and when Ex-4 is filled into the recording electrode, lowered into the brain for 
electrophysiological recording.  
 
IV-2-F-Drugs 
  All drugs and antibodies were purchased from Abcam (Biotechnology 
company, UK), except for secondary antibody (bs-0295G-HRP, Bioss antibodies UK), 
geniposide (Carbosynth Ltd, UK) as well as phencyclidine (Tocris, UK). The drugs were 
dissolved into Krebs (release assays) and HEPES (uptake) buffers, as appropriate. However, 
the drugs were dissolved in distilled water or saline for behavioural and electrophysiological 
studies. 
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IV-2-G-Statistical analysis 
  Please refer to paragraph I-2-G for analysis involving radiometric release and 
uptake assays, electrophysiology as well as D-AMP-induced locomotor studies. However, for 
NOR study, data were expressed according to (Aggleton et al., 2010; Ennaceur and Delacour, 
1988) studies, which stipulate that discrimination behaviour can be measured in two ways. 
The first discrimination index (DI) measurement for acclimatization phase is calculated by the 
difference between exploration time for the novel and familiar objects i.e. [D1 = (TN − TF)] 
where TN=Time spent with novel object and TF=Time spent with a familiar object. The 
second measurement of (DI) states that, there is a ratio that exists between differences in time 
explored with novel and familiar object, to the sum of the total time spent with novel and 
familiar object i.e. [DI’ = (TN  − TF)/(TN + TF)] of %.  In both cases, the results were expressed 
as a magnitude of +1, 0 and -1. Where it is positive, this shows more exploration time with 
the novel, and negative exhibits more time spent with the familiar and zero means null 
preference. We utilized % DI for our statistic and further explain in term of magnitude for 
data interpretation. For behavioural experiment involving PCP-induced hyperlocomotion, the 
sums of each movement across a quadrant were counted manually and taken as a factor of 4. 
This means, numbers of movement across a quadrant (Nq) ÷4, equal to the total rat's 
locomotor activity occurring during 15 minutes interval period up to and 60 minutes of total 
experiment duration. This is plotted against the drug administered. Results are expressed as 
the mean±standard error of the mean (SEM) of counts for each rat's movement per group. 
Repeated 2-way ANOVA was also conducted when a significant difference was tested.  
 DAT and GLP-1R protein quantifications were analysed using ImageJ software 
following visual membrane images captured by CCD-camera-based imager ChemiDoc MP 
(Bio-Rad). The expression of each protein was normalized to the housekeeping protein β-
131 
 
actin. Data were expressed as a percentage of the control group (saline, mean±standard error 
of the mean).  
 
IV-3- Results 
 IV-3-A-GLP-1 effect on striatal 3[H] DA and PFC 3[H] 5HT efflux 
  IV-3-A1-Neither Ex-4 nor GPO alters baseline 3[H] DA release 
 The application GPO (40µM) caused a significant reduction in dopamine efflux. 
Surprisingly, when Ex-4 (5µM) was applied, the effect on dopamine efflux remains 
statistically unchanged, yet with a slight reduction in [DA] efflux (Fig. 34A, B). This might 
suggest the seemly absence of GLP-1R on the dopamine terminals that resulted in a lack of 
activity on the baseline [DA] efflux. 
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Figure 34: Dose-response relationship of GLP-1 drugs on striatal 3[H] DA efflux. 
 (A): GPO caused a non-dose response significant reduction in dopamine efflux when 
applied, #P<0.05, Neuman-Keuls after significant one-way ANOVA (B): Ex-4 showed a 
slight non-significant reduction of striatal 3[H]DA efflux, even at an increased concentration. 
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IV-3-A2- Ex-4 and GPO moderately interact with D-AMP and KCL- induced DA 
efflux 
  In the striatum, a large amount of [DA] efflux was evoked in presence of 30 
mM KCL, as well as with 10 µM D-AMP  in the superfusion medium (Fig. 35A, B). The 
striatal slices pre-exposed to GPO 40 µM did not prevent the large DA releasing effects of D-
AMP or KCL (Fig. 35C, E). Similarly, Ex-4 1µM tends to reduce slightly D-AMP-induced 
DA efflux, but this effect was not statistically significant (Fig. 35D) there were no effects of 
GPO on AMPA-induced [DA] efflux (Fig. 35F). 
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Figure 35: GLP-1 effect on D-AMP and KCL-induced 3[H] DA efflux  
(A, C): Superfusion of GPO 40 µM in the presence of D-AMP and KCL did not affect the 
releasing magnitude of both drugs. (B): Ex-4 1 µM exhibited a slight inhibition of D-AMP-
induced DA efflux, but not statistically significant. (D): GPO 40 µM was tested on AMPA 
10µM, the GLP-1 had no effect on [DA] release ns: non-significant, **P<0.001, ***P<0.001 
vs. respective baseline, ns, ***P<0.0001, Student's t-test P>0.05 vs. specified condition, 
Neuman-Keuls after significant ANOVA. 
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IV-3-A3- GPO attenuates KCL-induced 3[H]-5HT on PFC slices 
We tested the activity of serotonergic terminals on KCL-induced DA efflux using 
PFC slices. The addition of GPO to the superfusion medium significantly (t=2.405 df=15) 
reduced 3[H] 5HT efflux (Fig. 36A). There was no apparent statistical interaction between 
KCL-induced 3[H] 5HT efflux and GPO when co-superfused (Fig. 36B).  
    
 
Figure 36: GLP-1 effect on serotonine terminals 
(A): Superfusion of GPO on 3[H]-5HT efflux. GPO exerts a significant reduction on baseline 
5-HT release from PFC slices. *P<0.05, student's t-test (B) KCL 30 mM significantly and 
dramatically increases the release of 3[H]-5HT (like for dopamine). This effect was not 
significantly affected in the presence of GPO 40 µM though, there was a tendency for a 
decrease.*P<0.05, **P<0.001 vs. respective baseline, ns, P>0.05 vs. specified condition, 
Neuman-Keuls after significant ANOVA. 
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IV-3-B- GLP-1 effect on striatal 3[H] DA uptake processes 
IV-3-B1-Ex-4 attenuates D2/D3 DA agonist-induced striatal
3 [H] DA uptake  
 We investigate the dose-response relationship of Ex-4 (1 and 5 µM) 
and GPO (40 and 80 µM) on striatal 3[H] DA uptake from striatal synaptosomes. Both 
drugs did not directly alter the uptake process (Fig. 37A, B). However, Ex-4 (1µM) 
significantly (F (2, 14) =27.61) inhibits QNP-induced striatal 3[H] DA uptake (Fig. 
37C). Similarly, Ex-4 treatment significantly reduced PPX-induced dopamine uptake 
in striatal synaptosomes (Fig. 37D). This significant neuromodulatory effect with 
dopamine D2/D3 receptor agonists may suggest the possibility of molecular and 
behavioural effects of GLP-1 on dopamine neurotransmission. 
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Figure 37: Effect of Ex-4 on quinpirole interaction on [DA] uptake transporter activity 
(A, B): Neither Ex-4 (1 and 5 µM) nor GPO (40 and 80 µM) has any effect on striatal 3[H] 
DA uptake (C): In the presence of 1 µM of Ex-4 quinpirole-induced [DA] uptake was 
significantly attenuated, an indication of neuromodulatory effect on dopamine transporter 
activity when co-administered with dopaminergic drug (D): Similar effect was exhibited with 
PPX a D3-prefered dopamine agonist.**P<0.001, ***P<0.0001 vs. specific conditions, 
Newman-Keuls, after significant ANOVA. 
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IV-3-B2-GPO inhibits uptake of 3[H] 5HT in the prefrontal cortex 
  We evaluate the impact of GPO on serotonin neurotransmission based on Cai 
et al., (2015) finding, that GPO possesses an antidepressant-like effect on a chronic 
unpredictable mild stress-induced rat. The mechanism of which is not fully understood. Here, 
through in vitro radiometric uptake assay of serotonin on the prefrontal cortex, GPO 40µM 
did not affect the uptake process (Fig. 38A). However, at a double dose of 80 µM of GPO 
3[H] 5HT uptake was slightly but significantly (t=2.244 df=16) reduced (Fig. 38B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Effect of GPO on prefrontal cortex 3[H] 5HT  
(A): GPO 40 µM did not alter 3[H] 5HT uptakes on the prefrontal cortex slices. (B): GPO at 
80 µM significantly reduced the uptake process of 3[H] 5HT to some degree. *P<0.04, 
Student's t test.  
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IV-3-B3- GLP-1 drugs alter uptake kinetics on striatal synaptosmes 
  Following a single acute intraperitonial administration of GPO (40 mg/kg) or 
Ex-4 (5µg/kg), derivation of uptake kinetic parameters (KM and Vmax) by Michaelis-menten's 
equation analysis were evaluated in striatal synaptosomes. Both Ex-4 and GPO significantly 
increased KM values over the control. The increase in KM is very similar for both agonists. 
This may further demonstrate a vital pharmacodynamic resemblance between Ex-4 and GPO, 
in terms of the effect on DA transmission. However, Vmax values in both groups remain 
unaltered when compared with the control. This was a preliminary finding and large sample 
size will be needed to ascertain the precision of the data. Data are means±s.e.m, R2 indicates 
the goodness of fit. *P<0.05 vs. control, one-way ANOVA followed by Neuman-Keuls post 
hoc test. 
 
 
 
 
  
 
Kinetic
parameters
Control
n=4
Ex-4 (5µg/kg)
n=4
GPO (80mg/kg)
n=4
Km (nM) 43.47±15.82 83.07* ±19.6 103.2* ±9.117 
Vmax (µm/s) 4.834±0.8730 5.14±75 3.53±20.81 
R2 0.9588 0.9894 0.9989
Table 2: Ex-4 and GPO increased KM for DAT-mediated uptake in striatal slices
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IV-3-C-GLP-1 drugs modulate behavioural traits 
  IV-3-C1- Ex-4 intraperitoneal administration improves memory and cognitive 
tasks in rats 
   In this study, we tested the impact of Ex-4 5 µg/kg on cognition, in 
three main categories of treatment namely, acute (Ex-4 administered on the training day and 
test day), sub-chronic (5days administration of Ex-4) and chronic (2 weeks administration of 
Ex-4) exposures. Significant group differences were not observed on all of the individual test 
days. Generally, in all the groups and across the 3 categories of exposures exploration time 
for the familiar object decreases as the training interval progresses. The control and test 
groups in each category of exposure exhibited similar exploration time for the familiar 
objects during the 3 days training period (Fig. 39A, C, and E). For the discriminating index 
(DI') which is the measure of preference for the novel object expressed in percentage, acute 
exposure to Ex-4 did not improve preference for the novel object on the treated rats (Fig. 
39B). However, sub-chronic and chronic exposures to Ex-4 induced significant (t=2.223 
df=12) and (t=6.538 df=6) preferences for novel objects than the control groups (Fig. 39D, 
F). We also note with interest that, preference for novel object time-dependently increased 
from acute to chronic administration of Ex-4 (17%, 22.2% and 46.2%). In another series of 
cognitive study, we investigated the acute effect of Ex-4 5 µg/kg (i.p.) on a single dose of 
PCP-induced cognitive impairment. The PCP-treated group spent significantly more time (F 
(2, 12) =5.4) exploring the objects during the 3-day familiarization phases than the Ex-4 pre-
treated group (Fig. 40A). The PCP group has in average total time (21.7sec) and Ex-4 pre-
treated has (8.8 secs) in each familiarization phase. However, Ex-4 pre-treated group showed 
a significantly longer time (t=7.592 df=6) on the novel object than the PCP treated group, 
which exhibited a complete cognitive impairment expressed in % negative value (Fig. 40B). 
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Figure 39: Effect of acute, sub-chronic and chronic Ex-4 treatment on NOR test 
(A, C, E): Ex-4 treated groups in acute (A, B), sub-chronic (C, D) and chronic (E, F) 
exposures did not show any significant differences in exploration time of the familiar object, 
during the training exploration period, when compared with the saline control group. P>0.05 
(B): In acute treatment, Ex-4 treated group did not show any significant alteration in 
preference for novel object P>0.05 (D, F): Ex-4 treated group in sub-chronic and chronic 
groups exhibited a significant increase in preference for the novel object than the control 
groups. *P<0.05, ***P<0.0001 vs. control, Student's t test. 
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Figure 40: Effect of acute Ex-4 treatment on PCP-induced cognitive impairment 
(A): The PCP treated group exhibited a significant increase in exploration time compared to 
the Ex-4 pre-treated group throughout the exploration period.*P<0.05 vs. Ex-4 group 
Bonferroni, after significant repeated measures two-way ANOVA. (B): Ex-4 treated group 
showed a significant increase above the PCP treated group during the preference test for the 
novel object. ***P<0.0001, Student's t test 
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IV-3-C2- Acute Ex-4 administration attenuates basal motor and PCP-induced 
hyperlocomotion 
   First, we tested the effect of Ex-4 5µg/kg on basal motor activity of the 
subjects (Fig. 41A). Briefly, the effect on motor activity was assessed after the single 
injection with Ex-4. The rats look calmer, but not drowsy, which did not last for a long 
period. Ex-4 caused a statistically significant (F (1, 12) =7.29) reduction in basal motor 
activity of the rats. Then, we investigated the impact of Ex-4 on hyperlocomotive behaviours 
of PCP 10 mg/kg, when acutely administered intraperitoneally. The PCP-induced 
hyperlocomotion is usually used to model positive symptoms of schizophrenia in rats. During 
the first 60 mins of observation, after intraperitoneal administration of PCP 10 mg/kg, 
animals that were pre-treated with Ex-4 5µg/kg exhibited a significant reduction (F (1, 16) 
=39.26)  in locomotor activity than those pre-treated with 0.8 ml/kg saline (Fig. 41B). There 
were also apparent significant reductions (F (2, 24) =54.6) in urination and headshaking 
stereotypic manifestation in Ex-4 pre-treated group when compared with the control (Fig. 
41C). 
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Figure 41: Impact of Ex-4 on basal and PCP-induced behavioural traits  
(A): Acute intraperitoneal Ex-4 exhibited a significant reduction in basal motor activity 
(assessed by the number of times the rat walks a distance of 10 cm) in the first 15 min observation 
(B): Exendin-4 5 µg/kg pre-treated group significantly reduced PCP-induced 
hyperlocomotion activity in the first 15 mins and last 15 min of behavioural observations. 
(C): Ex-4 5 µg/kg significantly reduced the numbers of head shaking stereotyped activity on 
the first 45 mins during the observation period. #P<0.05, ###P<0.0001, *P<0.05, **P<0.001, 
***P<0.0001 vs. control. Bonferroni post hoc tests after significant two way repeated 
measures ANOVA. 
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  IV-3-C3- Acute Ex-4 and GPO differentially modulate D2/D3 DA agonist-
induced behavioural traits 
The various effects of dopamine agonists like PPX and QNP on different dopamine-
dependent behaviours have been presented in chapter I. In PPX-induced behavioural traits, 
Ex-4 pre-treated rats exhibited significant reduced yawning (F (1, 32) =31.32) and pelvic 
grooming (F (1, 32) =31.32) activities throughout the observation time when compared with 
control (Fig. 42A, B), except for pica eating behaviour that showed no difference from the 
control (Fig. 42C). Similarly, Ex-4 pre-treated rats displayed a significant reductions (F (1, 
32) =43.30) in yawn, pelvic grooming (F (1, 32) =6.74) and pica eating (F (1, 16) =2.97) 
behavioural traits induced by QNP (Fig. 43A, B, and C).  
In another series of experiment, GPO was tested on these behavioural characteristics 
induced by D2/D3 agonists. Yawning (F (1, 32) =6.84) and pelvic grooming (F (1, 32) =23.09) 
effects were significantly reduced in GPO pre-treated group, when compared with PPX only 
treated rats (Fig. 44A, B). But, in GPO pre-treated group there was a significant (F (1, 32) 
=7.72) increase in pica eating activity compared to PPX treated group (Fig. 44C). In QNP-
induced behavioural testing, GPO pre-treated group exhibited significant reduction (F (1, 16) 
=18.18)  on yawning effect (Fig. 45A), while there was no alteration on pica eating as well as 
pelvic grooming behavioural activities in the presence of GPO (Fig. 45B, C). However, Ex-4 
has been reported to be associated with inducing mild pica response and reducing food intake 
due to nausea effect (Hernandez et al., 2018a). 
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Figure 42: Ex-4 inhibits PPX-induced yawning and pelvic grooming effects 
(A, B): Exendin-4 5 µg/kg pre-treated group significantly reduced PPX-induced yawning and 
pelvic grooming effect during the 60 mins observation (C): Ex-4 at the same dose 
administered (5 µg/kg) shows no apparent effect on pica eating activity ***P<0.0001 vs. PPX 
control. Significant two-way repeated measures ANOVA. 
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Figure 43: Ex-4 attenuates QNP-induced yawning and pelvic grooming effects 
(A, B, C): Exendin-4 5 µg/kg pre-treated group significantly reduced QNP-induced yawning, 
pica eating and pelvic grooming effect during the 60 mins observation *P<0.05, **P<0.001, 
***P<0.0001 vs. QNP control. Bonferroni post hoc tests after significant two way repeated 
measures ANOVA. 
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Figure 44: GPO reduces PPX-induced yawning and pelvic grooming effects 
(A, B): GPO 40 mg//kg pre-treated group significantly reduced PPX-induced yawning and 
pelvic grooming effects during the 60 mins observation (C): GPO at the same dose 
administered (40 mg/kg), significantly increased pica eating activity above the PPX control 
group. We show another evidence of probable inducement of pica response by GLP-1, albeit 
it is an inconsistent trait across the group. *P<0.05, ***P<0.0001 vs. PPX control, **P<0.001 
vs. Ex-4+PPX treated group. Bonferroni post hoc tests after significant two way repeated 
measures ANOVA. 
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Figure 45: GPO attenuates QNP-induced yawning effect 
(A): GPO 40 mg//kg pretreated group significantly reduced QNP-induced yawning effect 
during the 60 mins observation (B, C): GPO, at the same dose administered (40 mg/kg), did 
not affect both pelvic grooming and pica eating effects, ns: not significant, ***P<0.0001 vs. 
respective control at all times. Bonferroni post hoc tests after significant two way repeated 
measures ANOVA. 
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IV-3-C4- Acute Ex-4 and GPO administrations differentially modulate D-
AMP-induced locomotor activity 
   During  the  first  60  minutes  of  observation, following  
administration of the dopamine-releasing agent D-Amphetamine (DAMP, 1 mg/kg ip), 
animals  that  were  pre-treated  (15 min before the challenge) with Ex-4 5µg/kg. i.p. show a 
significant reductions in motor activity both pooled control group (F (1, 47) =20.69) and 
control group experiment at the same time with treated group (F (1, 47) =36.47)  when 
compared to the non-pre-treated rats (Fig. 46A, B). Similarly, GPO-pre-treated animals 
exhibited the same significant (F (1, 48) =14.31) inhibitory effect on D-AMP-induced 
locomotor activity, but at lower magnitude (Fig. 46C, D). We also access if the GLP-1 
antagonist Ex-9 could reverse the effect of Ex-4. Interestingly, in the presence of Ex-9 a 
GLP-1 receptor antagonist, there was no significant difference between the Ex-9 pre-treated 
group and D-AMP treated control (Fig. 47A). We took a further step to compare motor 
activity between D-AMP control group and rats already pre-treated with GLP-1R blocker 
(Ex-9, 2µg/kg) followed by Ex-4 5 µg/kg and then D-AMP. The pre-treated group (Ex-9 
+Ex-4) exhibited a significant reduction in motor activity when compared with D-AMP 
control which shows that the drug did not block the effect of Ex-4 at this dose (data not 
shown). However, at an increased dose of 100 µg/kg Ex-9, motor activity of the rats was 
partially restored and Ex-4 activity seems partially to be blocked (Fig. 47B). It is important to 
note that in all the behavioural experiments, controls were investigated exactly at the same 
time as treated for accuracy purpose, but when compared with a larger population of control 
such as n=23 for DA-MP,  we got the same results. 
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Figure 46: Impact GLP-1 on D-AMP-induced motor activity 
(A): Ex-4 (5 µg/kg) pre-treated group exhibited a significant reduction in locomotor activity 
and in particular at 30, 45 and 60 mins of observation compared to control animals run in 
parallel. (B): This is a similar figure than (A), but showing how the treated group deviates 
from the pool of control subject of 23 animals. (C):  GPO pre-treated group also exhibited a 
global significant reduction from D-AMP treated control run in parallel. (D): GPO-treated 
group deviation from a pool of total control subjects used in the experiment. The large error 
indicates pronounced variability within the wide control group of 23 rats. $$$P<0.0001, 
**P<0.001, ***P<0.0001 vs. respective control at all times. Bonferroni post-tests after 
significant two-way ANOVA.  
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Figure 47: Impact of Ex-9 on D-AMP-induced motor activity 
(A): Ex-9 2µg/kg, a GLP-1 antagonist pre-treated group showed no significant alteration in 
motor activity when compared to D-AMP control group. (B): The treated group in which the 
antagonist (Ex-9, 100 µg/kg) was first administered, followed by Ex-4 (15 mins interval) and 
later challenged by D-AMP, showed that Ex-9 to some extent did not block the effect of Ex-4 
agonist  compared with D-AMP control group. Thus, Ex-9 at 100 µg/kg partially attenuated 
the effect of Ex-4. **P<0.0001 vs. control. Bonferroni post-tests after significant two-way 
ANOVA.  
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 IV-3-D-Acute Ex-4 administration regulates DAT and GLP-R protein expression 
  Following behavioural assessments of Ex-4 acute treatment on D-AMP-
induced motor activity; the extent of DAT and GLP-1 protein expression in each treatment 
group was studied. We observed significant increases of DAT protein expressions in the 
striatum as well as in the mid brain (containing the VTA) with D-AMP treated group. 
However, in the groups pre-treated with EX-4 following D-AMP administrations, there were 
significant reductions in the level of DAT expressions both in the striatum (F (2, 11) =6.954) 
as well as the midbrain (F (2, 11) =17.35) (Fig. 48A, B). In another series of western blotting 
studies, we evaluated the impact of Ex-4 pre-treatment on GLP-1R protein expression. Here, 
we observed an increased in GLP-1R expression in group pre-treated with Ex-4 when 
compared with the control in the striatum, after 1 hr. of Ex-4 administration. Similarly, in the 
midbrain Ex-4 pre-treated group expressed significantly (F (2, 11) =9.595) more GLP-1R 
protein when compared with both control (saline) and D-AMP treated drug (Fig. 49A, B). 
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Figure 48: Ex-4 acute administration increases striatal and midbrain DAT protein 
expression. 
Following behavioural experiments with D-AMP, DAT protein expression levels were quantified in 
different regions. (A): In the striatum, D-AMP (1 mg/kg) exposed group significantly increased DAT 
protein expression when compared to both control (saline) and Ex-4+D-AMP groups. (B): In the 
midbrain, D-AMP (1 mg/kg) exposed group significantly increased DAT protein expression in 
comparison with control (saline) and Ex-4+ D-AMP groups. The more incremental effect was 
observed in the midbrain. The bottom is displayed representative immunoblots with protein sizes in 
kilodaltons (kDa). *P<0.05, ***P<0.0001, vs. control (saline), *P<0.05, **P<0.001 vs. Ex-4+D-AMP 
group, Newman–Keuls test after significant ANOVA. 
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Figure 49: Ex-4 pre-treated rats increase striatal and midbrain GLP-1R protein 
expression. 
Following behavioural experiments with D-AMP administration, GLP-1R protein expression levels 
were quantified in different regions. (A): In the striatum, Ex-4 pre-treated group in combination with 
D-AMP, significantly increased GLP-1R protein expression when compared with the vehicle, while a 
single administration of D-AMP has no significant effects. (B): In the midbrain, Ex-4 pre-treated 
group significantly increased GLP-1R protein expression in comparison with control (saline) and with 
D-AMP-only groups. Below are displayed representative immunoblots with protein sizes in 
kilodaltons (kD). *P<0.05, **P<0.001, vs. control (saline), *P<0.05vs.D-AMP group, Newman–Keuls 
test after significant ANOVA. 
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V-3-E-Impact of acute systemically administered GLP-1 agonists on the firing rate of 
midbrain dopamine neurons and pyramidal PFC neurons 
IV-3-E1- GLP-1 drugs modulate the firing rate of midbrain dopamine neurons. 
 
  In these electrophysiological studies, we assessed the effect of acute systemic 
administration of Ex-4 as well as GPO on the firing rate of DA neurons and pyramidal PFC 
neurons in anaesthetized rats. In the midbrain, we study the dose-response relationship of Ex-
4 and the firing activity of VTA DA dopamine neurons. We observed no effect on the firing 
activity of VTA DA neurons. When the dose was increased to 20 µg/kg Ex-4, the firing 
activity remains unchanged (Fig. 50A, B). However, following co-administration with insulin 
20 µg/kg, as indicated in the previous chapter, the firing rate of dopamine neurons became 
slightly and progressively reduced, when compared to saline treated animal in the same 
condition, indicating a possible synergetic effect between the 2 hormones on dopamine 
neurotransmission (Fig. 50A &C). Similarly, GPO 40 and 80 mg/kg tested on VTA dopamine 
neurons did not alter the firing activity of the DA neurons (Fig. 51A, B). We further tested 
the effect of two strengths of GPO (40 and 80 mg/kg) on non-dopamine VTA neurons. Our 
observation was homogenous to the effect of GPO on VTA DA neurons, as there was no 
alteration in the firing activity of non-dopamine neurons (Fig. 51C). The distribution of the 
responses of VTA neurons to the different treatments were compared using Chi-square test 
(no change; increase defined as 20% over baseline; decrease defined as 20% below baseline, 
following administration). The proportion of neurons responding to GPO (Fig. 52A) and Ex-4 
(Fig. 52B) administrations were different from the responses from saline administration (Fig. 
52C).  
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Figure 50: Electrophysiological effects of intravenously administered Ex-4 on VTA 
dopamine neurons  
(A): Firing rate histograms of a VTA dopamine neuron following 2 subsequent iv. 
administration of Exendin-4 (cumulative dose 20 µg/kg, iv.) followed by an administration of 
Insulin (20µg/kg, iv.).  
(B): Mean firing activity of VTA dopamine neurons recorded during and after 2 
administration of Exendin-4 (cumulative dose 20 µg/kg, iv.). Ex-4 administration did not 
alter the firing rate of VTA dopamine. However, when co-administered with insulin 20 µg/kg 
(iv.) a decrease in the firing was observed in some neurons. 
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Figure 51: Electrophysiological effects of intravenously administered GPO on non-
dopamine VTA neurons  
(A): Firing rate histogram of a confirmed VTA dopamine neuron (response to 
apomorphine/eticlopride) showing no response to administration of 40 and 80 mg/kg of 
geniposide (GPO, iv.)  
(B, C): Administration of 2 subsequent doses of geniposide did not alter the mean firing rate 
of VTA dopamine (B) and non-dopamine neurons, ns: non-significant, P>0.05. 
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Figure 52: Comparing the firing rate distributions of saline, GPO and Ex-4 on VTA DA 
neurons  
(A): Proportion of neurons showing changes in firing activity with intravenously 
administered GPO, about 35% of neurons responded to an increase in firing activity (B): 
Proportion of neurons showing changes in firing activity with intravenously administered Ex-
4, about 43% of the neurons displayed an increase in firing activity. (C): Change in firing 
activity with saline administered intravenously, showing 80% of the neuron's response to no 
effect. (D): There was no statistical significant difference in the population of neurons 
distribution within the three treatment groups, P>0.05 Chi square test  
 
IV-3-E2- Ex-4 diffusion in the brain modulates electrophysiological characteristics 
and sensitivity of VTA dopamine neurons 
In the first series of experiments, the recording electrodes were filled with 
exendin-4 (final concentration 100 µg/ml in saline) and lowered into the VTA for the 
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recording of dopamine neurons. As mentioned in the previous chapter, it is anticipated 
that during the recording Ex-4 can diffuse through the recording electrode into the 
VTA nearby the recorded neurons. In our laboratory, this method of administration of 
products directly to the neuron tested has proven to be efficient (Gronier, 2011a).  
Although, the amount of product applied to the neurons cannot be predicted and 
diffusion efficiency can vary from one electrode to one another. Whenever possible 
the dopamine neurons were recorded during two subsequent periods of 7 min and 
firing activity between period 1 and 2 was compared assuming that Ex-4 will 
progressively diffuse through the electrode and that neurons will be exposed to insulin 
for longer in the second period of the recording. Firing activity of dopamine neurons 
recorded this way was not significantly different from the firing activity of a control 
population of neurons (though it tends to be 20% higher, p<0.2). During the second 
period of the recording, the mean firing activity increased in the majority of the 
neurons tested, but this increase did not reach statistical significance (p<0.15; Fig. 
53A &B). The mean firing activity of these neurons (late recording period) was also 
39% higher than in the control population, but this was not statistically significant 
(p<0.2). Believe that this may be due to the small sample size of dopamine neurons in 
the tested group. 
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Figure 53: The mean firing activity of VTA dopamine neurons  
The recording was carried out with an electrode filled with Exendin-4 (left). There was an 
increase during the later period of the recording (7-15 min), during that time the firing is also 
significantly higher than the mean firing activity of VTA dopamine neurons recorded in 
normal condition (with saline-filled electrodes). Note that in control condition the firing rate 
of dopamine neurons do not decrease with time and the controls were obtained from previous 
experiments. 
 
 
IV-3-E3- Intra-VTA administration of Ex-4 
As discussed, previous data from our laboratory has shown that the 
administration of saline (1-2 µl) within the VTA did not change the 
electrophysiological characteristics of the dopamine neurons (Gronier, 2008). This 
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damage in this structure. Like in the previous study we have used our main control 
population (no VTA administration of saline) for comparison. Figure 54 shows the 
distribution of neurons recorded at least 40 min after the administration of insulin Ex-
4 (1.5 µg) into the VTA compared to controls. Treated neurons displayed generally 
higher baseline and burst activity than in the control population, and results were 
nearly significant for firing activity (p<0.08, unpaired Student’s t-test), but not for 
burst activity (p<0.3). Nevertheless, the proportion of neurons firing in the burst was 
particularly high in the treated group (16/19, 85% of neurons). 
 
 
 
 
 
 
 
 
 
Figure 54: Individual electrophysiological characteristics (firing rate and burst firing) 
of VTA dopamine neurons rats 
There were increases in both the firing rate and the burst firing of the VTA dopamine when  
Ex-4 (1.5 mg) doses were administered within the VTA at least 40 min before and in control 
animals (n=6).  
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IV-3-E4- Intra-VTA administration of GLP-1 changes the sensitivity of dopamine 
neurons towards the dopamine D3 agonist pramipexole 
We investigate the effect of a wide range of pramipexole (a Dopamine D3 
preferential receptor agonist, see previous the chapter) doses intravenously administered, 
with progressive 20 μg/kg increments and up to a cumulative dose of 100 μg/kg, in naïve 
and in VTA-treated animals (same condition as before: 1.5 µg Ex-4 injection within the 
VTA). As mentioned in chapter 2, naïve animals displayed a significant progressive 
reduction in firing rate upon each administration of PPX leading to a complete (or nearly) 
complete shutdown of the firing activity, an effect reversed by the administration of the 
potent D2/D3 receptor antagonist eticlopride (100-200 µg/kg). Neurons previously 
exposed to Ex-4 displayed a shift in their sensitivity to the D3 agonist, as seen in Figure 
55. Analysis indicates a significant dose and treatment effect. Equivalent results were 
obtained when % of firing decreases from baseline were considered (not shown). 
 
Figure 55: Intra-VTA exposure to exendin-4 induces partial desensitisation of dopamine 
neurons to the preferential dopamine D3 receptor agonist pramipexole. 
Compared to control animals, dopamine neurons from intra VTA-treated animals displayed 
significantly lower firing rate reductions following progressive pramipexole challenges, 
administered in a dose response manner and with progressive 20 μg/kg increments. *p<0.05; 
**p<0.01 vs. respective control, repeated measure ANOVA 
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IV-3-E5- GLP-1 drugs enhance the firing rate of pyramidal prefrontal cortex neurons  
Here, we tested the effect of GLP-1 on the firing rate of pyramidal neurons 
located in the PFC. Intravenous administration of Ex-4 dose-dependently (10 and 20 
µg/kg) increased the firing rate of pyramidal neurons in a significant pattern (Fig. 
57A, B). This provides us with potential evidence of correlation with behavioural 
paradigm on cognition and memory effect of Ex-4 in rats, as earlier demonstrated. 
However, in one neuron (about 11.6%), Ex-4 induced reduction in the firing activity 
of the pyramidal cells during the experiment (Fig. 56C). Similarly, GPO at a dose of 
40 mg/kg did not alter the firing activity of the neurons. But, at 80 mg/kg a significant 
excitatory effect was observed (Fig. 57A, B). Considering the total population of PFC 
pyramidal cells studied, about 33% of the neurones showed a reduction in firing 
activity (Fig. 57C). 
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Figure 56: Ex-4 administered intravenously increase the PFC pyramidal cell firing rate 
(A, B): Ex-4 (iv.) significantly increased the firing rate of pyramidal neurons in a dose-
dependent pattern showing firing rate histograms of an individual neuron in A, and mean 
firing rates in B.  
(C): Only one neuron out of the 9 PFC pyramidal neurons tested, exhibit no increase in firing 
rate following by Ex-4 (30 µg/kg). *P<0.05, vs. baseline, Newman–Keuls test after significant 
ANOVA. 
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Figure 57: GPO administered intravenously increase pyramidal cell firing rate 
(A, B): GPO at 80 mg/kg (iv.) significantly increased the firing rate of pyramidal neurons 
while the 40 mg/kg did not affect. (C): In the PFC pyramidal 2 neurons out of the 6 neurons 
exhibited a reduction in the firing rate induced by GPO, while the remaining neurons showed 
activation. *P<0.05 vs. baseline, Newman–Keuls test after significant ANOVA 
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IV-4-Discussion 
 In this chapter, we have demonstrated that the gastrointestinal role of GLP-1 receptor 
activation goes beyond feeding and glucostatic regulations, but also involves central nervous 
system action. Thus, we present for the first time that D-AMP-induced motor response and 
D2/D3 dopamine agonist-induced behavioural traits (yawning, pica eating and pelvic 
grooming), as well as PCP-induced cognitive impaired condition, are attenuated in rat 
intraperitoneally pretreated with GPO or Ex-4. We further unravel that dopamine transporter 
modulation may be involved in these processes. The previous study has reported a reduction 
in basal motor activity when GLP-1 analogue is intracerebroventricularly administered into 
the hypothalamus (Turton et al., 1996). As part of our pilot study, we initially tested the effect 
of single acute administration of Ex-4 on basal locomotor activity and observed significant 
attenuation in motor activity with rats treated with Ex-4 5 µg/kg when compared with the 
control (Fig. 41A).  Several studies have shown that Ex-4 easily transverses the BBB when 
given peripherally and may be partly responsible for the reduction in basal ambulatory 
activity by stimulating GLP-1Rs in the medial subnucleus of the NTS (Kanoski et al., 2011a; 
Kastin and Akerstrom, 2003a). While we observe reduced motor activity at 5µg/kg Ex-4, 
Erreger et al., (2012a) reported a reduction in  motor activity at doses 6 times (30 µg/kg) 
higher than in our study. Nevertheless, the tendency of Ex-4 and GPO to reduce the motor 
effect of D-AMP are partly modulated through GLP-1Rs located within the 
mesocorticolimbic DA pathway (Kastin and Akerstrom, 2003b). However, peripheral 
administration of GLP-1 may easily access expressed GLP-1Rs in the NTS, and can also 
elicit its effect through vagal interaction. Thus,  NTS, in part via GLPergic fibres, innervates 
the mesolimbic  dopaminenergic system, peripheral GLP-1 may be able to modulate reward-
mediated brain regions such as VTA and NAc (Alhadeff et al., 2012b; Alvarez et al., 1996; 
Rinaman, 2010). Some studies have also demonstrated that craving induced by highly 
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palatable foods was largely reduced when Ex-4 was locally administered in the main brain 
reward areas (Alhadeff et al., 2012b). Especially, in this chapter, we demonstrate through 
western blot the possibility  that GLP-1Rs that are abundant in striatal areas, particularly in 
the ventral striatum, are involved in weakening the motor stimulating activity to D-AMP 
(Chartoff et al., 2005; Dossat et al., 2011; Heusner et al., 2003). Albeit, GPO shows a lesser 
degree of attenuation of D-AMP-induced motor response compared with Ex-4 albeit, both 
still exhibited a significant level of reduction (Fig. 46A, C). We hypothesize that GLP-1R 
activation attenuate D-AMP-induced motor activity by interfering with DA D2/D3 
autoreceptor sensitivity, since we did not observe any significant modulatory effect on the 
release and basal DA uptake assays. This is a plausible mechanism, because Ex-4 weakened 
QNP and PPX-induced DA large uptake. Another possible mode of action is the possibility of 
change in the sensitivity or activity of post synaptic receptor (whether D2/3 or even D1) 
involved in the effects of DAMP that can be involved. This may occur in DA-rich region like 
in striatum. We also tested the effect of 2 µg/kg Ex-9, a GLP-1Rs antagonist on D-AMP-
induced locomotor response. However, the effect was similar to D-AMP treated group 
contrary to our expectation of increased locomotor activity (Fig. 47A). This might be due to 
low dose administered that was not enough to block the effect of endogenous GLP-1R. Next, 
we attempted blocking the effect of intraperitonially dosed Ex-4 by pretreatment with Ex-9 2 
µg/kg (GLP-1R antagonist) followed by Ex-4 5µg/kg treatment before D-AMP challenge. 
Our findings revealed that Ex-9 at 2 µg/ kg did not effectively block the agonistic effect of 
Ex-4 but, at 100 µg/kg there was a blockage of the GLP-1R to a lesser extent (Fig. 47B). It 
might be suggestive that intraperitoneal administered Ex-9, poorly transverses the BBB and 
blocks peripheral GLP-1R through efflux of Ex-9 from the brain to the periphery (Kanoski et 
al., 2011b). It is plausible that GLP-1Rs activation impede with the pharmacological effect of 
D-AMP to enhance the release or synthesis of DA or facilitate the activity of VTA DA via an 
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interaction with the dopamine transporter (Heusner et al., 2003; Koob and Volkow, 2010). 
An interesting hypothesis will be that GLP-1Rs activation may result in modification of DAT 
or dopamine receptor activity, which leads to attenuation of a rewarding trait of D-AMP 
(Owens et al., 2005b; Thompson et al., 2010). 
 The capacity of psychostimulants to induce dopamine release are familiarly connected 
with the boosting characteristic of habit-forming drugs and these variables are thought to be 
an integral part of craving or addiction process (Everitt and Wolf, 2002; Wise and Rompre, 
1989). By adopting in vitro radiometric 3[H] DA release assay protocol, we further elucidate 
the potential mechanism by which GLP-1 drugs attenuate D-AMP-induced motor activity 
using striatal slices. Here, we report that neither Ex-4 1µM and Ex-4 5µM nor GPO 40µM 
and GPO 80µM has a significant effect on basal 3[H] DA release from the striatal slices (Fig. 
34A, B). The null effect of GLP-1 drugs on basal dopamine release is in agreement with an in 
vivo microdialysis dopamine measurement experiment performed on mice by Egecioglu et 
al., (2013). They further reported that at a selected dose of 2.4 µg/kg Ex-4, there was no 
significant effect on accumbal DA release when compared with the saline treated group. We 
have also demonstrated an increase in DA efflux induced by D-AMP 10 µM on striatal slices, 
which may be key to locomotor and addiction effects of psychostimulant (Wise and Rompre, 
1989). Interestingly, in our radiometric release model we found that D-AMP-induced striatal 
dopamine release was slightly reduced by pre-treatment with Ex-4 although, not statistically 
significant (Fig. 35A, B). Since we didn’t find the same result in vitro and in vivo, models 
this indicates that Ex-4 may act indirectly to modulate D-AMP induced release and not 
directly on the dopamine terminal. These results show that activation of GLP-1Rs on the 
striatal DA terminals has an inhibitory effect on striatal DA efflux. These findings are in 
agreement with previous studies that reported reduction  of  alcohol, cocaine and D-AMP-
induced DA release in in vivo microdialysis experiment on mice following treatment with Ex-
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4 (Egecioglu et al., 2013e, 2013e; Erreger et al., 2012b; Sørensen et al., 2015). The slightly 
weaker effect of GPO on D-AMP-induced locomotor activity might be due to its lower 
efficacy on GLP-1Rs activation, having reported the drug as a putative GLP-1 agonist (Gong 
et al., 2014b).   
 As part of our investigation to unravel the mechanism of action of GLP-1 drugs 
attenuating effect on D-AMP-induced locomotor activity, we assessed the role of DAT and 
GLP-1R protein expressions in the striatum as well as in the midbrain within various groups 
of treatment. Here, we report that Ex-4 pretreated group significantly reduced DAT 
expression induced by D-AMP treated control group, both in the striatum and VTA (Fig. 
48A, B). However, this technique is limited by inability to express spatial distribution of the 
proteins from various anatomical point of view, as well as lack of probable antibodies 
specificity leading to off-target binding. DAT has been generally considered as a principal 
regulator of DA signaling process, by driving uptake of extracellular DA back into the 
presynaptic neurons (Vaughan and Foster, 2013a). In the clinical management of attention 
deficit hyperactivity disorder (ADHD), DAT is the major target for the pharmacological 
actions of psychostimulants such as, methylphenidate, methamphetamine (METH) and D-
AMP (Han and Gu, 2006a). DAT is thought to be the chief terminating transmembrane for 
dopamine transmission hence, controls and maintains the  strength as well as extent 
dopaminergic signaling (Giros and Caron, 1993). D-AMP is a potent substrate for DAT at 
which it competes with dopamine to enter the presynaptic dopamine terminals. Within D-
AMP the terminal, DAMP blocks the vesicular monoamine transporter (VMT) to cause 
massive dopamine depletion. Then excessive intracellular dopamine will be in part released 
by a reverse transport system (Fischer and Cho, 1976; Rothman and Baumann, 2003; Han 
and Gu, 2006b). Previous neurochemical investigations revealed an elevation in DAT protein 
surface expression when a striatal synaptosome was acutely treated by D-AMP through the 
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process of biotinylation to mark surface DAT  (Johnson et al., 2005). The studies further 
demonstrated that elevation of surface DAT expression by D-AMP was as a result of 
exocytosis emanating from continuous activation with D-AMP to facilitate DAT 
internalization. Further study by Furman et al., (2009) has also supported the evidence that 
DA, as well as D-AMP treatment on the striatal synaptosome, expeditiously elevate DAT 
trafficking to the cell surface with the aid of real- time internal reflection microscopy. Our 
findings on D-AMP-induced DAT overexpression is thus consistent with the earlier 
mentioned studies. It is possible that D-AMP can have access to the intracellular medium of 
the synapse and causes more depletion of the dopamine storage thus, leading to more DA to 
be reversely transported outside the synapse. We have for the first time, examined the 
neuromodulatory role of acute Ex-4 pretreatment on D-AMP-induced motor activity as it 
affects DAT degree of protein expression. A considerable body of literature has directly 
demonstrated that DAT (Fumagalli et al., 1998), change in temperature (Albers and Sonsalla, 
1995) as well as energy metabolism alteration (Burrows et al., 2000) are required for the 
dopaminergic neurotoxity induced by methamphetamine (METH). Fumagalli et al., (1998) 
further revealed that DAT is principally required for METH-induced dopaminergic 
neurotoxicity,  as confirmed by the pronounced change in dopaminergic cell integrity in wild-
type mice and a complete deficit of any alteration in DAT −/− mice. Also, Salahpour  et al., 
(2008),  through the use of transgenic mice model and western blotting technique revealed 
that D-AMP at a dose range of 0.5-2 mg/kg induced upregulation of DAT leading to a 
striking increase in hypersensitivity to locomotor and craving effect of D-AMP. The 
observations in these findings may also support the hypothesis that symptomatic 
manifestations of ADHD is probably more of persistent loss rather than a gain of DAT 
function in humans. We have consistently demonstrated that Ex-4 pretreated groups both in 
the striatum as well as in the midbrain show a pronounced reduction in DAT protein 
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expression compared with D-AMP control group thus, it prevents D-AMP-induced 
upregulation of DAT. In agreement with this finding, data from our laboratory have shown 
that blockage of transporters by methylphenidate prevents D-AMP effect (Di Miceli and 
Gronier, 2015). 
 Furthermore, in this present study Ex-4 has been shown to reduce variables that may 
indicate a rewarding process such as, motor activity enhancement and striatal dopamine 
release. Then activation of GLP-1R in the reward centre of the brain by GLP-1 drug should 
have an indirect effect on DAT regulation and may prevent, at least in part, psychostimulant 
(D-AMP)-induced neurotoxicity. Here, we report a significant increase in GLP-1R protein 
expression in Ex-4 pretreated group when compared with D-AMP treated group in the VTA 
brain sample (Fig. 49B). Interestingly, in the striatum, the increase in GLP-1R expression 
induced by Ex-4 pretreated group was significant when compared with the naive control, but 
not with D-AMP treated group (Fig. 49A). Earlier studies have identified the 
neuroanatomical evidence for a possible function of GLP-1 in reward, particularly the 
expression of GLP-1R mRNA and GLP-1 immunoreactivity in specific brain regions such as 
NAc and VTA, and also substantia nigra, hippocampus and hypothalamus (Merchenthaler et 
al., 1999b). Since GLP-1Rs are expressed centrally, it is plausible to report that activation of 
these receptors will attenuate drug-dependence and craving behaviours. Several emerging 
literature has reported the role of GLP-1Rs in food and drug reward processes (Hayes and 
Schmidt, 2016a; Schick et al., 2003). Thus, peptides that impact on feeding behaviour are 
relevant in drug reward and could be an important marker for targeting pharmacologic 
therapy in the management of addiction (Erreger et al., 2012b; Kenny, 2011b). Another study 
by Schmidt et al., (2016) revealed that stimulation of VTA GLP-1Rs remarkably attenuates 
the boosting reward magnitude of cocaine in the mesolimbic DA pathway. Interestingly, in 
our study, we found desensitization of dopamine D2/D3 receptor in VTA following 
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application of Ex-4. Since feeding behaviour and drug craving or dependence share an 
interrelated brain circuitry mechanism, we infer GLP-1R stimulation may be a potential 
modulator of addictive behaviour associated with DA pathway and uncontrollable 
psychostimulant use. 
 Next, we discuss our findings on the effect of GLP-1 drugs on well-defined 
behaviours such as yawning, pica eating, and pelvic grooming induced by D2/D3 receptors 
dopamine drugs. We also studied the possible mechanism of action by deploying ex vivo 
radiometric 3[H]DA uptake assay in striatal synaptosomes to corroborate the in vivo 
behavioural data. In chapter I, we demonstrated the behavioural effects (yawning, pica eating 
and pelvic grooming) of intraperitoneal acute administration of D2/D3 dopamine receptor 
agonists namely, PPX and QNP. The current investigations were aimed at assessing the 
effects of Ex-4 and GPO on putative D2/D3 agonist-induced behavioural traits such as 
yawning, pica eating and pelvic grooming by D3-preferring agonist PPX and QNP. Here, we 
report that Ex-4 5 µg/kg significantly attenuated both QNP and PPX-induced behavioural 
traits (Fig. 42A, B and 43A, C) except, pica eating activity that was not changed (Fig. 42C). 
Similarly, GPO 40mg/kg pre-treated group exhibited significant reductions in all the 
behavioural activities induced by PPX (Fig. 44A, B, C) but there was an exception for 
behaviour involving pica eating and pelvic grooming traits induced by QNP (Fig. 45B, C). 
Nevertheless, the yawning trait was remarkably reduced in GPO pre-treated group for QNP 
(Fig. 45A). The organic basis of yawning is attributed to be linked with alteration in 
physiological conditions of the body such as a reduction in lungs' oxygen volume as well as 
an increase in brain temperature, in response to environmental stimulus in the paraventricular 
nucleus (PVN) of the hypothalamus (Chan and Tseng, 2017). On the other hand, pelvic 
grooming arises from a series of a complex integrated neuronal and vascular episode that 
results in a build-up of blood in the phallus to attain rigidity (Andersson and Wagner, 1995). 
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While these two behavioural traits are positively correlated and majorly mediated by D2/D3 
receptor agonist (Collins et al., 2008). Pica eating, an index of nausea  induction does not 
share this mechanism (Takeda et al., 1993b). Paradoxically, while dopamine agonist has been 
widely implicated in inducing of all the behavioural traits under consideration, GLP-1 equally 
induces pica eating effect (Skibicka, 2013). This might be responsible for null effects 
exhibited by Ex-4 and GPO nearly in all the pica eating assessments. Previously, in this 
chapter, we have established the effects of GLP-1R activation on D-AMP -induced 
behavioural traits. A few numbers of works of literature has provided evidence for the 
presence of D1 receptors on GABAergic neurons, projecting directly to the midbrain 
(VTA/substantia nigra) in what is term "direct dopamine pathway" (Groenewegen et al., 
1999). The D1 receptor found in these regions performs an important role in mediating 
behavioural activities induced by DA receptors activating  drugs (Le Foll et al., 2009). Based 
on the few available data so far, Ex-4 has been suggested to potentially exert its effect 
through mediation of D1 receptor signaling pathways and by affecting psychostimulant-
induced striatal DA release (Sørensen et al., 2015). From our behavioural findings of the 
GLP-1 drug's effect effect on dopamine D2/D3 receptor agonist, it raises the curiosity that 
besides the documented data of Ex-4 effect on D1 receptor mediation in psychostimulant 
induced motor activity, attenuating effect of GLP-1 observed may also be connected to D2/D3 
receptor signalling. Besides, some experiments from our laboratory, not presented here, have 
shown that dopamine D1 receptor activation has rather a complex role on basal and drug-
stimulated motor activity. Indeed, we found that the selective dopamine D1 receptor agonist, 
A-68930 reduces basal as well as D-AMP-induced motor activity.   
 We further investigated the hypothesis that predicts an interaction with D2/D3 receptor 
signalling by GLP-1 with PPX and QNP-induced behavioural traits. Through in vitro uptake 
technique, using striatal synaptosomes, we were able to probe for a possible correlation 
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between our behavioural findings and neurochemical studies. Our data shows that neither Ex-
4 nor GPO dose-dependently altered basal 3[H] DA uptake activities (Fig. 37A, B). 
Interestingly, the two GLP-1 drugs under investigation differentially weaken PPX and as well 
as QNP-induced 3[H] DA uptake activities when incubated with striatal synaptosomes in 
specific conditions (Fig. 37C, D). Also, we assessed the impact of GLP-1 drugs on the kinetic 
parameters (KM/Vmax) in the treated rat before isolation of the striatum. Surprisingly, we 
observed an increase in KM value in both GLP-1 drugs, and no significant apparent change in 
Vmax when compared with the naïve group. This translates to a possible modulatory effect of 
GLP-1 on DAT activity. This data demonstrates that GLP-1R stimulation potentially alters 
dopamine uptake, and modulates D2/D3 receptor signaling process to possibly cause an 
inhibitory effect of well-defined behavioural traits. Whether this modulation is involved in 
the inhibitory effect of behavioural traits induced by dopamine agonists is an interesting 
question. We have previously demonstrated in chapter I that D2/D3 receptors agonists (PPX 
D3 preferred and QNP D2 preferred) presynaptically regulate extracellular DA output in the 
limbic brain areas, an effect that has been ascribed to alteration in DA release (Joseph et al., 
2002). There is more evidence that these agonists also interfere with dopamine transporter 
and uptake processes in the NAc  as well as VTA, resulting in an enhanced rate of DA 
clearance and large transport velocity (Zapata and Shippenberg, 2002; Zapata et al., 2007a). 
This neuronal effect has been identified to be dependent upon the duration of agonist 
exposure to the brain region under investigation. In addition, it was reported that rapid fast 
increase in DA uptake induced by D2/D3 agonist is associated with enhanced cell surface as 
well as large DA transporter exocytosis (Zapata et al., 2007b). In converse, D3 antagonist 
assessed under in vitro studies showed a reduced dopamine uptake when incubated with the 
striatal synaptosome (McGinnis et al., 2016).  Our current findings further agree with these 
previous studies on D2/D3 receptor agonist effect on DA uptake and transport velocity 
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enhancement. On GLP-1 agonist interaction, studies have investigated GLP-1 agonists effect 
on DA transporter and revealed an increase in 3[H] DA uptake in synaptosome prepared from 
the lateral septum of the brain region (Reddy et al., 2016a). Unfortunately, there are very few 
studies available that have provided a lucid neurochemical explanation for GLP-1R signalling 
effect on DAT and DA uptake activities. From our data, we can infer that GLP-1R signalling 
modulates DAT and alters DA uptake velocity. While, in the presence of D2/D3 receptor 
agonist, the activation of GLP-1R modulates and weakens D2/D3 induced DA uptake process.  
Whether this activity is partly responsible for perceived inhibition of behavioural traits such 
as yawning, pica eating and pelvic grooming exhibited by GLP-1 drugs, is a very interesting 
question to address. Interestingly, the same negative interaction between D2/D3 receptors and 
GLP-1 receptors seems to exist also in the VTA. We found then an intra-VTA administration 
of Ex-4 induced large desensitization of the inhibitory D2/D3 autoreceptors. The functional 
consequence of this effect remains to be elucidated. However, it may reflect a general role of 
GLP-1 R in the brain reducing dopamine receptor signalling, possibly via possible complex 
local interaction.  
 Besides ubiquitous presence of GLP-1Rs expression in the limbic system (Dickson et 
al., 2012c; Egecioglu et al., 2013d; Shirazi et al., 2013), we sought to investigate the possible 
impact of these peptides on the neurotransmitters present in cortical region (PFC) of the brain 
as well as drugs that impair memory and cognitive function in the brain. Recent data has 
demonstrated the presence of GLP-1Rs in the hippocampus, as well as cortical neurons of 
rodent brain regions critical for memory, cognitive and learning functions (Mossello et al., 
2011a). Furthermore, it potentially provides molecular explanation for neuroprotective effects 
impelled by Ex-4 exhibited in various cognitive and memory disorders connected with 
Alzheimer's disease (Li et al., 2010), type II diabetes mellitus (T2DM) (Chen et al., 2012b) as 
well as Parkinson's disease (Harkavyi et al., 2008; Kim et al., 2009a). From these behavioural 
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studies, we report that both sub-chronic and chronic Ex-4 treated groups exhibited a more 
cognitive enhancement effect than the control group (Fig. 39D, F). It is important to note that, 
both groups (Ex-4 and saline) exhibited a positive preference for novel objects albeit, Ex-4 
treated group demonstrated more profound cognitive effect. However, a single acute dose of 
Ex-4 5 µg/kg showed no statistical difference in cognitive task with the control (Fig.  39B). A 
study from Lovshin and Drucker, (2009) revealed that 5µg/kg Ex-4 administered twice daily 
improved glucostatic control, metabolic function and cognitive task in a rodent. In another 
cognitive task test demonstrated with water maze protocol, Ex-4 exhibited an enhanced 
learning performance in naive rats at the same dose when compared with saline-treated 
control (During et al., 2003b; Gault et al., 2010b). It was also reported that insulin resistance 
pathological condition, associated with the dysfunctional activity of GLP-1R is also 
connected with cognitive decline (Mossello et al., 2011b). Thus, enhancement of cognitive 
task after Ex-4 administration could be further evidence for a secondary effect of the drug on 
metabolic regulation and unmediated effect through direct activation of GLP-1Rs in the 
brain.  
 Next, we sought to test the hypothesis of cognitive and memory enhancement impact 
of GLP-1 on experimental rats' model of schizophrenia by acute single dose PCP-induced 
cognitive deficit and hyperlocomotion (Neill et al., 2016). Here, we report that acute 10 
mg/kg PCP increased the exploration of familiar objects (a reflection of cognitive deficit) 
compared to Ex-4 5 µg/kg pre-treated group. However, in preference for novel objects 
recognition (NOR) testing, PCP induced a pronounced NOR deficit, while Ex-4 pre-treated 
group exhibited a large degree of preference for novel object, an indication of significant 
enhancement in cognitive function. We also assessed the impact of acute Ex-4 on PCP-
induced hyperlocomotion activity. Our findings revealed significant inhibition in the 
locomotor activity of Ex-4 pre-treated group. Unlike D-AMP-induced motor activity, studies 
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have shown that dopamine is not essential for the hyperlocomotor activity of NMDAR 
blockers (Chartoff et al., 2005). The studies further suggested that glutamate, rather than DA 
is necessary for the motor and molecular responses of NMDAR blockers albeit, DA and 
glutamate can operate mutually. Other findings by Swanson and Schoepp, (2002) 
demonstrated that NMDAR antagonists increased locomotor activity in a rodent with 
depleted catecholamines and that this effect is distinguished from DA. There are substantial 
evidences that acute NMDAR antagonist treatment (Gilmour et al., 2012; Meltzer et al., 
2013), as well as sub-chronic administration (Dawson et al., 2014; Nomura et al., 2016) at 
therapeutically used doses, induce synaptic structural dysfunction in specific brain regions 
such as, PFC and hippocampus in both man and animal subjects (Elsworth et al., 2011; Yuen 
et al., 2012a). These anomalies are profoundly associated with  a glutamatergic aberration in 
the PFC (Yuen et al., 2012b), and GABAergic abnormality in the hippocampus (Nomura et 
al., 2016). More support for this evidence reported that an increased degree of  NMDAR 
hypofunction within the brain is linked to learning and memory impairments, in ageing 
patients leading to  psychotic  and Alzheimer's tendencies (Newcomer et al., 2000). Beyond 
NMDAR signaling implication in cognitive and memory functions, cerebral insulin signalling 
dysfunction also results in extensive impairment of synaptic hippocampal neurotransmission 
and cognitive task (Trudeau et al., 2004). Thus, it is evocative that inadequate insulin 
production (T1DM) or insulin insensitivity (T2DM) induces cognitive deficit and deficiencies 
of long-term potentiation (LTP) in the hippocampal (Gault et al., 2010b) and PFC (Erberk 
Ozen and Rezaki, 2007; Frith and Dolan, 1996) regions of the brain. Because of these 
neurochemical and behavioural data, it is suggestive that glutamatergic neurotransmission 
signalling, altered by PCP may be essential to account for hyperlocomotor and cognitive-
deficit responses of the drug (Adams and Moghaddam, 1998). Interestingly, some studies 
have found that GLP-1R activation in the NAc suppresses reward and craving activities by 
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enhancing presynaptic glutamatergic AMPA/Kainate transmission (McIntyre et al., 2013; 
Mietlicki-Baase et al., 2013a; Liu et al., 2017). Therefore in our study, Ex-4 action on PCP 
may be partly through augmenting or compensating a glutamatergic -deficient neuronal 
circuit. 
 Finally, we assessed the electrophysiological impact of Ex-4 and GPO on the VTA 
dopamine neurons as well as PFC pyramidal neurons. Our electrophysiological data shows 
that GLP-1R activation can change the excitability of prefrontal cortex neurons, an effect that 
can be associated with the putative pro-cognitive action of GLP analogues (Mansur et al., 
2018b). These electrophysiological findings suggestively correlate with behavioural data of 
Ex-4 effect on cognition, memory and PCP-induced hyperlocomotion activity. Previous 
studies using whole-cell voltage-clamp electrophysiological paradigm revealed that GLP-1 
elicited a stimulating effect on hypocretin neurons, located  in the lateral hypothalamic 
region, through rapid depolarization of membrane potential and enhanced spike frequency 
(Acuna-Goycolea and van den Pol, 2004c). The paper further illustrates that GLP-1R 
activation facilitated glutamate release at the axonal terminals partly by activation of 
presynaptic GLP-1Rs and that this effect was reversed in the presence of exendin (9-39), a 
GLP-1R antagonist. Another in vitro electrophysiological studies by Mietlicki-Baase et al., 
(2014), revealed that presynaptic GLP-1Rs in the NAc core was activated by Ex-4 to enhance 
the activity of medium spiny neurons (MSN) through the glutamatergic transmission. 
Importantly, the glutamatergic transmission sends a signal to the PFC, NAc, amygdala as 
well as the hippocampus (Kelley et al., 2005). Primarily, GLP-1Rs located in the NAc core 
physiologically control feeding behaviour in which the activation produces GLP-1 to 
facilitate presynaptic glutamatergic signalling and modulation (Alhadeff et al., 2012b; Dossat 
et al., 2011). From all the findings, we can infer that activation of presynaptic GLP-1R 
potentially modulates  glutamatergic PFC pyramidal neurons which are of prime relevance in 
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cognition, memory and drug-craving anomaly (Caballero et al., 2016; Dauvermann et al., 
2017a; Isherwood et al., 2018; Kelley et al., 2005). Thus, we provide an in vivo 
electrophysiological evidence to support these findings of Ex-4 activatory effect on the firing 
rate of PFC pyramidal neurons. Interestingly, on the VTA dopamine neurons, GLP-1 receptor 
activation through intravenous administration of Ex-4 did not affect the DA neurons in the 
midbrain. However, a moderate inhibitory action of insulin on firing activity was potentiated 
by Ex-4 when co-administered intravenously. This synergistic effect with insulin might be 
due to secondary neuronal inhibition synchronized in a pool of DA neurons in the VTA. To 
circumvent the problem of ineffective penetrability into the brain, we administered Ex-4 
directly into the VTA. Although, there was no significant effect on intravenously 
administered Ex-4 on the VTA DA neuronal activity however, we found a pronounced 
activatory effect on VTA DA neuronal activity when administered through intra-VTA. Ex-4 
may exert its central effect indirectly by activating a peripheral component (e.g. vagus nerve) 
that can alter CNS activity. It has been demonstrated that some of the effect of gut peptides, 
including GLP-1 were suppressed following vagotomy (Plamboeck et al. 2013).  However, 
BBB penetration is also possible in particularly at the level of the area postrema in the brain 
stem. Interestingly the area postrema is strongly connected to the nucleus of the solitary tract 
which contains a group of GLP neurons that innervate the VTA and also higher structures 
183). Our finding reveals relatively high firing DA neurons than the control and 
desensitisation of D2/D3 receptors following intra-VTA administration of Ex-4 (3 µg). The 
desensitization effect observed with dopamine D2/D3 may be general in the brain that GLP-
1R interacts negatively with authoreceptors. A few numbers of in vitro electrophysiological 
studies have demonstrated that GLP-1R activation in the VTA involves glutamatergic 
transmission which enhances excitatory postsynaptic current (EPSC) in the VTA DA neurons 
(Mietlicki-Baase et al., 2013b). Also, the studies show that intra-VTA administered Ex-4 
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enhances tyrosine hydroxylase in the VTA (Mietlicki-Baase et al., 2013b), demonstrating 
increased dopamine production. This group further revealed that Ex-4 did not change the 
phasic DA efflux in striatal  brain slices using fast-scan cyclic voltammetry, which further 
suggests that GLP-1Rs are possibly not found on the presynaptic DAergic terminals, but 
rather on the cell bodies of DA neurons (Mietlicki-Baase et al., 2014b; Schmidt et al., 2016). 
Our release radiometric studies of GLP-1 drugs on 3[H] DA are in agreement with these 
findings. We have earlier demonstrated through behavioural paradigm that GLP-1 drugs 
significantly attenuated D-AMP-induced reward, as metered by locomotor stimulation. The 
lack of effect of intravenously administered Ex-4 on VTA DA neurons is possibly due to the 
poor penetrability of the peptide in traversing the BBB when intravenously administered in 
anaesthetized rats as well as suboptimal dose inadequate to elicit an effect. It is noteworthy, 
that GLP-1 agonist may have low brain penetrability, yet it also activates a few neurons too, 
but a large proportion of GLP-1 in the brain comes certainly from GLP-1 neurons. Indeed, 
there is specific GLP-1 innervation for the NTS to the VTA. Therefore some of the effects we 
see in the VTA may be rather mediated via this innervation. Albeit, some studies have shown 
that GLP-1R activation may lead to inhibition of  excitatory synaptic VTA DA neurons 
through an in vitro electrophysiology paradigm using a striatal slice of whole-cell patch-
clamp recordings (Wang et al., 2015b). This effect potentially leads to reduced expression of 
VTA/NAc dopamine signaling and regulating drug and food reward (Volkow et al., 2011). 
More studies have revealed that, while food intake can be partly regulated by dopamine 
homeostatic signaling, the drug-craving signalling mechanism is controlled by the 
mesolimbic dopamine system (Kenny, 2011c). We can thus infer that dopamine neurons 
exhibit a reduction in excitatory synaptic ability and enhanced inhibitory synaptic inputs 
when Ex-4 is co-administered with insulin. In agreement with these studies, our data 
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demonstrate that administration of GLP-1 peptides for VTA electrophysiological recording is 
potentially implicated in reward behaviour.  
Finally, in this chapter, we have demonstrated that exendin-4 alters dopamine-
dependent behaviour with a remarkable inhibitory effect on D2/D3 DA agonist-induced 
yawning, pelvic grooming and pica eating. Evidence was also provided for GLP-1 inhibitory 
effect on D-AMP-induced motor activity, a DAT mediated mechanism from GLP-1R 
activation. In addition, we reported the precognitive effect of GLP-1on PCP-induced 
cognitive impairment as well as an excitatory effect on PFC pyramidal neurons. Also, we 
revealed the activatory effect of GLP-1 in the VTA and its desensitization effect on DA 
D2/D3 authoreceptors. We propose that GLP-1 interacts with DAT, an important 
transmembrane for D-AMP–induced reward activity, by attenuating its surface expression 
and cause less of it to be available for D-AMP to act on. This is to be transported inside the 
neuron to exert its depleting effect on dopamine vesicles besides DA D2/D3 autoreceptor 
sensitivity. These riveting data indicate that GLP-1R activation is essential for control of 
reward episode from drugs as well as cognitive and memory enhancing tendencies. 
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Chapter V- Ad libitum administration of 
sucrose during adolescence alters dopamine 
neurotransmission and dopamine-dependent 
behaviour modulation by glucagon-like peptide 
V-1- Introduction 
 Adolescence constitutes a transformational phenomenon that exists after 
prepubescence and before adulthood in all animals' lifespan. In human, neuroimaging 
researches have shown that specific brain regions such as PFC progress to maturity after the 
age of 20 years old (Sowell et al., 2001; Wahlstrom et al., 2010; Mills et al., 2014). However, 
different studies from functional magnetic resonance imaging (fMRI) on reward system 
during adolescence reported striatal hyper-responsiveness leading to a high reward-craving 
effect (Blum et al., 2000; Galvan, 2010). Conversely, it requires more repeated rewarding 
inducement to reach similar effect as in adulthood, due to hypo-responsiveness caused by a 
deficiency in the motivational task (Bjork et al., 2004; Blum et al., 2000). It is noteworthy 
that, brain development activity during adolescence is significantly impacted on by sex 
hormones (Sisk and Foster, 2004), which elicit  modulatory effect on  memory, cognition, 
reward as well as motivational changes (Martini and Melcangi, 1991; Zhou et al., 2002; 
Peper et al., 2011). In response to rapid brain developmental effect in adolescent, there is a 
high degree of sensitivity to  neural abuse as well as  manifestations of signs of various 
psychiatric disorders such as  feeding, emotional thought  and behavioural disorders (Paus et 
al., 2008; Spear, 2000). Unfettered consumption of extreme palatable sugary foods and fatty 
diets, which are affordable and easily accessible, play a principal part in the event of 
corpulence (Malik et al., 2013a). While there are well documented outcomes of 
overconsumption of sugar resulting in high risk of diabetes mellitus (Macdonald, 2016b), 
obesity (Delli Bovi et al., 2017), metabolic syndromes (Stanhope, 2016), cardiovascular 
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diseases (DiNicolantonio and OKeefe, 2017), acne (Melnik, 2015), cancers (Miles et al., 
2018) and chronic kidney disease (DiNicolantonio et al., 2016), little is known about how 
sugar influences memory and cognition, motivation and impulsivity, reward-seeking 
behaviour, depression  as well as other mental health conditions. Adults studies conducted on 
the individual that consumed high quantities of soft drinks of about 500 mL per day have 
been linked with a significant possibility of developing depression, suicidal tendency and 
some psychological disorders, then those individual adults that did not consume soft drink as 
control subjects (Shi et al., 2010). Additional studies revealed that probability for the 
occurrence of depressive traits was much higher in adults drinking a large quantity of soft 
drink (Yu et al., 2015). It is quite disturbing that sugar intake is more among adolescents than 
in adults (Bremer and Lustig, 2012). Thus, animal models have demonstrated that rats which 
excessively ingested sugar during adolescence were not motivated to response for saccharin, 
due to possible depressive behaviour. However, they are highly vulnerable to reward-related 
disorders as well as cocaine self-administration (Vendruscolo et al., 2010). More studies 
using  rat  models have revealed a neurobiological alteration in craving such as, a significant 
reduction in DA D2 receptors in the striatum and escalated D1 receptors binding in the NAc, 
in rats that were exposed to 25% glucose for several weeks (Colantuoni et al., 2001a). 
 The present investigation asked the question whether prolonged continuous 
consumption of sucrose solution (5%) by adolescent rats impacts on cognition and memory of 
the subjects and if sucrose consumption was sufficient to trigger alterations in the 
dopaminergic system. In particular, we tested the electrophysiological characteristics of the 
neurons such as DA firing and burst activities. We also studied the modulation of 
autoreceptor effect by PPX, a DA D3R preferred agonist. We further assessed the effect of 
dopamine-producing drugs (D-AMP, PPX) on dopamine dependent-behaviours, if these 
behaviours are altered by sucrose consumption. Finally, we examined whether the 
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behavioural traits could be modulated by glucagon-like peptide, a gut metabolic hormone 
which is known to interfere with food and drug rewarding systems (Jerlhag, 2018). 
  
V-2- Materials and methods 
 V-2-A-Subjects 
  Please refer to paragraph I-2-A for detail information on animal conditions 
and regulatory protocol on a study involving rodents. In this study, 4 groups (n=8) of male 
adolescent rats (PND 20-25) were administered sucrose 5% and water ad libitum, or water for 
2 weeks, with or without the stable glucagon-like peptide agonist analogue exendin-4 (0.01 
mg/kg/day, ip). 
 V-2-B- Sucrose, chow consumptions and weight measurement 
  Upon reception, animals were acclimatized to their housing conditions for at 
least 4 days before access to 5% sucrose solution. Fresh sucrose was made daily and was 
accessed by the rats continuously within 24 hrs for 15 days, with an option of water (two 
bottles choice). Sucrose and water consumptions were recorded by weighing the bottles 
before and after the 24 hrs periods. Rats were randomly assigned to one of the following 
groups, as indicated in figure 58: 
 Rats receiving vehicle alone throughout the experimental period-(Control)  
 Rats receiving 5% sucrose with an option of a vehicle (water) during the dark phase, 
and 5% sucrose alone throughout the light phase for 15 consecutive days and later 
received D-AMP and PPX treatment before electrophysiological recording.-
(Sucrose+D-AMP) 
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 Rats receiving 5% sucrose with an option of a vehicle (water) during the dark phase 
and 5% sucrose throughout the light phase as well as exendin-4 (0.005 mg/kg/day, ip) 
for 15 consecutive days. The group also received D-AMP and PPX treatments before 
electrophysiological recording.-(Sucrose+D-AMP+Ex-4) 
The weights of the rats and chow consumed were measured accordingly on every 3 days 
during the 15 days continuous sucrose access by comparing the weights of the animals before 
and at the termination of the treatment. The rats were isolated during night and reunited in the 
morning. It is mostly during the dark phase that they eat and drink.  We calculated the % 
chow consumed by measuring the quantity of chow consumed by each rat per day over the 
actual rat weight in %). Therefore, the weight ratio between the end and the beginning of the 
chronic treatment was measured for each animal and was a direct reflection of body weight 
change. 
 
Figure 58: Experimental timeline for the entire investigation 
Each of the group was treated with 5% sucrose for 15 days, except for the naïve and the D-
AMP only group. For an unbiased electrophysiological recording, we also added an 
additional group which was sucrose-only treated rats without exposure to D-AMP and PPX 
treatment before electrophysiological recording. 
 
V-2-C- Evaluation of glycaemic parameters 
  Briefly after the end of 15 days sucrose treatment, oral glucose tolerance test 
(OGTT) was assessed over a period of 2 hrs in the control (vehicle) as well as 5% sucrose 
treated group. This was carried out by making a slight prick on the lateral tail vein of the 
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animals to obtain a blood drop and the glycemic levels were consequently measured using the 
Accu-Chek® blood glucose system (Aviva). Previous studies have reported a glucose range 
levels between 5.6 and 7.9mMol/L in naïve rats (Florence et al., 2014; Wang et al., 2010). 
However, in experimentally-induced diabetes mellitus, the glycemic level may escalate to a 
mean value of 12.4 and 21.8 mMol/L in alloxan and streptozotocin-induced DM respectively 
(Howland and Zebrowski, 1976). 
 
V-2-D- Sucrose preference test (SPT) 
  Subsequent to 7 days washout period, animals were subjected to SPT 
according to previously published techniques (Mateus-Pinheiro et al., 2014; Tang et al., 2015; 
Xu et al., 2012). In essence, the animals were tested for sucrose preference for a 5 days using 
a two-bottle option test. Animals had ad libitum access to food and water throughout the 
experiment. On the first day, rats were housed singly and accustomed to drinking from two 
water bottles. On the following three days, rats were trained on the sucrose preference test, in 
which one out of the two water bottles was replaced by a bottle containing a 5% sucrose 
solution (w/v). Rats were allowed to drink freely from both bottles during the 12-hour 
nocturnal phase (7.30 PM until 7.30 AM). During the light phase, both bottles were replaced 
by bottles containing water only. The bottles were weighed and refilled each day at the same 
time in the morning. The positions of the bottles were switched daily to avoid position 
preferences, which has been observed in rodents (Gaudez and Cail, 2016; O’Connell, 1971; 
Sinclair, 1976; Velimirov et al., 2011). Sucrose preference was determined after the last trial, 
on the fifth day, by the quotient of sucrose consumption over 12 hours to the total liquid 
intake, consisting of both water and sucrose intakes. That is, the percentage of preference was 
calculated as follows: sucrose intake/total fluid intake × 100. A decrease in sucrose 
preference is classically used to determine anhedonia. A sucrose preference score lower than 
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65% was considered a depressive-like phenotype according to previously published protocols 
(Conti et al., 2017; Gueye et al., 2018a; Qin et al., 2019; Yun et al., 2016). 
 
 V-2-E- Novel object recognition (NOR) test  
  After 1 week washout period, the animals were tested for NOR task. Please 
refer to paragraph IV-2-D1 for detailed protocols on NOR test (Chater 4). 
 
 V-2-F- D-AMP and DA D2/D3 receptor agonist-induced behavioural studies 
  Please, refer to paragraph II-2-D for detailed behavioural protocols. In this 
study, each group was tested on D-AMP-induced motor activity, with the second challenge of 
D-AMP after a week from the first D-AMP exposure, except in the control and sucrose-only 
group. Similarly, PPX was tested on each group of the animal subject to assess the response 
to DA D2/D3-induced yawning effect (experiments not done in the control and sucrose-only 
group). Collectively, we investigated if the consumption of sucrose modulates DA associated 
behavioural traits. 
 
 
 
 
V-2-G-In vivo extracellular single-unit electrophysiology recording 
  Please refer to paragraph I-4 for detailed protocol. Recordings were done on 
VTA dopamine neurons.  In this electrophysiological studies, we assessed the impact of 
intravenously administered PPX (a D3 preferred DA agonist) on auto-receptor in the midbrain 
dopamine neurons. We compared the DA neurons firing rate and burst activity within the 3 
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groups. We investigated whether continuous sucrose consumption during adolescence can 
alter dopaminergic neuronal activity in the VTA. 
  
 V-2-H-Statistical analysis 
  Please refer to paragraph IV-2-G for detailed statistical analyses deployed in 
these studies. However, weight change analysis was deduced by finding the weight difference 
every 3days. The % chow consumption was calculated by measuring the quantity of chow 
consumed by each rat per day over the actual rat weight in %, while the percentage of 
preference was calculated as follows: sucrose intake/total fluid intake × 100.  
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V-3- Results 
 V-3-A-Effects of sucrose consumption on growth, feeding and glycaemic levels  
  The impact of continuous sucrose consumption during adolescence on the 
growth variables was investigated. We observe that at the end of 15 days continuous sucrose 
consumption, rats treated with vehicle and sucrose consumed similar quantities of chow. 
While the group treated with Ex-4 5 µg/kg along with continuous 5% sucrose demonstrated a 
significant reduction in chow consumed, particularly in the last days of treatment (Fig. 59A). 
Similarly, Ex-4 treated rats showed a pronounced weight reduction when compared with the 
control and sucrose treated groups. However, the sucrose (alone) treated rats manifested an 
increase in weight gain than all the other groups (Fig. 59B). Rats exposed to daily access of 
5% sucrose generally demonstrated increases in blood glucose levels compared to the control 
group (Fig. 59C). 
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Figure 59: Sucrose consumption does not alter weight and feeding pattern 
(A): There was no significant difference in the chow consumed between the sucrose (alone) 
treated and the control. However, during the last 3 days of the treatment, the Ex-4 treated rats 
displayed a significant reduction in the quantity of chow consumed when compared with the 
control. *P<0.05 vs. control, Bonferroni after significant repeated measures two-way 
ANOVA. (B): Sucrose consumption did not significantly affect the weight changes in all the 
groups. However, Ex-4 treated group showed the lowest AUC value (1.9, followed by the 
control (2) and the sucrose alone treated rats (2.2). This may indicate the anorexic property of 
Ex-4 that eventually culminates to low chow consumption, reflecting on the weight change. 
(C): Random plasma glucose levels were measured immediately at the end of 15days sucrose 
administration. The sucrose treated rats slightly became hyperglycaemic at the end of 30 mins 
treatment than the control albeit, no significant discrepancy in blood sugar level at the end of 
2 hrs observation following the end of 15 days sucrose treatment. 
0 5 10 15 20
0
20
40
60
Control-Saline
Sucrose 5%
Sucrose 5% +Ex-4(5g/kg)
Experimental Day%
 C
ho
w
 c
on
su
m
ed
 p
er
 a
ni
m
al
 w
ei
gh
t
0 5 10 15 20
0.0
0.1
0.2
0.3
0.4
Control-Saline
Sucrose 5%
Sucrose 5%
+Ex-4(5g/kg)
Experimental Day
%
 W
ei
gh
t c
ha
ng
e
0 50 100 150
6
7
8
9
10
Vehicle
Sucrose 5%
Interval (Mins)
B
lo
od
 g
lu
co
se
 le
ve
l (
m
M
ol
/L
)
n=8
n=8
n=8
A
B
C
192 
 
V-3-B-Effects of sucrose consumption on depressive-like phenotypes in adulthood 
  Three days after the termination of the washout period, the rats were 
investigated for sucrose preference test which is an index for depressive-like behaviour. We 
observed, that rats treated with sucrose alone as well as those treated with sucrose plus Ex-4, 
showed a strong preference for sucrose (about 100% preference); indicating that sucrose 
preference was not prevented by Ex-4 ip. Administration, although there was a statistical 
significant difference (F=8.6, DFn=2, DFd=36) within the group (Fig. 60A). Interestingly, 
controls show a slightly lower preference index than the treated, but this was not found to be 
significant (Fig. 60B). We equally observed a pronounced increase effect in total fluid 
consumption both in sucrose alone and sucrose plus Ex-4 treated groups (Fig. 60C). 
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Figure 60: Adolescent exposure to chronic consumption does not induce depressive-like 
phenotype 
(A, B): In all the 3 groups of adolescent rats exposed to continuous sucrose consumption, 
there was an apparent preference for sucrose in adulthood (above 90%), with no depressive-
like phenotype exhibited.  A two-way repeated measure ANOVA show significant difference 
among the groups (A), but no significant difference at any time.  ##P<0.001 within the group. 
(C): Adolescents exposed to both sucrose as well as sucrose plus Ex-4 consumed the same 
volume of fluid when compared with the control group ns: not significant. 
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V-3-C- Sucrose consumption induces cognitive impairment  
  In this study, we investigated the impact of continuous sucrose consumption 
on cognitive activity, as well as whether Ex-4 intraperitoneally administered concurrently for 
2 weeks may affect sucrose-induced cognitive impairment. During the exploration period, 
sucrose-treated (alone) group spent significantly less time exploring the objects during the 3 
day familiarization phases than sucrose +Ex-4-treated rats, while the control (vehicle) group 
spent the most time during exploration period. There was no significant difference within the 
group (Fig. 61A). We found that during the familiarization phase the control groups 
significantly differ from sucrose groups. At test period, the discriminating index, which is the 
ratio of the differences in time explored with novel and familiar object, to the sum of the total 
time spent with novel and familiar object i.e. [DI’ = (TN  − TF)/(TN + TF)] of %), differs 
moderately although, not statistically significant between control and the sucrose groups, but 
significant difference (F=5.694, df=2) exists within the group (Fig. 61B). There was a varied 
disparity in DI' among the groups, while the control exhibited 85% in DI', the sucrose and 
sucrose +Ex-4 treated displayed -8.3 and -20% for mean DI' respectively. In this instance, the 
control group spent the most time exploring the novel object than the sucrose access rats. In 
addition, the total amount of time spent exploring the novel object during the experimental 
phase was deduced as control=13 sec, sucrose=11 sec and sucrose+Ex-4=6 sec. Interestingly, 
preference for the familiar object during the test period was reported as control group having 
the least time spent, while the sucrose (only) group spent significant (F=1.073, df=2) longest 
time with the familiar object Preference for familiar was introduced to further appreciate the 
level memory deficit associated with higher preference for familiar object over novel object 
(Fig. 61C). 
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Figure 61: Effect of concomitant Ex-4 treatment on continuous sucrose-induced 
cognitive impairment 
(A): During the exploration period, the sucrose treated (only) group, as well as sucrose+Ex-4 
treated group exhibited a significant reduction in familiarization time when compared with 
the control group(B): Ex-4 treated group object did have a significant impact on sucrose 
consumption on preference for novel (DI’). Indeed, sucrose induced a long term cognitive 
impairment and this was not reversed by Ex-4 concurrent administration. (C): Interestingly, 
sucrose (only) treated group displayed the longest time spent on the familiar object during the 
test phase than the control, similar results were observed in sucrose+Ex-4 treated rats 
#P<0.05, *P<0.05,**P<0.001, ***P<0.0001 vs. control. Bonferroni post hoc tests after 
significant two way repeated measures ANOVA. 
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V-3-D- Ex-4 concomitant treatment with sucrose alters DA drugs induced behavioural 
traits. 
  After 1 week of washout, rats were challenged with D-AMP 1 mg/kg to assess 
response to motor activity. Rats that were treated with sucrose-only displayed a significant 
(F=65.37, DFn=2, DFd=84) motor response than the naïve rats to the administration of D-
AMP (1 mg/kg), as shown by a larger increase in rearing activity (Fig. 62A). There is also a 
significant difference within the group. Following 1 week of D-AMP 1 mg/kg treatment, we 
acutely challenged the rats with additional D-AMP 1mg/kg to assess if there may be 
behavioural proportionality from the first treatment and the second challenge. Interestingly, a 
more significant increase (F=94.85, DFn=3, DFd=84) in motor response within the group was 
observed in D-AMP challenge II within the group (Fig. 62B). In another series of experiment, 
we tested the effect of D3 preferred agonist PPX 0.1 mg/kg) on yawning activity (Fig. 63A). 
There was a significant difference within the group and sucrose-treated rats also displayed a 
significantly (F=36.29, DFn=3, DFd=36) larger response than naïve animals to the D3 
preferential agonist PPX (0.1 mg/kg, ip) on yawning activity. Yawning effect was also 
markedly reduced in rats that were co-administered exendin-4 with sucrose than in sucrose 
treated alone. 
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Figure 62: Ex-4 treatment alters D-AMP-induced motor activity in sucrose-treated rats 
after double challenge 
(A): Sucrose-only treated group exhibited a higher statistical significant motor activity than 
the control and the sucrose/exendin-4 treated rats when challenged with D-AMP, except 
during the 0-15 min interval. (B): In the second D-AMP challenge, the sucrose+Ex-4 group 
exhibited significant motor reduction (assessed by measuring rearing-like activity) when 
compared with the control and the sucrose-only treated rats. However, the entire group still 
displayed relative increase in motor activity than in the first D-AMP challenge ##P<0.05, 
###P<0.0001, *P<0.05, **P<0.001, vs. control, Bonferroni post hoc tests after significant 
two-way ANOVA. 
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Figure 63: Ex-4 treatment alters DA drug-induced behavioural traits in sucrose-treated 
rats  
Sucrose-only rats exhibited a significant increase in yawning activity following PPX 
administration than the control. Furthermore, the yawning effect was significantly reduced in 
sucrose+Ex-4 group ###P<0.0001, *P<0.05, **P<0.001 vs. control, Bonferroni post hoc tests 
after significant two-way ANOVA. All animals have been exposed to D-AMP once. 
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V-3-E1- Rats treated with sucrose altered neuronal sensitivity to acute PPX 
administration 
  In this experiment, we investigated the effects chronic treatments on the ability 
of the preferential dopamine D3 receptor agonist PPX (cumulative doses 20-100 µg/kg, iv) to 
reduce the firing activity of VTA dopamine neurons (to test dopamine D2/D3 autoreceptor 
sensitivity). The naïve rats displayed a complete inhibition to PPX at the 4th dose 
administered and the firing rate was reversed by administration of the D2/D3 antagonist 
eticlopride 0.2 mg/kg to initial baseline firing (Fig. 64A, B) as shown also in chapter I. 
Animals treated with sucrose only displayed a partial decrease in their responses to PPX (Fig. 
64C, D) compared to controls. Surprisingly, the desensitization effect was more prominent in 
VTA dopamine neurons from rats that were co-administered sucrose with exendin-4 (Fig. 
64E, F). Fig. 65 shows a comparison among the different groups (naïve, sucrose-only, 
sucrose+Ex-4 treated). Apo (Apomophine) in doses of 10 µg/kg and Apo max (maximum 
dose of apomorphine) of 20 µg/kg was injected shortly before the administration of 
eticlopride to test the response of the neurons to DA D1/D2 agonist. 
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Figure 64:  Sucrose consumption reduces VTA dopamine neurons sensitivity to the 
dopamine D2/3 receptor agonist pramipexole (PPX), an effect potentiated by ex-4 co-
administration. 
(A, B): In naïve rats, the VTA dopamine (DA) neurons exhibited a complete inhibition to a 
cumulative administration of PPX (up to 80 µg/kg, iv). The cells were reactivated by the 
selective dopamine D2 antagonist eticlopride (0.1 mg /kg) to their original firing rate.  
(C, D): In sucrose-only treated rats, the VTA DA cells exhibited a significant desensitization 
to PPX acute administration. The inhibition of firing was only statistically significant at the 
high doses of  60 and 80 µg/kg PPX.  
(E, F): In sucrose+Ex-4 treated rats, the desensitization was remarkably more pronounced.  
ns: non-significant, *P<0.05, **P<0.001, ***P<0.0001 vs. baseline firing. Newman-Keuls 
post hoc test after one-way ANOVA.  
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Figure 65: Statistical comparison among the groups (naïve, sucrose-only and 
sucrose+Ex-4)  
Control rats compared with sucrose-only and sucrose+Ex-4 treated rats exhibited significant 
difference in sensitivity to PPX within the groups. ###P<0.0001 vs. all conditions, *P<0.05, 
**P<0.001 vs. naïve rats. Bonferroni post-tests after significant two-way ANOVA within the 
3 groups. 
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V-4- Discussion 
 In this study, we continuously exposed adolescent rats (PND 20-25) to a 5% sucrose 
solution for 15 days and subsequently investigated their cognitive behaviours, impact on 
D2/D3 dopamine agonist drugs, as well as the effect of electrophysiological characteristics on 
VTA DA neurons. We also examined if the co-administration of exendin-4 to sucrose can 
modulate the effects of sucrose. First, sucrose consumption was assessed on growth 
parameters. We found that 2 weeks sucrose feeding on the rats induced a slight weight 
increase compared to both controls and sucrose+Ex-4 treated rats (Fig. 59B). This is in 
agreement with previous findings by Bes-Rastrollo et al., (2016); Bissonnette et al., 2017; 
Malik et al., 2013; Vermunt et al., (2003) in which sucrose sweetened food enhanced weight 
gain in adolescent rats as well as young human subjects. Interestingly, rats that were treated 
with sucrose+Ex-4 displayed relatively lowest weight change and consumed fewer chows 
(Fig. 59A). This is suggested to be as a result of the ability of GLP-1R agonist to quell 
feeding via satiety induction which may lead to weight loss (Bradley et al., 2010; Yang et al., 
2014a). Additional studies, including our findings (see chapter IV), have implicated 
hypothalamic homeostatic and dopaminergic reward pathway in playing a vital role in the 
reduction of food intake elicited by peripheral Ex-4 administration (Brunetti et al., 2008; 
Dalvi et al., 2012; Lu et al., 2018). The studies further explained that Ex-4 potentially 
decreases energy intake and facilitates energy dissipation although, a debate arises on which 
of the processes takes the lead when it comes to weight loss. We also observed that chow 
consumption was significantly low with sucrose+Ex-4-treated rats than in both control and 
sucrose-only treated rats. A direct correlation between weight change and food consumption 
has been reported in previous studies (Chow and Hall, 2008; Yang et al., 2014b), our findings 
undoubtedly agree with these reports. Notably, while sucrose+Ex-4 treated rats were able to 
exhibit a significant reduction in chow consumption and weight loss, Ex-4 did not seem to 
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affect the volume of sucrose intake throughout the experiment (Fig. 60C).We also assessed 
the impact of sucrose consumption on the glycaemic level when compared with the control. 
Previous findings have shown that high intake of sugar apparently causes some health risks, 
due to excessive ingestion of energy and may not necessarily disrupt metabolic or glycaemic 
homeostasis (Johnston et al., 2013; Macdonald, 2016c). Here, there was no significant 
glycaemic alteration at the end of 15 days continuous sucrose treatment, although, the rats 
were slightly hyperglycemic the effect quickly faded out within 60 mins of observation (Fig. 
59C). Next, we investigated the impact of chronic sucrose consumption during adolescence 
whether it may induce depressive-like phenotype, an index for anhedonia in adulthood. Our 
finding revealed that continuous 5% sucrose consumption during adolescence does not lead 
to depressive-like phenotype at adulthood (Fig. 60A, B). Generally, the sum of the fluid 
intake increased on the first day of the test and later became constant on the remaining 4 days 
across the groups. However, sucrose-only treated rats, as well as sucrose+Ex-4, the treated 
group exhibited escalated increase in daily fluid intake and reached about 100mls per day 
initially at PND 44. There have been seemly conflicting findings on whether unlimited access 
to sucrose consumption during adolescence in rats can induce depressive-like phenotype or 
not. We have previously reported from our laboratory that rats exposed to 5%  sucrose did 
not induce any long-term anhedonia traits, whether early adolescence or adulthood treated 
(Di Miceli et al., 2019b). In support of our findings, another study by Gueye et al., (2018) 
reported that continuous sucrose consumption by adult Wistar rats had no impact on sucrose 
preference and anxiety-like behaviour. In essence, all these findings indicate that unlimited 
sucrose consumption even at adulthood may likely not induce a long-lasting impression on an 
emotional trait. It has also been reported that rats with a history of sucrose consumption 
during adolescence demonstrated a decrease in hedonic activity as well as reduced reward 
efficacy to 1% saccharin preference (Naneix et al., 2016; Vendruscolo et al., 2010). In the 
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following experiment, we assessed the impact of sucrose consumption on cognitive processes 
and whether GLP-1 administered concomitantly with sucrose intake might positively affect a 
potential deficit or has no direct correlation. We discovered that sucrose+Ex-4 treated rats 
spent relatively same time exploring the familiar objects when compared with a sucrose-only 
treated group (Fig. 61C). While the control rats spent the shortest time in exploration of the 
familiar object. Furthermore, in the control rats, the total exploration time spent during 
training was the longest with familiar objects (Fig. 61A). It has been reported that total time 
spent in exploration of a familiar object is not an adequate parameter to make a meaningful 
inference on cognitive interference (Morellini et al., 2010).  Yet, our finding is indicative of 
the fact that unlimited sucrose intake adversely affects exploratory behaviour possibly by 
inducing fear and anxiety which eventually culminate into loss of attention to explore, as well 
as more interested in the familiar object, an indication of cognitive disturbance (Haagensen et 
al., 2014). In particular, NOR is based on the hypothesis that inherent novelty-seeking of 
rodents steers them to spend extra time investigating a novel object against the familiar one 
(Mathiasen and DiCamillo, 2018). In agreement with previous accounts (Beilharz et al., 
2014; Heyward et al., 2012; Ross et al., 2009), sucrose-only treated rats exhibited a 
pronounced cognitive decline when compared with the control rats (Fig. 61B). Surprisingly, 
in sucrose+Ex-4 treated rats the cognitive deficit was not corrected. More studies have shown 
that daily controlled sucrose exposure during adolescence induces a long-term consequence 
on the role of the prefrontal cortex, which presents in form of cognitive impairment and 
memory deficit (Reichelt et al., 2015a). Hence, it is plausible that high sucrose diet in 
adolescence potentially induces long-term adverse effects on specific brain regions concerned 
with cognitive mediated behaviour involving the PFC. We also observed with interest that, 
Ex-4 could not reverse the cognitive deficit elicited by sucrose-treated rats. This may be due 
to a suboptimal concentration of peripherally administered Ex-4 able to transverse the BBB 
205 
 
central effect. Thus, we have demonstrated in the previous chapter that acutely administered 
Ex-4, as well as its chronic treatment, aids cognitive functions. Another study using Morris 
water maze test on STZ-induced T2DM plus high sucrose intake, demonstrated that GLP-1 
ameliorates hyperglycemia as well as improved learning and memory (cognitive abilities) 
deficits in T2DM rats (Cai et al., 2017). Our data reveal that Ex-4 works on cognition only, in 
a condition of hyperglycemia, by correcting the hyperglycemia in inducing insulin release. 
Chronic sucrose treatment seems to induce a kind of long-lasting deficit in cognition, not 
corrected by exendin-4. Thus, we saw in previous chapter sub-chronic and chronic effects of 
Ex-4 on cognition in non-treated rats, here it is a different condition in treated rats (sucrose 
exposed) and after a washout. 
 Next, we report our findings on the impact of continuous sucrose intake on D-AMP-
induced motor activity as an index for impulsivity and reward-related traits. We observed that 
sucrose-only treated rats exhibited a remarkable hypersensitivity to D-AMP-induced motor 
activity when compared with both the control and sucrose+Ex-4 groups (Fig. 62A). The 
behavioural sensitization effect was further escalated on the second challenge with D-AMP 
after 7 days of the previous acute treatment (Fig. 62B). A well-liked and persevere 
speculation that has lasted for about 3 decades, is that sugar intake promotes hyperactive or 
vigorous behaviour, especially in children (Dykman and Dykman, 1998; Hoover and Milich, 
1994; Wolraich et al., 1995a; Kim and Chang, 2011a). This perspective was supported by 
previous investigations, demonstrating a positive relationship between sugar intake and 
devastating-truculent behaviours arising from restlessness in children (Prinz et al., 1980). 
Early research also showed that there was a marked improvement in the behaviour of 
adolescent prison inmates as well as hyperactive teenagers when sugar was removed from 
their diet (Crook, 1974; Schoenthaler, 1983). Further prevalence human study in adolescents 
demonstrated that odd ratios (the connection between exposure and result) for mental 
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disorders such as anxiety, hyperactivity and attitudinal anomalies were elevated in subjects 
on excessive sugar consumption (Lien et al., 2006). However, the connection between sugar 
and hyperactivity observed in some survey investigations is in variance with vast 
experimental researches which have discovered no causal relationship effect between sucrose 
intake and behavioural anomalies (Benton, 2008; Kim and Chang, 2011b; Wender and 
Solanto, 1991; Wolraich et al., 1995b).  For example, in the study with Wolraich et al., 
(1995b), they found that  sugar intake does not impact on the behaviour or cognitive execution 
of children and in Wender and Solanto, (1991) investigation, it was observed that ADHD 
children were significantly more aggressive than the control, when both were exposed to 
sugar ingestion. Nevertheless, a growing evidence from animal models shows that rodents fed 
with excessive sucrose exhibit cognitive disorders (Beilharz et al., 2015; Gueye et al., 2018c; 
Reichelt et al., 2015b) and may change response to drug-induced behaviour (Colantuoni et 
al., 2001b, 2002), while having not much effect on basal behavioural activity. Gosnell, (2005) 
has earlier discovered that sucrose consumption in rats facilitates behavioural sensitization 
elicited by cocaine, as well as enhancement of sensitization after repeated cocaine 
administration. Our data demonstrated that sucrose-only treated rats displayed 
hypersensitivity to D-AMP treatment as well as D3 preferred DA agonist (PPX) yawning 
effect. We also found out, that the double challenge of D-AMP corresponds to double 
behavioural responses (Figure 62A, B). In other words, repeated administration of D-AMP (2 
doses) resulted in about twice behavioural responses in all the groups. This may suggest that 
repeated D-AMP exposure can result in continuous disturbance of dopaminergic homeostasis, 
which may further impede cognitive and behavioural activities consistent with the 
psychostimulant addict. (Tse et al., 2011). Our finding is in line with Gosnell, (2005 ) and 
Avena and Hoebel, (2003) studies who also demonstrated that sugar dependency leads to 
behavioural cross-sensitization to D-AMP administration. The pharmacological interaction 
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involved in this events is likely to be initiated by the tendency of excessive sucrose intake to 
activate brain regions implicated in reward processing as well as energy homeostasis (Kenny, 
2011b, 2011d). Precisely, the stimulation of brain reward system by highly palatable sugary 
foods is considered to reverse energy regulation and facilitates uncontrollable eating 
behaviour that leads to obesity (Kuźbicka and Rachoń, 2013; Volkow and Wise, 2005; Chen 
et al., 2019). In addition, excessive sucrose intake has been shown to activate opioid (Mysels 
and Sullivan, 2010) as well as triggers  DA release (Avena et al., 2008; McCutcheon et al., 
2012; Pritchett and Hajnal, 2011; Skibicka et al., 2012) in the NAc, accompanied  by indirect 
signaling effects on the corticolimbic regions of the brain (Grimm et al., 2002; Murray et al., 
2016; Pomonis et al., 2000; Shariff et al., 2016). In this case, DA and opioid antagonists can 
specifically reverse the reinforcing effects of excessive sucrose intake (Levine et al., 2003). 
From our data, sucrose+Ex-4 rats displayed the lowest motor activity response to D-AMP 
challenge as well as minimal yawning effect to PPX (Fig. 63). Although Ex-4 did have any 
effect on the intake of sucrose during the chronic treatment, we observed with interest the 
remarkable lower effect exhibited by this group to D-AMP and PPX-induced DA mediated 
behavioural traits. A rich body of literature has previously provided evidence for the 
inhibitory role of GLP-1R activation in food craving and feeding incentive, implicating 
hypothalamic homeostatic regulation to produce anorexigenic effects (Dickson et al., 2012d; 
Montelius et al., 2014; Pritchett and Hajnal, 2011, 2012). We have also mentioned in chapter 
IV that GLP-1R activation may inhibit drug-seeking behaviour demonstrated in the form of 
increased motor activity and impulsivity effect to D-AMP treatment (Hernandez et al., 
2018b). Bringing all the available data together, the new emerging role of GLP-1R activation 
in food and drug-reward behaviour such as, psychostimulant addiction is further underpinned 
by the implication of mesolimbic DA reward pathway, playing a critical role in the process 
(Hayes and Schmidt, 2016b; Skibicka, 2013; Dickson et al., 2012c). 
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 In view of this background, we investigated the electrophysiological characteristics 
(firing, burst and population activity) of DA neurons in the VTA for sucrose-only, naïve as 
well as sucrose+Ex-4 treated groups. We then tested the effects of these chronic treatments 
on the ability of the preferential dopamine D3 receptor agonist PPX (cumulative doses 20-100 
µg/kg, iv) to reduce the firing activity of VTA dopamine neurons (to test dopamine 
autoreceptor sensitivity). We found out the different groups exhibited non-significantly 
different electrophysiological characteristics (firing, burst and population activity) throughout 
the recording period. However, sucrose-only treated group tends to exhibit lower firing 
activities (38.3±5.2), compared with the naïve (43±5.0) rats (figure not shown). Specifically, 
VTA DA neurons in naïve rats displayed complete sensitivity to PPX autoreceptor activity.  
While sucrose treated exhibited desensitization to PPX administration. Addition of Ex-4 
pronounced the degree of desensitization. Interestingly, previous behavioural studies have 
demonstrated that craving effect of sucrose ingestion induced an increasing ratio 
performance, which was dose-dependently terminated by raclopride a DA D2/D3R blocker 
(Cheeta et al., 1995). Ratio performance technique is used as a means of evaluating the power 
of a reinforcing occurrence by an addictive substance, without reference to the degree of 
response (Hodos and Kalman, 1963). This is an arrangement in which each reinforcer is 
presented on the completion of a particular number of responses and the number of responses 
required increases after each reinforcement. In addition, more neurochemical and behavioural 
studies have supported this hypothesis with implication of DA D1/D2R being involved in 
sucrose induced craving, as well as dependency, rather than its tonic and metabolic activity 
(Hajnal and Norgren, 2001; Hajnal et al., 2004; Hsiao and Smith, 1995; Yu et al., 2000). 
More recent reports have indicated the role of high sugar intake on the neuronal activity of 
specific brain regions such as, the hippocampus (Lemos et al., 2016; Mitra et al., 2016), 
nucleus accumbens shell (NAcSh) (Villavicencio et al., 2018) as well as the prefrontal cortex 
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(Petykó et al., 2009). However, there is still a paucity of data on the impact of continuous 
intake of sucrose on electrophysiological parameters of DA neurons in the VTA, a region that 
is largely implicated in food and drug-reward. In some studies on the cortico-hippocampal 
slices using extracellular electrophysiological recordings, chronic sucrose (35%) 
consumption did not alter the general hippocampal metabolic configuration, nonetheless 
exhibits a critical hippocampal impairment through long-term potentiation (LTP) that is 
associated with behavioural (memory and cognitive) deficits (Lemos et al., 2016; Wang et al., 
2014). A few numbers of studies has further demonstrated that high sucrose ingestion in rats 
causes upregulation of DAT (Bello et al., 2003) and enhances mesoaccumbens dopamine 
release (Hajnal et al., 2004), providing more evidence for rewarding effect of sucrose and 
increased behavioural hypersensitivity to DA drugs treatment in such manner similar to drugs 
of abuse (Volkow et al., 2011a). Thus, continuous sucrose intake enhances both accumbal 
DA release as well as upregulates DAT which in turn acts on DA D2/D3R to cause an 
alteration in firing rate. Future consideration must investigate the time-course effect of 
sucrose consumption and concentration variations. Finally, we tested the effect of sucrose 
treatment on the tendency of preferential DA D3R agonist PPX (cumulative doses 20-100 
µg/kg, iv) to reduce the firing activity of VTA dopamine neurons. In this study, we aimed to 
test for DA autoreceptor sensitivity in each of the group. We discovered that sucrose 
treatment induced a partial but significant decrease in the sensitivity of dopamine 
autoreceptors (Fig. 64C, D, G), which was surprisingly exacerbated by Ex-4 co-
administration, indicating that Ex-4 may exert differential pre and postsynaptic neuronal 
effect (Fig. 64E, F). We previously reported in chapter I of this thesis that, PPX D2/D3 
autoreceptor in the VTA resulting in a decrease in the firing rate of DA neurons in naïve rats 
(Fig. 64A, B). However, the partial but pronounced decrease in the sensitivity of DA 
autoreceptors in sucrose-only treated rats to PPX might be attributed to a decreased DA 
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D2/D3R sensitivity induced by chronic intake of sucrose. This possibly induced 
downregulation of the of DA receptors leading to desensitization to acute PPX  
administration (Bello et al., 2003). In addition, DA D2/D3R are associated with behavioural 
plasticity and loss of cognitive control and lack of goal-directed attention (Yawata et al., 
2012). On the other hand, Ex-4 (5µg/kg) co-administered with sucrose, amplified 
desensitization of PPX to DA D2/D3R autoreceptors. This last series of study involving the 
investigation of PPX sensitivity to autoreceptors in sucrose+Ex-4 rats demonstrates that VTA 
DA neurons in the presence of Ex-4 activates the GLP-1R, and may  lead to further 
downregulation of DA signalling in the mesolimbic pathway. Our finding agrees with Wang 
et al., (2015) that demonstrated through in vitro electrophysiological technique, the 
abolishing effect of GLP-1R activation on mesolimbic DA pathway involving VTA/NAc 
signalling process to regulate homeostatic and hedonic signals. Few reports on the function of 
Ex-4 in controlling synaptic activity reveal that activation of GLP-1R enhances the neuronal 
firing of orexin and hypocretin in the hypothalamus via modulation of vital membrane 
characteristics such as neurotransmitter release and uptake as well as channel conductivity of 
Na+ /Ca2+ ions (Acuna-Goycolea and Pol, 2004). This desensitization process may be a 
general effect common to any structure containing GLP-1R and DA D2/D3 receptors. 
Whether it is on the cell body of dopamine neurons or on the postsynaptic neurons in 
dopamine rich area, such as striatal neurons, the mechanism involved is unknown. It may also 
be an interaction at the molecular level on intracellular signalling, do GLP-1 receptors and 
dopamine coexist on the same neuronal membrane, or is it an indirect effect. Thus, it is 
plausible to suggest that Ex-4 elicits a paradoxical effect of neuronal desensitization on the 
presynaptic DA neurons to attenuate the behavioural effect of DA releasing drugs.  
 In conclusion, the present findings consolidate the negative impact of continuous 
sucrose consumption on memory and cognitive tasks. We further infer that prolonged ad 
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libitum access to sucrose in adolescent rats may alter brain circuits related to dopamine 
neurotransmission. It also increases the behavioural traits to dopamine agonists and is 
possibly associated with hypersensitivity of some postsynaptic dopamine receptors. These 
effects were partially prevented by exendin-4, which may elicit some protective and 
therapeutic effects on dopamine receptor function, but with further desensitization effect on 
the VTA DA authoreceptors. On the other hand, we noticed that sucrose treatment induced a 
partial but significant decrease in the sensitivity of dopamine autoreceptors which was 
surprisingly exacerbated by exendin-4 co-administration, indicating that exendin-4 may exert 
differential effects on pre- and post-synaptic dopamine receptors, provided DA receptor and 
GLP-1R are present. It will be of particular interest to find out how long these differential 
effects will last.  
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Chapter VI – Concluding remarks and 
perspectives. 
 
The overall goals of this study were to explore the gut-brain interaction phenomenon, as it 
relates to gut peptides effect on neurotransmission, behavioural traits as well as the impact on 
altered nutrition in animal studies. This study has contributed to our understanding of GBA 
involvement in various central activities such as reward, motivation, and cognitive tasks 
(Carabotti et al., 2015). 
 Finding from chapter I, serves as a template for subsequent studies in the thesis. We 
found from this study that D-amphetamine (DAMP) triggers a huge dopamine efflux in the 
striatum (Fig.  6B), when superfused on striatal slices (as expected), and caused an increase in 
motor activity in particular rearing associated activity (Fig. 9A), an effect certainly due to 
increased dopaminergic transmission in the mesolimbic DA system (Zetterström et al., 1983). 
We were able to also establish that D-AMP can induce sensitization in the form of escalated 
motor activity triggered by the challenge administration of the drug after repeated-dose (Fig. 
10A). This effect is likely associated with activation of the cortico-limbic system, with initial 
propagation in the NAc (Chinen et al., 2006). Although, there are still unanswered questions 
of how long can this neuroadaptive process last?  And if this time lag is accompanied with 
some neurochemical alteration that could be quantified? Indeed, it was accompanied by 
electrophysiological alteration. Another crucial investigation carried out was to investigate 
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potential behavioural correlate of varying degree of motor activity (Fig. 10B), with DA 
neurons electrical firing activity in the VTA (Fig. 14). We observed from our results, that a 
slight correlate exists between behavioural phenotypes and the rate of DA neuron firing. This 
indicates that rats with low or moderate motor activity response to D-AMP possibly possess a 
reduced rate of DA neuronal firing in the VTA. We show that a causal link exists between the 
behavioural traits that are DA-dependent and DA firing rate (Hamidovic et al., 2009). 
However, we used very limited samples and there is an absolute need for a more expanded 
investigation by increasing the sample size and adopt more consistent criteria for the 
classification of degree of motor activity. The indispensable functional role of DA D2/D3 
receptors in the modulation of D-AMP-induced motor activity was established. Dopamine 
D2R blockage through eticlopride, drastically reduced D-AMP induced motor activity (Fig. 
11A), while NGB 2904 a selective DA D3 antagonist, augments the motor activity (Fig. 11B). 
On the other hand, things appear more complicated concerning DA D1 receptors involvement 
as preliminary data shows that dopamine D1 agonist, such as SCH-23390 unexpectedly block 
this locomotor effect. All the results taken together, revealed an indirect modulatory activity 
of DAT, through DA D2/D3 receptor signaling  (Beaulieu et al., 2007; Bolan et al., 2007; 
Boyd and Mailman, 2012). The more expansive study is required in term of DAT 
quantification in both acute and chronically administered DA D2 blockers. We and other 
reported that acute administration of dopamine D3 preferential agonist  PPX reveals a dose-
dependent inhibition on the neuronal firing of VTA dopamine neurons of  naïve rats (Piercey, 
1998; Chernoloz et al., 2009c) (Fig. 13A, B). However, in once weekly single intraperitoneal 
D-AMP 1 mg/kg injection for a period of two weeks, the DA neurons exhibited significant 
desensitization after low dose PPX administration (Fig. 13C, D). Thus, disturbance in D2/D3 
autoreceptors functions with repeated D-AMP (once weekly for two weeks) led to abnormal 
dopamine activity in the VTA which can be part of the basis for the drug-craving behavioural 
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anomaly (Gorter et al., 2016; Keebaugh et al., 2017).  Whether this partial desensitization is 
indeed related to the increased motor response to DAMP remains to be demonstrated. 
 The radiometric in vitro results from chapter II show that insulin can modulate striatal 
[DA] uptake (Fig. 17A, B), likely through an indirect effect on the DAT. This further 
underpins the role of insulin in dopaminergic transmission (Stouffer et al., 2015; Patel et al., 
2018b). Particularly, the DA signaling processes involved is possibly mediated through 
interaction with DA D2 receptors (Fig. 17C). Our studies were based on the premise that 
insulin receptors (InRs) are distributed throughout the brain with high density in the striatum 
and cerebral cortex (Schulingkamp et al., 2000). In spite of this vast distribution, peripherally 
administered insulin under anaesthetized rat using in vivo electrophysiology paradigm seems 
not to alter the firing activities of both DA VTA neurons, though an excitatory effect was 
observed with a high dose on PFC pyramidal neurons (Fig. 22B, C). However, slight 
progressive decreases in DA neurons firing were observed when insulin was administered 
through an electrode to allow for gradual diffusion into the VTA (Fig. 23A, B), as well as 
when co-administered with the stable GLP-1 agonist Ex-4 in intravenous administration (Fig. 
22D, E).  We posit that insulin crossing from the plasma through the BBB into the brain may 
not be inadequate concentration to alter the electrophysiological activity of dopamine neurons 
in a short time frame. The situation may be slightly different in the PFC, brain penetration of 
insulin, which involved selective transporter at the levels of the endothelial cells can be 
different depending on the brain region (Strubbe et al., 1988; Wallum et al., 1987; Zhou et al., 
2017). For different complex reasons, locally produced insulin may be more efficient than 
administered insulin in regulating  brain function, likely in a glucose-regulated manner 
(Molnár et al., 2014; Begg, 2015; Gray and Barrett, 2018). We further performed an intra-
VTA administration of insulin, which produced significant attenuating effects in both firing 
and burst activities of VTA DA neurons (Fig. 24). These effects show that there was  an 
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interaction with the local insulin receptors for a direct response (Zhou et al., 2017). 
Furthermore, using a novel approach to impair insulin secretion with intraperitoneal 
administration of DZ 150 mg/kg, we report that in the absence of insulin, D-AMP-induced 
motor activity response was significantly inhibited and the effect was restored when insulin 
was administered (Fig. 19C, D). Our finding on the modulatory effect of insulin on D-AMP-
induced motor activity was in line with the classical streptozotocin-induced diabetes model 
(Sevak et al., 2008). We propose that DZ model be tested within a wider range of sample size 
and different strain of animals with varied concentration to ensure repeatability, precision and 
reproducibility of data. Modulatory effect of insulin on dopamine neurotransmission was 
further confirmed with DA D2/D3 receptor agonist-mediated behavioural responses such as 
yawning, pica eating and pelvic grooming, induced by PPX and QNP. We demonstrated that 
insulin modulates these responses by inhibition of the behavioural traits (Fig. 20, 21), an 
effect also confirmed by radiometric [DA] uptake inhibition of QNP (Fig. 17C). The fact that 
insulin weakens QNP and PPX-induced behavioural and neurochemical effects (dopamine 
uptake) indicate a potential interaction with D2/D3 receptor signaling. Clinical consideration 
of insulin dysregulation is of importance in disease management, as brain insulin 
dysregulation has been linked with Parkinson (Athauda and Foltynie, 2016; Folch et al., 
2018), Alzheimer (Cholerton et al., 2013; Neth and Craft, 2017) and other neurodegenerative 
disorders (Craft and Watson, 2004). In addition, this chapter demonstrates a possible 
association between insulin level and psychostimulant induced craving indexed as an 
enhanced motor activity. 
Results in chapter III on the KATP blocker tolbutamide (TBT), indicates a modulatory 
role of the Kir6.2/KATP on dopamine neurotransmission and neuronal excitability that can be 
of therapeutic interest. This provides evidence for likely modulatory action of Kir6.2/SUR1 
in reward/motivation as well as cognition processes (Héron-Milhavet et al., 2004; Moriguchi 
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et al., 2018). First, we qualitatively established the presence of Kir6.2/KATP channel on the 
PFC, striatum and the mid-brain containing the VTA (Fig. 32). We suggest more studies on 
this investigation to ascertain the level and proportion of distribution of the channel in 
different brain regions, as well as a possible alteration in protein expression of the channels 
after TBT administration. A very interesting finding is that a high dose of TBT (20 mg/kg) 
induced a biphasic effect on the dopamine neurons (Fig. 27A, B, C). We also observed that 
period of inhibition (hyperpolarization) may be due to GABA interneurons or as possible 
negative feedback from activated accumbens neurons which send strong GABA inhibitory 
innervations to VTA and in the SN (Schiemann et al., 2012b) (Fig.28A). We are yet to fully 
confirm this theory and it will be possible in the future to try the use of specific GABA 
agonist and blockers to support this hypothesis (a similar mechanism is known to occur with 
the effect of nicotine on VTA dopamine neuronal activity). Conversely, TBT activatory effect 
on pyramidal neurons of the PFC is monophasic (Fig. 29A, B) and may indicate it could exert 
a positive effect on cognition and memory due to its ability to activate glutamatergic neurons 
on the PFC (Yuen et al., 2009; Dauvermann et al., 2017b). There was a pharmacokinetic 
problem of penetrability of TBT into the brain tissue. An attempt was made to circumvent 
this problem by the use of a large dose of TBT and co-administration with sodium 
deoxycholate. A more viable delivery mechanism of TBT into the brain might be developed 
in the future for an effective central response. The neurochemical studies show evidence of a 
significant reduction in specific dopamine uptake with TBT and glucose (Fig. 30A, 31B), 
these indicate a possible interaction of the drugs with dopamine neurotransmission (Sidló et 
al., 2008). This chapter shows that although, TBT is an insulin secretagogue, yet its effect on 
the brain is mediated by antagonistic action on Kir6.2 channels. 
 Finding in chapter IV is crucial to understanding the role of GLP-1 beyond feeding 
and glucostatic regulations, but also as a vital mediator in reward, motivation and cognition. 
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Our results show that GLP-1 alters dopamine-dependent behaviour with a significant 
inhibitory effect on D2/D3 DA agonist-induced yawning, pelvic grooming and pica eating 
(Fig. 42, 43, 44, 45). We also provide evidence for GLP-1 inhibitory effect on D-AMP-
induced motor activity (Fig. 46A, B, C, D). Indeed, we found that DAT protein was 
significantly up regulated with D-AMP-treated rats and remarkably downregulated in Ex-4 
pre-treated rats (Fig. 48A, B). This could be attributed to some degree of plasticity of DAT, 
resulting from synaptic alterations which have been found in some studies (Vaughan and 
Foster, 2013b; German et al., 2015). The western blot analysis was conducted within an hour 
of experimental treatment of the animal; it will be of interest to see how long such 
dysregulation of DAT is sustained after the D-AMP treatment discontinuation. Further 
research is needed to unravel the impact of DAT protein expression following acute GLP-1 
administration, whether DAT is regulated by complex processes such as phosphorylation 
(Foster et al., 2012; Gorentla et al., 2009),  protein–protein interactions (Egaña et al., 2009; 
Eriksen et al., 2010) and changes in intracellular localization (Lee et al., 2007; Vaughan and 
Foster, 2013b). We observed a direct correlation between GLP-1 acute treatment and 
upregulation of GLP-1R protein expression, particularly with Ex-4+D-AMP treated rats (Fig. 
49A, B).  This is suggestive of GLP-1R activation partly involves in reward  and motivation 
associated with the drug of abuse (Reddy et al., 2016b; Suchankova et al., 2015). Indeed, we 
report the precognitive effect of GLP-1 on PCP-induced cognitive impairment (Fig. 40B), as 
well as a clear excitatory effect of Ex-4 on PFC pyramidal neurons (Fig. 56A, B). These data 
further indicate that GLP-1R activation may have a positive impact on cognition, learning as 
well as memory, which might be indirectly associated to its neuroprotective effect to  resist 
oxidative stress on all neurons that express GLP-1R (Oka et al., 1999; During et al., 2003a; 
Gault et al., 2010c; Tweedie et al., 2013; Hölscher, 2014b; Li et al., 2016; Gault and 
Hölscher, 2018). It will be of interest to know the extent of this cognitive effect in chronic 
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treatment and if specific blocker of GLP-1R could reverse such action. We also suggest 
carrying out a dopaminergic lesion with 8-OHDPAT and then proceed to GLP-1R 
measurement via WB analysis to precisely validate the presence of GLP-1R on the striatal 
terminal. We have initially presumed that the effect might not be presynaptic as there was no 
effect with radiometric [DA] release on the striatal slices (Fig. 34A, B). Notwithstanding, we 
found an interaction between Ex-4 and quinpirole or pramipexole-induced dopamine uptake 
(Fig.  37C, D) indicating that GLP-1R may be present on DA terminals and there, GLP-1R 
signaling may negatively interact with DA D2/D3 receptors. This was in a way also confirmed 
in our study on intra VTA administration of Ex-4 which appears to impair D2/D3 autoreceptor 
function on firing rate of DA cells (Fig. 54). Also, a study has demonstrated that Ex-4 
reduced nicotine-induced motor response as well as accumbal DA release through the use of 
in vivo microdialysis (Egecioglu et al., 2013a). Since our in vitro (release assay) study did not 
agree with this, it is suggestive to adopt another neurochemical assay to ascertain the actual 
mechanism of GLP-1effect on the attenuation of psychostimulant-induced motor response. 
GLP-1 effect on electrophysiological paradigm, when given through intravenous 
administration, elicits excitability of prefrontal cortex neurons, an effect that can be due to the 
cognitive-enhancing property of GLP-1 analogue as demonstrated in this chapter (Fig. 56A, 
B).  A direct administration of GLP-1 into the VTA seems to induce an increase in firing and 
burst activities of DA neurons than the control (Fig. 54). But, this effect needs to be 
confirmed with a larger population of neurons. Even more, interestingly, the intra-VTA 
administration of the GLP-1R agonist also showed pronounced desensitization of D2/D3 
receptors upon PPX administration (Fig. 55). This confirms the negative relationship between 
D2/D3 receptors and GLP-1 receptor function, which may exist at every level of the 
dopaminergic system (cell bodies, neuron terminals, post-synaptically). Whether GLP-1R and 
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dopamine D2/D3 receptors coexist on the same membrane and interact negatively with each 
other will be a very interesting question to explore.  
The final chapter (chapter V) discusses how GLP-1 modulates the impact of diet 
alteration in form of continuous sucrose consumption on behavioural and 
electrophysiological parameters. Our data shows that there is a long-term negative impact of 
continuous sucrose consumption on memory and cognitive task (Fig. 61B, C), and also on 
behavioural response to psychostimulants (Fig. 62A, B).  Indeed, this effect was not reversed 
by acute administration of GLP-1 although, co-administered for two weeks with sucrose. 
Previous studies have shown the involvement of PFC and hippocampus in adolescent rats 
exposed to daily sucrose intake (Reichelt et al., 2015b). We also observed that prolonged ad 
libitum access to sucrose in adolescent rats may alter brain circuits related to dopaminergic 
neurotransmission (Bello et al., 2003; Hajnal et al., 2004; Alsiö et al., 2011; Marella et al., 
2012) (Fig. 64C, D). It also increases the behavioural traits to dopamine agonists (Fig. 63), 
and is possibly associated with changes in sensitivity of some postsynaptic dopamine 
receptors. Indeed, these effects were partially prevented by GLP-1, which may elicit some 
protective effects on dopamine receptor function (Kim et al., 2009b; Li et al., 2012; Darsalia 
et al., 2014). However, we also observed that sucrose treatment (on its own) induced an 
incomplete but significant decrease in the sensitivity of dopamine autoreceptors which was 
surprisingly exacerbated by exendin-4 co-administration (Fig. 64F, H) indicating; again, that 
exendin-4 may exert similar desensitizing effects on pre- and post-synaptic dopamine 
receptors. It will be of particular interest to find out how long these differential effects will 
last, as well as possible neurochemical and molecular parameters that may be involved in 
these changes. Putting the results together, our findings suggest that consumption of sugar by 
adolescents may impair neurocognitive functions affecting decision-making and memory, 
response to addictive drugs, potentially rendering them at risk for developing mental health 
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disorders such as ADHD. More studies are required to validate this finding whether the effect 
is long-term or short-term induced. 
 In the future, GLP-1R agonist might potentially find a new use in the 
management of neuropsychiatric, neurodegenerative and addiction disorders. As 
demonstrated in this thesis, exendin-4 alters dopamine-dependent behaviour with a 
remarkable inhibitory effect on D2/D3 DA agonist-induced yawning, pelvic grooming and 
pica eating. Evidence was also provided for GLP-1 inhibitory effect on D-AMP-induced 
motor activity, a DAT mediated mechanism from GLP-1R activation. These might suggest a 
potential use in the management of addiction, reward and other dopamine-dependent 
disorders. In addition, we reported the precognitive effect of GLP-1on PCP-induced cognitive 
impairment as well as an excitatory effect on PFC pyramidal neurons. Also, these effects 
might be potentially explored in neurodegenerative disorders such as, Alzheimer disease 
associated with memory loss and cognitive dysfunction. TBT has been investigated and 
explored in the early clinical practice days in the management of Parkinson disease. In this 
thesis, a potential new role has emerged due to its biphasic effect on VTA. Data presented on 
sucrose consumption is vital to help understand how our diet influences drugs use in CNS. In 
this thesis, limitation encountered in various techniques deployed has little impact on the data 
presented. In radiometric release assay, leakages of tritiated neurotransmitter as well as other 
drugs loaded on the chamber could result in suboptimal concentration of the drug to elicit an 
efficient efflux. Thus, another neurochemical techniques such as, microdialysis and static 
release assays may provide a more precise neurochemical data. In radiometric uptake assay, a 
careful consideration of how to preserve the integrity of the synaptosome is of concern. We 
circumvented this challenge by reducing the numbers of strokes utilized during 
homogenisation, a vital step to achieving an experimentally viable synaptosome. The western 
blot technique would have also be synergized with the aid of immunohistocytochemical 
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elucidation, which provides a vital information on spatial distribution of protein. This 
information is however absent with western blot protocol. All the behavioural assays were 
conducted using visual manual scoring. This approach potentially introduces some errors due 
to manual spotting of behavioural trait. The use of cam camera coupled with software that 
can record either online or offline for data analysis will be of help to minimize this error. 
Anesthesia and invasive surgical procedures greatly alter the physiology of the CNS 
environment, directly affecting neurotransmission and motility. To fully realize the 
advantages of in vivo brain electrophysiology, neural recording and stimulation must be 
conducted in conscious animal models. Advancing with the tools for single-unit recordings in 
awake animal models demands new and innovative neural microelectrode technology. 
However, unlike in anesthetized animal, signal quality in awake animal might be a challenge. 
It is also worth noting that anaesthetics used throughout our study did not have any 
neuromodulatory effect on the tested drugs. 
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